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CANCER REGISTRY IN THE NETHERLANDS 
Since 1989, the Netherlands has a nation-wide population-based cancer registry, the 
Netherlands Cancer Registry (NCR). Data collection for the NCR is organized by nine 
regional registries. Although in the Eindhoven region cancer registration already 
started in the 1950s, most Dutch cancer registries did not start their activities until the 
1980s. The regional cancer registries in the Netherlands are hosted by the nine Com-
prehensive Cancer Centres (CCC) and together they completely cover the Netherlands. 
During the 1980s the CCCs made agreements with all hospitals in their regions to start 
cancer registration in the respective hospitals. This procedure was finalized during 
1988 and on January 1st 1989 the cancer registry in the Netherlands reached national 
coverage. All regional registries submit their data to the NCR, which allows national 
analyses. Before accepting data from the regional registries in the NCR, the data are 
extensively checked for inconsistencies and duplicate records.  
The collection of data for the regional cancer registries in the Netherlands is performed 
by registration clerks on the basis of data from the medical records of the cancer pa-
tients. As the registration clerks are trained and educated by the CCCs, and use na-
tional coding guidelines, data quality is high. New cancer cases are reported to the 
registration clerks by all pathology laboratories in the Netherlands on a weekly basis. 
Cancer cases who were not microscopically confirmed are reported annually by the 
national hospital discharge registry. With these two notification sources the complete-
ness of the NCR is at least 95%. 
In 1997, the data of the NCR covering 1989-1992 were accepted by the International 
Association of Cancer Registries (IACR) for publication in Volume VII Cancer Incidence 
in Five Continents1. Five years later, the data covering 1993-1997 were included in 
Volume VIII of Cancer Incidence in Five Continents2. In addition to the minimum data 
set of the IACR (date of birth/age, sex, date and basis of diagnosis, site and morpho-
logical type of the tumour), the regional registries collect stage data for all relevant 
tumours, as well as data on primary treatment. The treatment data increase the possi-
bilities for use of the regional cancer registries substantially, but they are not (yet) 
included in the national database. 
THE AMSTERDAM CANCER REGISTRY  
The Amsterdam Cancer Registry (ACR), 
the cancer registry of the Comprehensive 
Cancer Centre Amsterdam (CCCA), started 
its activities in 1984 in Medisch Centrum 
Alkmaar, the largest community hospital 
of the CCCA. In the following years, the 
ACR gradually expanded by the inclusion 
of more hospitals. In 1988, the ACR 
reached region-wide coverage. Due to 
mergers and closing of several small hos-
pitals, the number of hospitals of the 
CCCA gradually decreased from over 30 
during the 1980s to 20 in the second half 
Figure 1.  
The region of the Amsterdam Cancer Registry 
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of the 1990s. Subsequently, the number of hospitals has been stable, but the hospitals 
who have two or three locations following a merger, tend to centralize their activities 
at one location. Among the hospitals which participate in the ACR are two university 
hospitals and a specialized cancer hospital, all located in Amsterdam. These three hos-
pitals are the ones with radiotherapy facilities. As of 1996, radiotherapy facilities are 
also available in one of the community hospitals. 

























Figure 2. Population pyramid of North-Holland/Flevoland, 1-1-2004 
 
The region of the CCCA and the ACR comprises the province of North-Holland as well 
as the major part of the province of Flevoland. Due to the merger of two hospitals in 
Flevoland, the remaining part of Flevoland will be included in the near future. The ACR 
is the largest of the nine regional cancer registries in the Netherlands and covers a 
population of 2.885 million on January 1st 2004, which is about 18% of the total popu-
lation of the Netherlands. As figure 2 shows, the proportion of elderly people is still 
relatively small. Since 1988, the proportion of people of 65 years or older has been 
stable at 13 percent. However, the proportion of people of 85 years or older gradually 
increased from 1.2 to 1.4 percent. As of 2008, when  he first ‘baby-boomers’* reach 
                                               
* The ‘baby-boom’ started in the Netherlands in 1943, when the number of births increased 10% in com-
parison to 1942 and exceeded 200 000 for the first time in history, and came to an end 30 years later in 
1973, when the number of births decreased below 200 000 again. The average annual number of births 
during the ‘baby-boom’ was 237 000, compared to 175 000 in the decades before and 187 000 in the dec-
ades after the ‘baby-boom’. 
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the age of 65 years, the proportion of people of 65 years will gradually increase. This 
demographic development will increase the cancer burden during the next decades 
substantially, as cancer is most common among the elderly3. 
The number of migrants in North-Holland and Flevoland gradually increased during the 
past decades. On 1-1-2004, the proportion of first generation migrants was 14% (na-
tional figure: 10%), while 12% were second generation migrants4. In Amsterdam, 
even more than half of the population is a first or second generation migrant. Migrants 
originate primarily from the former Dutch colonies (Indonesia [former name: Dutch 
East-Indies], Surinam and the Netherlands Antilles), Morocco and Turkey. Migrants 
from the latter two countries originally came to the Netherlands as labour migrants in 
the 1960s, but the vast majority came to the Netherlands as part of family reunion or 
marriage. During the 1990s, a new category of migrants emerged, namely asylum 
seekers. These originate primarily from the former Yugoslavia, Iraq, Iran, Afghanistan 
and Somalia. However, their numbers are relatively small in comparison to the ‘tradi-
tional’ migrants. 
CANCER INCIDENCE, MORTALITY AND PREVALENCE IN NORTH-HOLLAND & 
FLEVOLAND 
Incidence of invasive cancers in North-Holland/Flevoland 
In 1988, 9 532 invasive cancer cases were diagnosed in residents of the region of the 
ACR (table 1). In 2002, this number had increased to 11 987, an increase of 26%. 
However, this increase was mainly 
caused by growth of the population. 
The age-standardized incidence rate 
per 100 000 persons only increased 
by 3% (both sexes combined). Until 
the year 2000, the number of cancer 
cases in males exceeded the number 
in females. Since then, more females 
were diagnosed with cancer than 
males. The fast increase in the num-
ber of diagnosed cancers in females 
during the beginning of the 1990s is 
mostly due to the introduction of the 
breast cancer screening, which has 
led to an increase of the number of 
breast cancers of about 50% (or 700 
cases) between 1988/89 and 
2001/02. The number of lung cancers 
in females doubled between 1988 and 
2002 (from 250 to 500 cases). 
The crude incidence rate per 100 000 (figure 3) gradually increased in females and 
almost equalled the crude rate in males in 2001/2002. The crude rate in males has 
Table 1. Incidence of cancer in North-
Holland/Flevoland 
Number of cases per year Year of 
diagnosis both sexes 
combined males females 
1988 9 532 4 990 4 542 
1989 9 711 5 004 4 707 
1990 10 275 5 413 4 862 
1991 10 317 5 378 4 939 
1992 10 776 5 590 5 186 
1993 10 858 5 598 5 260 
1994 11 130 5 684 5 446 
1995 11 313 5 839 5 474 
1996 11 365 5 851 5 514 
1997 11 492 5 910 5 582 
1998 11 522 5 852 5 670 
1999 11 597 5 938 5 659 
2000 11 791 5 922 5 869 
2001 12 066 6 008 6 058 




been rather stable during the last decade. The age-standardised incidence rate* for 
both sexes combined increased from 377 per 100 000 in 1988 to 409 in 1995. Subse-
quently, the rate decreased to 389 per 100 000 in 2002. Throughout the whole period 
the incidence rate in males was higher than in females, but the difference decreased 
from 131 per 100 000 in 1988 to only 72 in 2002 (the male/female ratio decreased 
from 1.4 in 1988 to 1.2 in 2002). 


















both sexes males females
 
Figure 3. Cancer incidence rates in North-Holland/Flevoland, 1988-2002 
 
Cancers of the breast, lung, colon & rectum and prostate account for 50% of all can-
cers (table 2). In 1988, lung cancer was the most common cancer, but as of 1991, 
breast cancer is the most common cancer. Colorectal cancer ranks third, and prostate 
cancer fourth (7.3% in 1988, 9.6% in 2002). The proportion of skin cancer† increased 
between 1988 and 2002, while the proportion of stomach cancer decreased (4.8% in 
1988, 2.6% in 2002). In 3% to 4% of all registered cases, the primary site of the can-
cer is unknown. In males, lung cancer and prostate cancer changed position between 
1988 and 2002 (table 3), while colorectal cancer remained the third cancer in males. 
Due to the increase in oesophageal cancer incidence, this cancer, which was not 
among the most frequent cancers in the 1990s, became the 10th cancer in males in 
2002. In females, breast cancer is by far the most common cancer and its proportion 
even increased between 1988 and 2002 from 29% to 33%. The proportion of cancers 
of the female genital organs decreased between 1988 and 2002 (cervix uteri from 
                                               
* European standardised rate (ESR), i.e. standardised according to the European standard population 
† Excluding basal cell carcinoma (the most common type of skin cancer), which is not registered by the ACR 
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3.4% to 2.1%, corpus uteri from 4.9% to 4.0%, ovary from 4.3% to 3.3%), while the 
proportion of skin and lung cancer increased. 
 
Table 2. The ten most frequent cancer sites in North-Holland/Flevoland (both sexes com-
bined) 
1988 2002 
site n % site n % 
Lung 1 448 15.1 Breast 2 035 16.4 
Breast 1 350 14.1 Lung 1 603 12.9 
Colon & rectum 1 163 12.2 Colon & rectum 1 575 12.7 
Prostate 698 7.3 Prostate 1 190 9.6 
Skin*  
- melanoma 






- other skin cancers* 
1 067 8.6 
4.0 
4.6 
Stomach 458 4.8 Lymphatic tissues† 500 4.0 
Lymphatic tissues* 411 4.3 Bladder & oth. ur. tract 451 3.6 













Head & neck 322 3.4 Stomach 328 2.6 
 
Table 3. The ten most frequent cancer sites in males in North-Holland/Flevoland  
1988 2002 
site n % site n % 
Lung 1 200 24.0 Prostate 1 190 19.2 
Prostate 698 14.0 Lung 1 073 17.3 
Colon & rectum 550 11.0 Colon & rectum 813 13.1 
Skin†  
- melanoma 










Bladder & oth. ur. tract 298 6.0 Bladder & oth. ur. tract 344 5.5 
Stomach 286 5.7 Head & neck 289 4.7 
Lymphatic tissues‡ 233 4.7 Lymphatic tissues† 283 4.6 
Head & neck 224 4.5 Stomach 192 3.1 
Pancreas 139 2.8 Bone marrow‡  176 2.8 
Bone marrow§ 133 2.7 Oesophagus 168 2.7 
Second cancers 
Second and subsequent cancers are not uncommon. Of all registered invasive cancers 
in 1988 7 percent was not the first cancer if the IACR-rules for multiple cancer were 
applied to the data5. This percentage increased to more than 10 percent in 2002. 
Among the second and subsequent cancers, colorectal cancer, lung cancer, non-
melanoma skin cancer and urinary tract cancers are relatively common. As the NCR 
also registers contralateral cancers (mainly breast cancer) and multiple cancers of the 
colon, the proportion of second or subsequent cancers is 2 percent higher if these 
cancers are also included. 
                                               
* Lymphoma 





Table 4. The ten most frequent cancer sites in females in North-Holland/Flevoland  
1988 2002 
site n % site n % 
Breast 1 337 29.3 Breast 2 024 32.8 









- other skin cancer* 
537 8.7 
    4.8 
    3.9 
Skin*  
- melanoma 




Lung 530 8.6 






Ovary 197 4.3 Lymphatic tissues† 216 3.5 
Lymphatic tissues† 178 3.9 Ovary 205 3.3 
Stomach 172 3.8 Stomach 136 2.2 
Pancreas 126 2.8 Head & neck 134 2.2 
Bladder & oth. ur. tract 102 2.2 Bone marrow‡ 133 2.2 
Mortality due to cancer in North-Holland/Flevoland 
In males, the annual number of cancer 
deaths was rather stable during the 
period 1988-2002. In females, there 
was a 10% increase in the number of 
cancer deaths (table 5). The age-
standardised mortality rate per 100 000 
persons decreased from 240 in 1988 tot 
202 in 2002, a decrease of 16% (figure 
4). This decrease was mostly due to the 
decrease in males: from 312 in 1988 to 
245 in 2002 (-22%). In females the 
decrease of the age-standardised rate 
was 5%. In males, the decrease in can-
cer mortality was caused by a decrease 
in the mortality due to lung cancer (-
36%), stomach cancer (-48%) and 
prostate cancer (-26%). In females, 
there were decreases in the mortality 
due to breast cancer (-15%) and ovar-
ian cancer (-29%), but the mortality due to lung cancer increased by 161%. 
Cancer prevalence in North-Holland/Flevoland 
On January 1st 2003, 61 100 persons in whom cancer had been diagnosed in North-
Holland/Flevoland since December 31st, 1987 were still alive (table 6). This number is 
the 15-year cancer prevalence. The total cancer prevalence is even higher, because 
there are also people still alive in whom cancer was diagnosed before 1988, the start 
of the ACR. 
Table 5. Mortality due to cancer in North-
Holland/Flevoland  
Number of deaths per year Year of 
diagnosis both sexes 
combined males females 
1988 6 161 3 456 2 705 
1989 6 114 3 388 2 726 
1990 6 189 3 380 2 809 
1991 6 118 3 333 2 785 
1992 6 177 3 389 2 788 
1993 6 165 3 339 2 826 
1994 6 227 3 374 2 853 
1995 6 176 3 375 2 801 
1996 6 257 3 361 2 896 
1997 6 229 3 291 2 938 
1998 6 257 3 408 2 849 
1999 6 290 3 393 2 897 
2000 6 317 3 352 2 965 
2001 6 235 3 252 2 983 






















both sexes males females
 
Figure 4. Age-standardised cancer mortality rates in North-Holland/Flevoland, 1988-2003 
 
This includes mostly indi-
viduals who were cured 
from breast cancer, colorec-
tal cancer, cervical cancer, 
skin melanoma, testicular 
cancer or Hodgkin’s dis-
ease. Cancer prevalence is 
an important measure of 
the occurrence of cancer, 
since it provides informa-
tion on the total number of 
patients with need for care. 
Such information is crucial 
for health care planning. 
The age-standardised 15-
year prevalence per 100000 
persons was 1947 (males 
1796, females 2099). 
Breast cancer, skin cancer and colorectal cancer have the highest prevalence. Cancer 
prevalence comprises a heterogeneous group of (ex-)patients, who may have com-
pletely different needs for care. The following phases, each with its specific need for 
care, may be distinguished6:  
• diagnostic phase 
• treatment phase 
• disease-free phase 
• palliative or terminal phase 
• cured phase 
Table 6. The ten most prevalent cancer sites in North-
Holland/Flevoland (both sexes combined), January 1st 
2003 (15-year cancer prevalence) 
site number ESR 
1. Breast 16 300 497 
2. Skin*  
  - melanoma 







3. Colon/rectum 7 500 230 
4. Prostate 6 600 235 
5. Uterus 
  - cervix  







6. Lymphatic tissues 2 850 93 
7. Lung 2 500 85 
8. Head & neck 
  - larynx 







9. Bladder/other urinary tract 2 100 70 
10. Kidney 1 250 40 
All sites 61 100 1 947 
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The longer the length of the prevalence period, the more heterogeneous the cancer 
prevalence is. The 1-year prevalence comprises mostly patients in the diagnostic and 
treatment phase. One to five years after diagnosis the majority of the patients is either 
disease-free or develops a recurrence and reaches the terminal phase. The majority of 
the patients who survive the first 5 years are cured. In general, the longer the length 
of the prevalence period, the higher the proportion of cured patients is. Therefore, 
when a relation with the need for care is requested, it is better to choose a prevalence 
period which does not exceed for example 10 or 15 years. Only for long-term survivors 
who are at risk for second cancers and other late treatment-related effects, a longer 
prevalence period might be informative. 
FOLLOW-UP OF CANCER PATIENTS 
In order to be able to determine cancer survival rates, complete follow-up of the regis-
tered cancer cases is essential. However, the follow-up of cancer patients is one of the 
most difficult tasks of a cancer registry. Follow-up may include the following items: 
• occurrence of local and/or regional recurrence 
• occurrence of distant metastasis 
• vital status and the date of death 
• cause of death 
The collection of information on the first two items requires access to the medical re-
cord. Although the ACR has access to the patients’ records, the collection of follow-up 
data is time-consuming and therefore the ACR only collects such data in registration 
studies for a limited number of cancers over a limited period. An example of such a 
registration study is discussed in chapter 4.4. 
For the vital status and the date of death the following main sources are available in 
the Netherlands: 
1. the hospital where the tumour was registered 
2. the general practitioner 
3. the municipal population registers 
4. the Central Bureau of Genealogy (CBG) 
For this thesis, the general practitioner was only incidentally used as the source of 
follow-up information. We performed the following procedure for obtaining complete 
vital status and date of death information. For patients with residence in the ACR re-
gion and diagnosed in 1988-97, the vital status was updated by linking electronic files 
with deceased persons to the cancer registry. These files were made available in 
1999/2000 by 54 municipal population registers (covering 90% of the population of 
the region) out of a total of 74 registers in the region. The files included all deceased 
residents (irrespective of cause of death) of those municipalities, generally covering 
the period 1988-99. Active follow-up was performed in the hospitals for all patients 
with residence in the remaining 20 municipalities and in case the datafile made avail-
able by the municipal population register only partly covered the period 1988-99. In 
case of missing data in the hospital, the municipal population registers were asked for 
the date of death of individual patients. 
In September 2003, the vital status of all patients (diagnosed 1988-2001) still alive at 
last follow-up was updated by linkage to the electronic death register of the CBG, 
Chapter 1 
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which contains all deceased residents of the Netherlands as of October 1st 1994. This 
electronic register is updated on a daily basis with data from all municipal population 
registers in the Netherlands. Patients who probably died before October 1st 1994 ac-
cording to hospital information, but with unknown date of death, were checked in the 
personal record card register of the CBG which contains all Dutch residents who died 
before October 1st 1994. Finally, all patients not known by CBG were assumed to be 
alive at 1 September 2003, one week before record linkage with the electronic death 
register was performed. 
Checks on the vital status of patients assumed to be alive at 1 September 2003 were 
performed in the hospitals for all patients with metastatic disease at diagnosis, patients 
over 95 years of age in 2003 and patients with cancer of the oesophagus, stomach, 
liver, gallbladder, bile ducts, pancreas, and lung. These hospital checks revealed that 
the number of patients who were assumed to be alive after record-linkage but ap-
peared to have died, was negligible. Missing dates of death are estimated to be well 
below 0.5%. 
As neither the municipal population registers nor the CBG possess information regard-
ing the cause of death and the collection of the cause of death in hospitals and from 
general practitioners is extremely time-consuming, information on the cause of death 
is absent for the majority of the cases and could not be used in survival analysis. Al-
though the individual causes of death are available at Statistics Netherlands, this in-
formation was hardly accessible for cancer registries because of strict privacy regula-
tions, and could not be used in this thesis. 
In the studies of chapter 4 follow-up data were used for the calculation of survival 
probabilities, local recurrence rates and hazard ratios for the risk of dying. 
CANCER SURVIVAL IN NORTH-HOLLAND & FLEVOLAND 
As an alternative to disease-specific survival, we calculated relative survival with soft-
ware written by Dickman et al7, based on a computer package developed by Hakulinen 
et al8. This method corrects observed survival for expected mortality according to an-
nual life tables of the general population. We used national age-, sex- and calendar 
year-specific life tables from Statistics Netherlands9.  
As shown in figure 5, there is a large variation in cancer survival by site of the tumour. 
Cancers with the highest survival rates are skin cancer (including melanoma) and tes-
ticular cancer. Breast cancer, prostate cancer, Hodgkin lymphoma and thyroid cancer 
also have a fairly good prognosis. Cancer of the digestive organs (colorectal cancer 
excluded), lung cancer, mesothelioma and brain cancer have the worst survival rates. 
The most important prognostic factor for survival is stage and many differences in 
survival probabilities between cancer sites can be attributed to differences in stage 
distribution. This will be discussed extensively in chapter 4.1 of this thesis. 
For several cancers, such as colorectal cancer, cancer of the cervix & uterine corpus 
and primary bone cancer, the 5-year relative survival rate (RSR) is almost equal to the 
10-year RSR. However, for other cancer sites, such as breast cancer, prostate cancer 
and haematological malignancies there is still substantial excess mortality between 5 
and 10 years after diagnosis in comparison to the general population. 
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During 1988-2001, survival slightly improved for all cancer sites combined. This was 
due to improved survival of some common cancers (breast cancer, colorectal cancer, 
prostate cancer) as well as changes in cancer incidence: the proportion of several can-
cers with poor survival (lung cancer, stomach cancer) has decreased between 1988 
and 2001, while the proportion of cancers with a relatively favourable prognosis 
(breast cancer, prostate cancer, skin cancer) has increased. 
 


































1-year RSR 5-year RSR 10-year RSR
 
Figure 5. Relative survival rate (RSR) by cancer site, North-Holland & Flevoland, 1988-2001 
STUDIES WITH A POPULATION-BASED CANCER REGISTRY 
Apart from the obvious way to use a cancer registry for the calculation of cancer inci-
dence rates, there are numerous possibilities for research with population-based can-
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cer registries, ranging from descriptive epidemiological studies and health care plan-
ning to aetiological and clinical research. In this thesis, the various uses of a popula-
tion-based cancer registry are illustrated by migrant studies, studies of the association 
between environmental factors and the occurrence of cancer, and research on progno-
sis and survival of cancer patients. Below, the various types of research are briefly 
discussed. 
Descriptive epidemiology 
A population-based cancer registry enables the description of cancer patterns in rela-
tion to characteristics such as age, sex, residency, year of diagnosis and country of 
birth. This information is valuable for medical specialists and health authorities, may 
assist in the planning of (new) health care services and may also provide clues for the 
aetiology of cancer and hypotheses for further research. The migrant studies in chap-
ter 2 are examples of descriptive epidemiology. For these studies, information about 
the country of birth was essential. Although this item is routinely collected by the 
Netherlands Cancer Registry, the country of birth is often unknown in the hospitals and 
the available data were supplemented with information from the breast cancer screen-
ing organisation and several other sources. 
The research questions for the migrant studies were: 
• Are there differences in breast cancer risk between migrant women from non-
western countries in comparison to women born in the Netherlands? 
• Are there differences in cervical cancer risk between migrant women from 
non-western countries in comparison to women born in the Netherlands? 
The research questions with regard to breast cancer screening were also aimed mainly 
at migrant women (see ‘evaluation of screening programmes’). 
Aetiological research 
Descriptive studies can provide interesting clues to cancer aetiology, but in-depth stud-
ies are required to test the proposed hypotheses. In an ecological (or correlation) 
study design groups of individuals are the subject of study (and unit of analysis) and a 
comparison is made between these groups.10 In many ecological studies, the disease 
data and the exposure data are routinely collected. In order to investigate possible 
associations a comparison is made between two ore more populations, often based on 
geographical entities (geographical correlation study) or by comparing different time 
periods. A combination of geographical entities and time periods is also possible. A 
major deficiency of ecological studies is the use of aggregated data instead of individ-
ual data and, hence, the interpretation of the outcome of ecological studies is difficult. 
By contrast, in analytical study designs, such as cohort or case-control studies, data of 
individuals are used. For prospective or retrospective cohort studies, it is possible to 
link data files which include exposure data of participating individuals with the cancer 
registry. Since the start of the NCR in 1989, two large prospective cohort studies11,12 
and several smaller studies have made use of this possibility. In case-control studies, 
which compare cancer patients with disease-free controls, detailed data on life style 
factors are needed. Such data are not available in the cancer registry, but the cancer 
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registry is a powerful, unbiased (population-based) tool for the selection of patients 
eligible for a case-control study.13 
In chapter 3, two ecological studies which investigated the relation between air pollu-
tion and cancer risk are presented. Both studies are based on the address of the pa-
tient at diagnosis. In the study regarding the incidence of cancer in the area around 
Schiphol, no individual information regarding exposure to air pollution was available 
and we use an ecological study design. 
In the study which investigated the relation between air pollution and residency along 
the main roads in Amsterdam, individual information regarding the exposure to main 
road traffic was available. Traffic intensity (with separate data for trucks and cars) for 
all separate segments of the main road network was used as a measure for traffic-
related air pollution. This information enabled a comparison between heavily exposed 
and less exposed residents of Amsterdam in a study with a cohort-design. Because the 
standard address information in the cancer registry was insufficient to answer the re-
search question, supplementary address data were used from the population registry 
of Amsterdam. The exposure data (traffic density on the main roads) were subse-
quently linked to the individual cancer patients. 
The following research questions were studied: 
• Is there an association between residency in the Schiphol area and the risk to 
develop cancer? 
• Is there an association between residency along the main roads of Amsterdam 
and the risk to develop cancer and does the risk of specific cancers increase 
with exposure to higher levels of air pollution as assessed by residency along 
roads with the highest traffic density? 
Clinical research 
The effect of various treatments on cancer recurrence and survival can best be studied 
in randomised clinical trials. However, a major drawback of clinical trials is that they 
are always performed in selected patient populations which are often healthier than 
the general population. By using a population-based cancer registry, the effects of 
changes in treatment modalities on recurrence and survival rates can be studied in an 
unselected population. In chapter 4 the results of four prognostic, registry-based 
studies are presented. For three studies we used standard information, as available in 
the cancer registry. For the bladder cancer study, supplementary information on the 
occurrence of local recurrence was collected. 
The following research questions were studied in chapter 4: 
• To what extent does TNM-stage at diagnosis influence survival in patients with 
epithelial cancers (chapter 4.1)? 
• Has stage-specific survival changed over time (chapter 4.1)? 
• What are the survival rates of carcinoid tumours and has an in improvement of 
the survival of metastatic carcinoid disease occurred after the introduction (in 
1992) of octreotide into clinical practice (chapter 4.2)? 
• What has been the effect of population-based cervical cancer screening on the 
incidence and survival of cervical cancer (chapter 4.3)? 
• What is the risk of local recurrence after cystectomy for bladder cancer and 
what is the prognosis after recurrence (chapter 4.4)? 
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Evaluation of screening programmes 
A population-based cancer registry plays an important role in the evaluation of screen-
ing programmes. For example, although ultimately the effect of the breast cancer 
screening programme can be evaluated by monitoring the mortality due to breast can-
cer, the cancer registry additionally offers the possibility to monitor trends in cancer 
incidence, stage distribution, treatment practices in screen-detected versus non-
screen-detected cases. The cancer registry can also supply information on interval 
carcinomas. The study in chapter 2.3 regarding the screening results in migrant 
women is an example of supplementary information that can be offered by the cancer 
registry. In collaboration with the breast screening organisation, the following re-
searched questions were studied with data from the regional breast cancer screening 
program: 
• What are the attendance rates of migrant women from non-western countries 
in the screening programmes for breast cancer? 
• What are the results of the screening for those women who did attend the 
breast cancer screening? 
The study in chapter 4.3 regarding incidence and survival of cervical cancer also inves-
tigated the effect of the cervical cancer screening programme. 
Pattern of care studies 
Finally, a population-based cancer registry is an excellent tool for the study of cancer 
care, for example for the study of the use of guidelines or the study of determinants of 
the care process. As no pattern of care studies are presented in this thesis, prospects 
for future use of the cancer registry for this purpose will be discussed in chapter 5. 
The results of the presented studies in this thesis will also be discussed in chapter 5.  
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MIGRANTS AND CANCER 
 
 
2.1 Incidence of cervical cancer in women in 
North-Holland by country of birth, 1988-
1998 
Visser O, Busquet EH, van Leeuwen FE, Aaronson NK, Ory FG. [Incidence of cervical 
cancer in women in North-Holland by country of birth from 1988-1998] 
Ned Tijdschr Geneeskd. 2003 Jan 11;147(2):70-4 
ABSTRACT 
Objective 
To describe the incidence of cervical cancer in North-Holland by country of birth. 
Design 
Descriptive epidemiological study based on data from cancer registries. 
Method 
The number of cases of cervical cancer in North-Holland for the period 1988-1998 was 
determined on the basis of data available from the regional cancer registry of the 
Comprehensive Cancer Centre Amsterdam. Based on data from the Netherlands Can-
cer Registry, a comparison was made between the observed and the expected number 
of cases by area of residence (i.e., Amsterdam versus the rest of North-Holland) and 
by country of birth.  
Results 
In the period 1988-1998, the incidence of cervical cancer among women living in 
North-Holland was significantly higher than that of the nation as a whole (O/E-ratio 
1.2; 95% CI 1.1-1.2). In particular, the incidence of cervical cancer for women living in 
Amsterdam (O/E-ratio 1.5; 95% CI 1.4-1.6), and for women born in Morocco (O/E-
ratio 2.1 95% CI 1.4-3.1) or Surinam (O/E-ratio 1.5 95%CI 1.1-2.0) was much higher. 
The percentage of patients with higher stages (TNM-stages II-IV) did not differ be-
tween women born in the Netherlands and those born abroad. 
Conclusion 
The incidence of cervical cancer during the period 1988-1998 was significantly higher 
for women living in Amsterdam and for women born in Morocco or Surinam than that 
for the Netherlands as a whole. No significant difference in stage of disease at diagno-




In the Netherlands, about 700 cases of cervical cancer are diagnosed annually, 2.5% 
of all newly diagnosed malignancies in females. The age standardised incidence rate 
(world standardised rate: WSR) was 6.5 per 100 000 women in 1997 (1). 
Large worldwide variation exists in the incidence of cervical cancer. In Latin America 
the incidence is very high, while it is low in Israel (2). Moreover, differences have been 
found between immigrants or ethnic minorities and the local population, i.e. in England 
& Wales (3), the Unites States (National Cancer Institute. Cervix Uteri Cancer. US Ra-
cial/Ethnic Cancer Patterns. www.cancer.gov/cancerinfo/doc.aspx?viewid=1c763de8-
c2ef-4501-b440-09e836342fe9) and Israel (2). During the past decades many mi-
grants from high incidence areas have settled in the Netherlands, especially in the 
major cities. Nevertheless, the incidence of squamous cell carcinoma of the cervix de-
creased during 1989-1997 (1). There was also a decrease in Amsterdam. 
For some time, screening programmes for cervical cancer have been in operation in 
the Netherlands. The attendance was unsatisfactory and consequently in 1996, a new 
programme was introduced. This new programme aims at an attendance of at least 
60%, but in several migrant groups this percentage is not met (4,5). In this study, we 
investigated differences in the incidence of cervical cancer among women born in the 
Netherlands and foreign-born women to be able – if necessary- to aim extra informa-
tion activities at groups with an increased cervical cancer risk. 
METHODS 
Since 1988, cancer patients are registered in all hospitals in the region of the Compre-
hensive Cancer Centre Amsterdam (CCCA): this region covers the province North-
Holland and the major part of Flevoland. All information is extracted from the medical 
records by trained registration clerks. Apart from demographic items, which includes 
the place of birth or – if a patient was born outside the Netherlands – the country of 
birth, information on the type of cancer and the primary treatment are registered. For 
the year 1988, stage was classified according to the Fédération Internationale de Gy-
nécologie et d’Obstétrique (FIGO) (6) and for 1989-1998 according to the 4th edition of 
the TNM-classification (6). 
For this study all women with residence in North-Holland and invasive cervical cancer 
diagnosed between 1 January 1988 and 31 December 1998 were selected. If women 
with residence in North-Holland were registered in a hospital outside the region, the 
data from the nation registry were used. 
Definition migrants  
In this study a migrant was defined as a Dutch resident who was born outside the 
Netherlands. 
Population data 
Starting from 1995, Statistics Netherlands published annual population data for North-
Holland and Amsterdam of persons born in Turkey, Morocco, Surinam, Indonesia or 
the Netherlands Antilles/Aruba (considered as one country). For the preceding years 
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population data for 1992 (5 countries) and 1989-1994 (Surinam and Netherlands Antil-
les/Aruba) were supplemented with extrapolations for the remaining years, using also 
data according to nationality. Separate data for persons born in the Netherlands were 
not available. 
Statistical analysis 
Incidence rates were calculated as WSR. The WSR uses the world standard population 
for age standardisation (7). 
Using the population data (according to age group) and incidence data from the Neth-
erlands Cancer Registry for 1989-1997 we calculated expected numbers of cervical 
cancer in North-Holland (E) for the period 1988-1998 (1). The numbers were com-
pared with the observed numbers (O) and O/E-ratios were calculated. Exact 95% con-
fidence intervals (95% CI) based on the Poisson distribution were calculated with Stata 
6.0 (8). 
RESULTS 
In North-Holland, 1530 women with cervical cancer were registered in the period 
1988-1998 (table 1). 
 
Table 1. Number of women (%) with cervical cancer in North-Holland, 1988-1998 
with residence in  total 
Amsterdam other North-Holland 
total 1530 572 958 
    
age    
 0-29 years 89 (6) 32 (6) 57 (6) 
 30-59 years 937 (61) 338 (59) 599 (63) 
 60 years or older 504 (33) 202 (35) 303 (32) 
    
country of birth    
 Netherlands 1138 (74) 386 (67) 752 (78) 
 abroad 232 (15) 143 (25) 89 (9) 
  Turkey 16 (1) 10 (2) 6 (1) 
  Morocco 26 (2) 22 (4) 4 (0) 
  Surinam 50 (3) 44 (8) 6 (1) 
  Ned. Antilles/Aruba 7 (0) 4 (1) 3 (0) 
  Indonesia  30 (2) 7 (1) 23 (2) 
  other 103 (7) 56 (10) 47 (5) 
 unknown 160 (10) 43 (8) 117 (12) 
 
TNM-stage at diagnosis (FIGO-classification) 
 I  774 (51) 275 (48) 499 (52) 
 II 286 (19) 95 (17) 191 (20) 
 III 323 (21) 143 (25) 180 (19) 
 IV 102 (7) 41 (7) 61 (6) 
 unknown or not applicable 45 (3) 18 (3) 27 (3) 
     




About 6% was below the age of 30 years, something over 60% was between 30 and 
60 years old, while one third was 60 years or older. Of the total of 1530 women, 1138 
(74%) were born in the Netherlands and 232 (15%) were born abroad. The country of 
birth could not be retrieved for 160 women (10%). The percentage of foreign born 
women in Amsterdam (25%) was 2.5 times as high as in the remaining part of North-
Holland (9%). In Amsterdam, the number of women born in Surinam and Morocco 
was relatively high. 
 
Table 2. Age standardised incidence of cervical cancer per 100 000 
women per year in North-Holland according to country of birth and in 
the country of origin, 1988-1998* (9) 
country of birth in North-Holland  in country of origin[9] 
Turkey 10.5 4.5 
  5.4 (Izmir 1993-94) [10] 
Morocco 15.3 19.5 
Surinam 12.9 33.4 
Netherlands Antilles/Aruba 6.1 20.4 [11]  
Indonesia 6.3 15.9 
   
* The total age standardised incidence in North-Holland was 8.2 per 100 000 
women per year 
 
The age standardised incidence rate for cervical cancer in North-Holland was 8.2 per 
100000 women in 1988-1998 (table 2) (9-11). For women born in Turkey (10.5), Mo-
rocco (15.3) and Surinam (12.9), the incidence was clearly higher. For women who 
were born in Indonesia and the Netherlands Antilles/Aruba, the incidence was some 
what below the rate for the total of North-Holland. With the exception of Turkish 
women, the incidence rate among migrant women in the North-Holland was below the 
rate in their country of origin.  
 
Table 3. Observed (O) and expected (E) numbers of cervical cancer in North-Holland accord-
ing to country of birth for the period 1988-1998 (reference population: Netherlands 1989-
1997) (1) 
area of residence 
Amsterdam  other North-Holland  total North-Holland 
country of birth 
O E O/E-ratio 
(95% CI) 
 O E O/E-ratio 
(95% CI) 
 O E O/E-ratio 
(95% CI) 
Turkey 10 7.4 1.4 
(0.6-2.5) 
 6 5.9 1.0 
(0.4-2.2) 
 16 13.3 1.2 
(0.7-2.0) 
Morocco 22 9.4 2.3* 
(1.5-3.5) 
 4 2.9 1.4 
(0.4-3.5) 
 26 12.3 2.1* 
(1.4-3.1) 
Surinam 44 25.2 1.7* 
(1.3-2.3) 
 6 7.1 0.8 
(0.3-1.8) 




4 3.7 1.1 
(0.3-2.8) 
 3 3.0 1.0 
(0.2-2.9) 
 7 6.7 1.0 
(0.4-2.2) 
Indonesia 7 10.2 0.7 
(0.3-1.4) 
 23 18.8 1.2 
(0.8-1.8) 
 30 29.0 1.0 
(0.7-1.5) 
other (including the 
Netherlands and 
unknown) 
485 333.7 1.5* 
(1.3-1.6) 
 916 885.7 1.0 
(1.0-1.1) 
 1401 1219.4 1.1* 
(1.1-1.2) 
total 572 389.6 1.5* 
(1.4-1.6) 
 958 923.4 1.0 
(1.0-1.1) 
 1530 1313.0 1.2* 
(1.1-1.2) 
 
* p < 0.05 for the difference between the observed and expected number 
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The observed number of cervical cancers in North-Holland (table 3) was slightly in-
creased in comparison to the national average (O/E-ratio 1.2; 95% CI 1.1-1.2). This 
was caused by the high incidence in Amsterdam (O/E-ratio 1.5; 95% CI 1.4-1.6). 
Among women in Amsterdam who were born in Morocco or Surinam, the number of 
cervical cancers was strongly increased. However, the number of cervical cancers 
among women in Amsterdam who were born in the remaining countries (mainly the 
Netherlands) was also strongly increased. Among women born in Turkey, the Nether-






















number of women (%)  country                               percentage 
< 50
50 years or older
 
Number (%) of women in North-Holland with cervical cancer with extension outside the uterus 
(TNM-stage II-IV) according to country of birth, 1988-1998 
 
The figure shows for two age groups the percentage of patients with extension of the 
cancer outside the uterus (TNM-stages II-IV). There was no statistically significant 
difference in stage at diagnosis between the different age groups, although the per-
centage of advanced stages below the age of 50 was lower among women who were 
born in the Netherlands than among foreign-born women. 
DISCUSSION 
In the period 1988-1998 the incidence of cervical cancer in North-Holland was slightly 
increased in comparison to the national incidence (O/E-ratio 1.2). The incidence was 
strongly increased among women with residence in Amsterdam (O/E-ratio 1.5) and 
among women born in Morocco (O/E-ratio 2.1) and Surinam (O/E-ratio 1.5). There 
was no statistically significant difference in stage at diagnosis between Dutch women 
and migrant women. 
Based on the increased relative risks, the lifetime risk for cervical cancer for women 
born in Morocco and Surinam can be estimated at 1.5% and 1.1%, respectively. The 
Chapter 2.1 
 30 
average lifetime risk for the Netherlands is 0.7% (1 out of every 140 women will get 
the disease) (12). So, the increase in the absolute risk to get the disease is limited. 
For the determination of a person as a migrant or not, only the country of birth was 
available in this study. Although this information is objective, it has the limitation that 
it is impossible to investigate for example second generation migrants or the different 
ethnic groups of Surinam. For 10% of the cases, the country of birth could not be 
retrieved, because in a number of hospitals this information is not available in the 
medical records. Because we included the ‘unknown’ cases into the rates for Dutch 
women, the incidence for migrant women was underestimated, while the incidence for 
Dutch women was overestimated. 
Cancer incidence rates have been published for the Turkish province of Izmir (10) and 
for the Netherlands Antilles; data for the other foreign countries in this study are 
sparse. Therefore, we compared the observed rates in North-Holland with estimations 
from the International Agency for Research on Cancer (IARC) (9). The differences in 
incidence between migrants in North-Holland and their country of origin could have 
been caused by changes in life style of the migrants or the absence of cervical cancer 
screening in the countries of origin. Moreover, it is not impossible that the estimations 
are incorrect, for example because of incompleteness of the mortality registration, 
which has been used by the IARC for their estimations. Possibly, the cancer registry of 
Izmir is also incomplete. Finally it is unclear whether migrants with residence in the 
Netherlands are representative for the residents in their country of origin or only for 
selective groups. 
In many studies, it has been shown that the human papilloma virus (HPV) is the main 
factor in the etiology of cervical cancer (13-16), and that this relation is independent 
from other risk factors and consistent in different countries (13). It can be concluded 
that over 90% of the cervical tumours is related to HPV-infection (13-15), and HPV-
DNA is present in virtually all patients (16). There are no statistically significant differ-
ences in the prevalence of HPV between different countries (13). However, differences 
in the prevalence of the different HPV-subtypes have been demonstrated (13, 17). 
This could be an explanation for the differences in cervical cancer incidence in different 
populations. 
In this study, apart from age group, no correction has been made for other factors 
that may have influenced the incidence, such as smoking, the number of sexual part-
ners or socio-economic status. Differences in socio-economic status may explain part 
of the differences in health status between migrants and the Dutch population (18). 
However, information on these factors was not available in the cancer registry. Conse-
quently, it was impossible to explain, for example, the high incidence among Dutch 
women in Amsterdam. 
Mortality due to cervical cancer in the Netherlands has been decreasing for 40 years (a 
60% decrease between 1960 and 2000). Probably, half of the decrease was the result 
of screening programmes (19). The existing programme is aimed at women between 
30 and 60 years of age. Attendance in Amsterdam (46% in 1996) is the lowest of the 
province of North-Holland and is far below the target (60%) (personal communication 
E. Kenter, 1999). Although the attendance reached 53% in 1999, in particular the 
attendance of women born in Morocco and the Netherlands Antilles was still far below 
the target (table 4). Also in Gooi & Vechtstreek (4) and Flevoland (B.Schouten, per-
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sonal communication, 1997) the attendance of migrant women was lower than of 
Dutch women. 
 
Table 4. Percentage attendance (A) and protec-
tion grade (P) in the screening programme for 
cervical cancer in Amsterdam in 1996 and 1999  
Country of birth 1996  1999 
 A P  A P 
Netherlands 48 62  56 73 
Turkey 49 54  53 60 
Morocco 38 44  45 51 
Surinam 46 55  52 62 
Netherlands 
Antilles/Aruba 
45 51  45 56 
other 38 47  45 57 
total 46 59  53 68 
      
Source: Municipal Health Service, Amsterdam 
 
The epidemiology of cancer among ethnic minorities may offer understanding of the 
aetiology and in biological factors which may differ for different ethnic groups (20). 
Besides, epidemiological research may contribute to the identification of population 
subgroups who are less accessible for preventive activities, treatment and follow-up, 
as has been demonstrated in the United States (21). In order to reduce differences in 
health status it is important to reach groups of people with health problems and to 
give them access to health care and prevention activities. The aforementioned out-
weighs arguments of institutions to decide not to register ethnicity. Systematic regis-
tration of ethnicity under the observation of privacy regulations is essential for epide-
miological research if we want to diminish differences in health status, in accordance 
with (inter)national agreements and policy objectives (22). 
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2.2 Breast cancer risk among first-generation 
migrants in the Netherlands 
Visser O, Van der Kooy K, Van Peppen AM, Ory FG, Van Leeuwen FE. Breast cancer 
risk among first-generation migrants in the Netherlands. 
Br J Cancer. 2004 Jun 1;90(11):2135-7. 
ABSTRACT 
Background 
In view of the world-wide variation in breast cancer incidence this study aims to inves-
tigate breast cancer incidence in migrants in the Netherlands. 
Methods 
The number of cases of breast cancer in North-Holland and The Hague for the period 
1988-1998 was determined on the basis of data available from the regional cancer 
registries of the Comprehensive Cancer Centres Amsterdam and West. Based on data 
from the Netherlands Cancer Registry, a comparison was made between the observed 
and the expected number of cases by country of birth.  
Results 
In 1988-1998, the standardised incidence ratio (SIR) for breast cancer in Northwest-
Netherlands was statistically significantly reduced for women born in Surinam (0.56), 
Turkey (0.29) and Morocco (0.22). For women from the latter two countries, the SIR 
was considerably higher below the age of 50 (Turkey 0.35; Morocco 0.33) in compari-
son to older women (Turkey 0.22; Morocco 0.10). In women born in Indonesia, the 
opposite was found (<50 years 0.83; 50 years or older 1.03). 
The proportion of women with advanced stages (III and IV) did not differ significantly 
between migrants and women born in the Netherlands. 
Conclusion 
Although the risk of breast cancer among women resident in the Netherlands but born 
in Surinam, Turkey and Morocco is still close to the risk in their country of origin, the 
higher risk in younger women compared to older women from Turkey and Morocco 
indicates that a change in the breast cancer risk profile towards the risk profile of na-




Breast cancer is the most common cancer in women world-wide. Its incidence is par-
ticularly low in Central- and East-Africa, as well as in East-Asia (Ferlay et al., 1998). 
Most western countries have high incidence rates, while the rates in the Netherlands 
are among the highest in the world (Van der Sanden et al., 1995). In the United 
States, differences in breast cancer incidence have been observed between different 
ethnic groups (Ziegler et al. 1993; Brinton et al., 1997). Studies of Japanese migrants 
to Hawaii have shown that breast cancer incidence adjusts to the incidence in the new 
homeland within one or two generations. This indicates that life style and environ-
mental factors are important factors with regard to breast cancer risk (McPherson et 
al., 2000). 
In the last decades, immigration has changed the composition of the population of the 
Netherlands, especially in the large cities. In 2002, 10 percent of the population of the 
Netherlands and even 28 percent of the population of Amsterdam was foreign-born 
(StatLine, 2003). Migrants originate primarily from the former Dutch colonies (Indone-
sia [former name: Dutch East-Indies], Surinam and the Netherlands Antilles), Turkey 
and Morocco.  
In view of the large world-wide variation this study aims to investigate differences in 
the incidence of breast cancer between migrants and women born in the Netherlands.  
MATERIALS AND METHODS 
Cancer registry data 
Data have been used from the cancer registries of the Comprehensive Cancer Centre 
Amsterdam (CCCA) and the Comprehensive Cancer Centre West (CCCW). Both are 
part of the nation-wide Netherlands Cancer Registry (Van der Sanden et al., 1995). 
Information is extracted by registration clerks from medical records in all regional hos-
pitals. If available in the hospital, the country of birth is routinely collected. Because 
the country of birth is unknown in many hospitals, only cases with residence in The 
Hague and the province of North-Holland have been included in this study. For women 
who participated in the breast cancer screening and who had agreed to record linkage 
of screening data to the cancer registry, the country of birth in the cancer registry has 
been validated with the country of birth as available in the screening data. In case of 
discrepancy or missing data in the cancer registry, the country of birth as available in 
the screening data has been used. 
Population data according to country of birth. 
Statistics Netherlands receives population data from municipal population registers via 
the computerised population network that operates since October 1994. Annual over-
views (as of 1995) of the population according to age group, sex and country of birth 
(Turkey, Morocco, Surinam, the Netherlands Antilles and Indonesia) for North-Holland 
and the city of The Hague have been used. For 1988-1994, estimations of Statistics 
Netherlands for 1992 and 1989-1994 (Surinam and the Netherlands Antilles only) have 
been used, completed with extrapolations for the remaining years. North-Holland and 
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The Hague combined cover 18 percent of the total population of the Netherlands, but 
approximately one third of the migrant population of the Netherlands. 
Statistical methods 
Based on the population data according to 5-year age category and country of birth 
and the age category specific breast cancer incidence rates from the Netherlands Can-
cer Registry for 1989-1998, expected numbers of breast cancer (E) for North-Holland 
and The Hague were calculated for women born in Turkey, Morocco, Surinam, the 
Netherlands Antilles and Indonesia, as well as for the total female population. The 
observed numbers (O) of breast cancer were adjusted for cases with unknown country 
of birth, assuming that the distribution according to country of birth for unknown cases 
was equal to the distribution of cases with known country of birth. The expected num-
bers were compared with the adjusted observed numbers and standardised incidence 
ratios (SIRs) were calculated as the ratio between the adjusted observed and expected 
numbers. Exact 95 percent confidence intervals (CI) based on the Poisson distribution 
of the adjusted O were calculated using STATA 7.0 (StataCorp. Stata Statistical Soft-






























Standardised incidence ratio (SIR) for invasive breast cancer according to country of birth in 
1988-1998 in North-Holland & The Hague, the Netherlands (bars represent 95 percent confi-
dence intervals; reference population: the Netherlands 1989-1998) 
Breast cancer incidence 
In 1988-1998, a total number of 16 499 invasive breast cancers were diagnosed in 
North-Holland (among which 28 percent in women with residence in Amsterdam) and 
3 517 in The Hague (table). Eighty three percent of the women were born in the Neth-
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erlands, while the percentage of foreign-born was 12 percent in The Hague and 13 
percent in Amsterdam, compared to 6 percent in North-Holland (excluding Amster-
dam). The country of birth was unknown for 8 percent of the cases. 
The figure shows that the overall SIR for breast cancer in North-Holland & The Hague 
was almost equal to the national average (SIR 0.98; 95 percent confidence interval 
[CI]: 0.97, 1.00), slightly higher in women below the age of 50 (SIR 1.01) than in 
women of 50 years or older (SIR 0.97). For women born in Indonesia the SIR was also 
almost equal to the national average (SIR for all ages: 0.99, 95 percent CI: 0.92, 
1.08), but for women below the age of 50 the rate was below the average (SIR 0.83, 
95 percent CI: 0.67, 1.01). For women born in the Netherlands Antilles, we observed a 
SIR of 0.84 (95 percent CI: 0.65, 1.08) and for women born in Surinam a statistically 
significantly decreased rate of 0.56 (95 percent CI: 0.49, 0.64) was found. Very low 
rates were observed for women born in Turkey (SIR 0.29, 95 percent CI: 0.21, 0.39) 
and Morocco (SIR 0.22, 95 percent CI: 0.15, 0.32). In women born in Turkey or Mo-
rocco, the SIRs were lower among women of 50 years or older than among women 
below the age of 50 (0.23 versus 0.35 and 0.10 versus 0.33, respectively). 
 
Number of invasive breast cancers in Northwest-Netherlands (The Hague and North-Holland) 
according to TNM-stage and country of birth, 1988-1998 
All stages  TNM-stage at diagnosis (n=16 297)* Country of birth 
Number %†  Stages I-II (%¶) Stages III-IV (%¶) 
Netherlands 16 702 83.3% 85%  15% 
Western countries 1 233 6.2%   
- Indonesia 583 2.9% 85% 15% 
- Germany 245 1.2% 83% 17% 
- Other western countries 405 2.0% 82% 18% 
Non-western countries 466 2.3%   
- Surinam 218 1.1% 83% 17% 
- Turkey 40 0.2% 87% 13% 
- Morocco 26 0.1% 86% 14% 
- Netherlands Antilles 59 0.3% 78% 22% 
- Other non-western countries 123 0.6% 82% 18% 
Unknown 1 615 8.1% 84% 16% 
Total 20 016 100.0%  85% 15% 
 
* unknown TNM-stage was included in I-II; cases for which TNM was not applicable (n=202) and cases with 
residence in The Hague (n=3 517) excluded 
† percentage calculated vertically 
¶ percentage calculated horizontally 
Stage distribution 
The table shows the distribution according to TNM-stage and country of birth for 
women with invasive breast cancers in the province of North-Holland. Cases with un-
known stage (two percent of all cases), mainly due to unknown tumour size, were 
considered as localised. Eighty five percent of all cancers were localised (stage I or II). 
Fifteen percents of the patients had locally advanced disease or distant metastases 
(stages III or IV). The proportion of advanced stages ranged from 13% for women 
born in Turkey to 22% for women born in the Netherlands Antilles. A logistic regres-
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sion analysis showed that, corrected for age group, the proportion of patients with 
advanced disease did not differ significantly between foreign-born women and women 
born in the Netherlands (15%). 
DISCUSSION 
The risk of breast cancer among women resident in the Netherlands but born in Suri-
nam, Turkey and Morocco is still close to the risk in their country of origin. Although no 
national incidence data are available for these countries, estimates for the year 1990 
show incidence rates that were 48 percent, 29 percent and 35 percent, respectively, of 
the rate for the Netherlands (Parkin et al, 1999). In the Netherlands Antilles, the inci-
dence was 60.9 per 100 000 women (European standardised rate) in 1987-1991, 
about 60 percent of the rate of the Netherlands during that period (Schakenraad et al., 
1995). The relatively high breast cancer risk of women born in the Netherlands Antilles 
with residence in the Netherlands, is probably due to selective migration of higher 
educated women to the Netherlands. Until recently, further education was one of the 
main motives for women to migrate to the Netherlands. 
Although the screening attendance was low for women born in non-western countries 
(personal communication A.M. van Peppen), the percentage of cases with advanced 
stages was not significantly different from the percentage in women born in the Neth-
erlands. In part, this may be explained by the relatively low number of cases among 
women born in non-western countries in the age group eligible for screening. Of all 
cases in women born in Turkey, 61 percent occurred in women below 50. For women 
born in Morocco this percentage was even 77, compared to 25 percent for women 
born in the Netherlands.  
The low incidence of breast cancer in women born in Turkey and Morocco can proba-
bly be attributed to differences in risk factors for breast cancer in comparison to native 
women, especially in relation to reproduction. Compared to women of Dutch descent, 
women born in Turkey and Morocco have more children and have their first child at an 
earlier age. Due to the fact that these women came to the Netherlands as a partner of 
(male) migrant workers, the percentage of unmarried women without children is negli-
gible (StatLine, 2003). Reproductive factors in women born in Surinam are intermedi-
ate between those in native women and women born in Turkey or Morocco. So, it is 
not surprising that breast cancer incidence among women born in Surinam is also in 
between the rates for women of Dutch descent and women born in Turkey or Mo-
rocco. The smallest differences as far as reproductive factors are concerned exist be-
tween women of Dutch descent and women born in the Netherlands Antilles. This 
probably explains why breast cancer risk among these women is close to the risk for 
women of Dutch descent. 
The higher breast cancer risk in younger women (below the age of 50) born in Mo-
rocco or Turkey when compared to older women, is probably caused by a change in 
risk factors in younger women, such as lower parity. The slightly lower breast cancer 
risk for women below the age of 50 born in Indonesia (SIR 0.83) is remarkable, al-
though the decrease is not statistically significant. Possibly this reflects differences 
between older and younger women born in Indonesia. Older women are mainly of 
Caucasian (Dutch) origin with a risk factor profile resembling that of Dutch women, 
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while younger women born in Indonesia, especially those born after the independence 
of Indonesia in 1949, are more often of ethnic Indonesian origin. So, the risk factor 
profile of young women born in Indonesia is more likely to differ from the risk factor 
profile of Dutch women than that of older women born in Indonesia. 
In conclusion, in Northwest-Netherlands, women born in Surinam, Turkey and Morocco 
have a significantly decreased breast cancer risk when compared to women born in 
the Netherlands. It will be of interest to examine the risk of second generation mi-
grants in the future. 
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ABSTRACT 
Background 
To determine breast cancer screening results according to country of birth data were 
used from the breast cancer screening organisation of the Comprehensive Cancer Cen-
tre Amsterdam, the Netherlands.  
Results 
Overall (age adjusted) attendance of the breast cancer screening was 76 percent for 
women aged 50-69. Attendance was significantly lower for women born in non-
western-countries (Surinam 59%, Turkey 44%, Morocco 37%) and for women with 
residence in Amsterdam (68%). Referral and detection rates for women from non-
western countries were 5.1 and 2.2 per 1000 screened women, respectively, compared 
to 8.8 and 4.0 for women born in the Netherlands (p<0.05). The positive predictive 
value was 45 percent for women born in the Netherlands and western countries and 
43 percent for women born in non-western countries. 
Conclusions 
Although women born in non-western countries attend breast cancer screening less 
frequently than women born in the Netherlands, they also have a low detection rate. 




Breast cancer is the most common cancer in women world-wide. Incidence rates by 
country, however, show large variations. Breast cancer incidence is particularly low in 
Central- and East-Africa, as well as in East-Asia (Ferlay et al., 1998). Most western 
countries have high breast cancer incidence rates, while the rates in the Netherlands 
are among the highest in the world (Van der Sanden et al., 1995). In the United 
States, differences in breast cancer incidence have been observed between different 
ethnic groups (Ziegler et al. 1993; Brinton et al., 1997). Studies of Japanese migrants 
to Hawaii have shown that breast cancer incidence adjusts to the incidence in the new 
homeland within one or two generations. This indicates that life style and environ-
mental factors are important factors with regard to breast cancer risk (McPherson et 
al., 2000). 
In the last decades, extensive immigration has changed the composition of the popula-
tion of the Netherlands, especially in the large cities. On January 1st 2003, 19 percent 
of the population of the Netherlands (ten percent first generation, nine percent second 
generation) and even 47 percent of the population of Amsterdam (28 percent first 
generation, 19 percent second generation) was of foreign origin (StatLine, Statistics 
Netherlands). Migrants originate primarily from the former Dutch colonies (Indonesia 
[former name: Dutch East-Indies], Surinam and the Netherlands Antilles) as well as 
Turkey and Morocco. There is also a large population of German origin. The vast ma-
jority of the second generation is still below the age of 30. 
In 1990, a national breast cancer screening programme for women between 50 and 70 
years was started in the Netherlands, its primary goal being a reduction in mortality 
due to breast cancer. In 1999, the programme was extended to women between 70 
and 75 years old. As a result of the screening, breast cancer incidence in the Nether-
lands increased by over 20 percent between 1990 and 1998 and breast cancer was 
diagnosed at an earlier stage (Van Dijck et al., 2000). Moreover, since 1997 a decrease 
in mortality was observed in the age groups 55-65 and 65-75, which is probably also 
related to the breast cancer screening (Verbeek and Broeders, 2003).  
In view of the large world-wide variation of breast cancer incidence this study aims to 
investigate whether the results of the breast screening were equal for women of Dutch 
descent and migrant women. 
MATERIALS AND METHODS 
Data on breast cancer screening 
The Comprehensive Cancer Centre Amsterdam (CCCA) hosts one of the nine regional 
organisations, responsible for breast cancer screening in the region of the CCCA, which 
covers the province of North-Holland and the major part of the province of Flevoland. 
The total population numbered 2.8 million on January 1st, 2003. Breast cancer screen-
ing for women aged 50-69 years started in 1990 and was extended in the region 
gradually, to reach region-wide coverage in 1997. As of 1999, women aged 70-74 
years are also invited. Women are invited every other year for mammography in mo-
bile screening units. Population data are derived from municipal population registers 
via the computerised population network, which operates since October 1994. These 
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data include the country of birth and as of 1995, the country of birth is available for 
almost all women. 
For this study, screening data have been used of women aged 50-74 years who were 
invited and/or screened in a second or subsequent round between January 1st 1995 
and December 31st 2002. Age has been calculated as the age at January 1st. For the 
most common countries of birth (Netherlands, Indonesia, Germany, Surinam, Turkey, 
Morocco and the Netherlands Antilles), the attendance rate (percentage of women 
screened after invitation and one recall invitation), the referral rate (RR; number of 
referred women per 1000 screened women), the detection rate (DR; number of re-
ferred women diagnosed with breast cancer per 1000 screened women), the positive 
predictive value (PPV; number of breast cancers in referred women) and the interval 
carcinoma rate (IR; number of non-referred women diagnosed with breast cancer 
within 24 months after screening per 1000 screened women) have been calculated. 
Ductal carcinoma in situ was included in the number of breast cancers. Age-
standardised rates for women aged 50-69 years have been calculated by taking the 
average of the rates for 50-54 years, 55-59 years, 60-64 years and 65-69 years. The 
countries of birth have been divided into western countries (all European countries, 
Australia, Canada, Japan, New Zealand, the United States of America and Indonesia) 
and non-western countries (all other countries). In this study, Indonesia is regarded as 
a western country, because Dutch residents born in Indonesia are predominantly of 
Dutch descent. They mainly returned to the Netherlands in the 1940s. After the inde-
pendence in 1949, immigrants from Indonesia were more often ethnic Indonesian, but 
their numbers are relatively small. 
 
Table 1. Attendance of women aged 50-69 years in the breast cancer screening programme of 
the Comprehensive Cancer Centre Amsterdam in second or subsequent rounds according to 
country of birth, 1995-2002 
Area of residence 
Amsterdam   Outside Amsterdam   Total 













Netherlands 152 440 72%  571 050 81%  724 490 79% 
Western countries:         
- Indonesia 7 440 66%  16 276 73%  23 716 71% 
- Germany 2 375 63%  6 683 72%  9 058 69% 
- Other western countries 7 446 54%  11 498 62%  18 944 59% 
Non-western countries:         
- Surinam 13 728 57%  6 042 61%  19 770 59% 
- Turkey 4 310 43%  4 256 45%  8 566 44% 
- Morocco 6 086 36%  1 931 38%  8 017 37% 
- Netherlands Antilles 1 746 57%  2 302 60%  4 048 59% 
- Other non-western countries 4 470 49%  4 444 54%  8 914 51% 
Total** 200 053 68%   624 863 79%   824 916 76% 
 
* age-adjusted 




Crude referral, detection and interval carcinoma rates, as well as the positive predictive 
values for women born outside the Netherlands were compared to the rates for 
women born in the Netherlands using the Chi2 test. 
RESULTS 
Screening attendance 
In the region of the CCCA, the number of invited women aged 50-69 years in second 
or subsequent rounds increased from 119 860 in 1995/96 to 266 820 in 2001/2002. In 
1995-2002 a total of 824 916 women were invited. The age adjusted attendance rate 
was 76 percent for all women combined (table 1). In Amsterdam, the attendance rate 
was only 68 percent, compared to 79 percent in the remaining area. Women born in 
the Netherlands had the highest attendance rate (79 percent), while for all foreign-
born women attendance was below the average. For women born in Germany or In-
donesia, the attendance rate was around 70 percent. For women born in other west-
ern countries or in non-western countries, the attendance rate was 60 percent or 
lower. Very low attendance rates were observed for women born in Turkey and Mo-
rocco (44 percent and 37 percent, respectively). For all countries of birth, attendance 
in Amsterdam was lower than outside Amsterdam, but the largest difference (nine 
percent) was observed for women born in the Netherlands and Germany. For women 
born in non-western countries the difference was much smaller. 
Table 2 shows that the attendance for all women combined was almost equal for the 
four age groups below 70 (50-54, 55-59, 60-64 and 65-69). Attendance in women of 
70 years or older was about 10 percent lower. Women born in Turkey and Morocco 
attended clearly more often below the age of 60, when compared to women of 60 
years or older. 
 
Table 2. Attendance in the breast cancer screening programme of the Comprehensive Cancer 
Centre Amsterdam in second or subsequent rounds according to age group and country of 
birth, 1995-2002 
Age group Country of birth 
50-54 55-59 60-64 65-69 70+* 
Netherlands  78% 80% 80% 77% 68% 
Western countries:      
- Indonesia  70% 70% 72% 71% 61% 
- Germany  68% 70% 72% 67% 60% 
- Other western countries 60% 60% 58% 57% 51% 
Non-western countries: 
- Surinam  61% 61% 58% 55% 46% 
- Turkey  50% 48% 40% 39% 33% 
- Morocco  39% 39% 36% 33% 27% 
- Netherlands Antilles  63% 62% 59% 50% 32% 
- Other non-western countries 54% 52% 50% 49% 34% 
Total** 76% 77% 77% 76% 67% 
 
* 1999-2002 
** including women with unknown country of birth and women born at international territory 
 Results of breast cancer screening in first generation migrants 
 43 
Referral and detection rates 
In 1995-2000 in second and subsequent screening rounds, 3 535 out of 408 963 
screened women aged 50-69 years were referred to a hospital for further examination. 
The age adjusted referral rate was 8.7 per 1000 screened women (table 3). The refer-
ral rates for women born in the Netherlands and in western countries were almost 
equal (8.8 and 8.9, respectively). The referral rate for women born in Indonesia was 
slightly higher (9.9), while the rate for women born in Germany was slightly lower 
(6.9), but this difference with women born in the Netherlands was not statistically 
significant. The referral rate for women born in non-western countries was only 5.1, 
almost half the rate for all women combined (p<0.05 when compared to women born 
in the Netherlands). Only for women born in the Netherlands Antilles the referral rate 
was close to the average for all women combined. 
 
Table 3. Referral, detection and interval carcinoma rates for women aged 50-69 years in the 
breast cancer screening programme of the Comprehensive Cancer Centre Amsterdam in second 
or subsequent rounds according to country of birth, 1995-2000 
Country of birth screened women 
RR* DR* PPV* IR* 
Netherlands 373 432 8.8 4.0 45% 2.2 
Western countries: 21 521 8.9 4.0 45% 2.4 
- Indonesia 10 881 9.9 4.7 47% 1.9 
- Germany 4 127 6.9 3.4 49% 3.1 
- Other western countries 6 513 8.3 3.3 39% 2.2 
Non-western countries: 13 896 5.1† 2.2† 43% 1.2† 
- Surinam 6 690 4.5† 1.5† 38% 1.5 
- Turkey 1 943 4.0† 1.8† 33% 2.1 
- Morocco 1 493 4.6 0.8 17% 0.0 
- Netherlands Antilles 1 378 8.5 6.8 75% 1.4 
- Other non-western countries 2 392 6.9 2.8 32% 0.5 
Total** 408 963 8.7 3.9 45% 2.2 
 
† p<0.05 when compared to women born in the Netherlands 
* RR = age-adjusted referral rate (number of referrals per 1000 screened women); DR = age-adjusted 
detection rate (number of breast cancers in referred women per 1000 screened women); PPV = age-
adjusted positive predictive value (number of breast cancers per 100 referred women); IR = age-adjusted 
interval carcinoma rate (number of breast cancers in non-referred women within 2 years after screening per 
1000 screened women) 
** including women with unknown country of birth and women born at international territory 
 
Breast cancer (DCIS included) was diagnosed in 1 577 out of 3 535 referred women 
(PPV 45 percent). The age adjusted detection rate for all women combined was 3.9 
per 1000 screened women in 1995-2000 (table 3). The detection rates for women born 
in the Netherlands and western countries were close to this average and the PPV was 
almost equal. In women born in non-western countries the detection rate was only 2.2 
(p<0.05 when compared to women born in the Netherlands). Very low detection rates 
were observed for women born in Surinam, Turkey and Morocco (1.5, 1.8 and 0.8, 
respectively). Due to very small numbers (only 2 cancers detected) the rate for women 
born in Morocco was not statistically significantly different from the rate for women 
born in the Netherlands. The detection rate for women born in the Netherlands Antilles 
was rather high (6.8 per 1000 screened women), but due to small numbers this was 
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not statistically significant either. The PPV of all non-western women combined (43 
percent) was almost equal to the PPV for women born in the Netherlands (45 percent). 
Table 3 also shows the interval carcinoma rates (DCIS included). Like the referral and 
detection rates, the interval carcinoma rates for women born in non-western countries 
were about half the rates of women born in the Netherlands (p<0.05), with the excep-
tion of women born in Turkey (2.1). 
DISCUSSION 
Attendance rates for breast cancer screening for women born in non-western countries 
are lower than for women born in the Netherlands and western countries. Women 
born in Morocco and Turkey have the lowest attendance rate, followed by women born 
in Surinam. The referral and detection rates of attending women born in non-western 
countries are also low, but the positive predictive value is almost equal to the positive 
predictive value of women born in the Netherlands and western countries. 
A low screening attendance of especially women born in Morocco and Turkey, in com-
parison to women of Dutch descent, has also been observed in cervical cancer screen-
ing in the Netherlands (Visser et al., 2003). However, in cervical cancer screening, the 
attendance rate of Dutch women is also relatively low and the difference between 
migrant women and women born in the Netherlands is smaller than for breast cancer 
screening. The relatively low attendance of migrant women in the breast cancer 
screening may be related to the higher average age of women invited to the breast 
cancer screening (50-69) when compared to the cervical cancer screening (30-60). For 
women born in Turkey and Morocco, we found a clear association between age and 
attendance (the higher the age, the lower the attendance).  
This study did not investigate the motives of women for non-attendance. However, a 
pilot study among Turkish women about (non-)attendance of the cervical cancer 
screening, revealed that command of the Dutch language and contentment with the 
general practitioner were associated with attendance, while ‘absence of symptoms’ has 
often been mentioned as a reason for non-attendance (Lâle et al., 2003). Absence of 
symptoms could also be a motive for not attending the breast cancer screening. Be-
cause the invitational letter for breast cancer screening is in Dutch, command of the 
language can also be associated with the (non-)attendance of Turkish and Moroccan 
women in the breast cancer screening, as the ability of these women to speak and 
understand the Dutch language is often poor. The majority of women born in Surinam 
or the Netherlands Antilles, however, speak Dutch and this may be an explanation for 
their higher attendance when compared to women born in Turkey or Morocco. Finally, 
religion (most women born in Morocco and Turkey are Moslem) may also have influ-
enced the attendance. 
In other countries differences in attendance to screening programmes have also been 
observed for various ethnic minorities, for example in the United Kingdom, Singapore 
and the United States (Kernohan, 1996; Seow et al., 1997; Suarez et al., 1994). In 
Sweden, immigrants from non-Nordic countries were more than twice as likely to be 
non-attenders compared with Swedish-born women (Lagerlun et al., 2002). 
Although attendance of foreign-born women in Amsterdam was slightly lower than 
outside Amsterdam, residence in Amsterdam was of less relevance than for women of 
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Dutch descent. In high-income districts of Amsterdam, breast cancer surveillance out-
side the screening programme, for example because of an increased breast cancer 
risk, may be an explanation for the relatively low attendance of women of Dutch de-
scent in Amsterdam when compared to women residing outside Amsterdam. In low-
income districts, there may be an association with socio-economic status.  
The low referral, detection and interval carcinoma rates in women born in non-western 
countries reflect the low breast cancer incidence in these women (Visser et al, 2004). 
The low incidence of breast cancer in women born in Turkey and Morocco can proba-
bly be attributed to differences in risk factors for breast cancer in comparison to native 
women, especially in relation to reproduction. Compared to women of Dutch descent, 
women born in Turkey and Morocco have more children and have their first child at an 
earlier age. Due to the fact that these women came to the Netherlands as a partner of 
(male) migrant workers, the percentage of unmarried women without children is negli-
gible (StatLine, Statistics Netherlands). Use of hormones during menopause is proba-
bly also lower than among women of Dutch descent. Reproductive factors in women 
born in Surinam are intermediate between those in native women and women born in 
Turkey or Morocco. So, it is not surprising that breast cancer incidence among women 
born in Surinam is also in between the rates for women of Dutch descent and women 
born in Turkey or Morocco. The smallest differences as far as reproductive factors are 
concerned exist between women of Dutch descent and women born in the Netherlands 
Antilles. This probably explains why breast cancer risk among these women is close to 
the risk for women of Dutch descent. 
In conclusion, the majority of women born in Turkey and Morocco and more than one 
third of the women born in Surinam do not attend breast cancer screening. Because 
these women also have a low breast cancer risk, a passive attitude towards the low 
attendance of first generation migrants seems as yet justified. This may not apply to 
second generation migrants. It will, however, take at least 20 to 30 years before sec-
ond generation migrants are old enough to participate in breast cancer screening or 
develop breast cancer in substantial numbers.  
ACKNOWLEDGEMENTS 
We thank the registration clerks of the Comprehensive Cancer Centre Amsterdam for 
the data collection of screened women referred to a hospital for further evaluation. 
REFERENCES 
Brinton LA, Benichou J, Gammon MD, Brogan DR, Coates R, Schoenberg JB (1997). Ethnicity and variation in 
breast cancer incidence. Int J Cancer 73: 349-355 
Ferlay J, Parkin DM, Pisani P (1998). GLOBOCAN1: Cancer Incidence and Mortality Worldwide. CD-ROM of 
International Agency for Research on Cancer, World Health Organization. Lyon: IARC Press 
Kernohan EE (1996). Evaluation of a pilot study for breast and cervical cancer screening with Bradford's 
minority ethnic women; a community development approach, 1991-93. Br J Cancer Suppl. Sep; 29: 
S42-46 
Lagerlun M, Maxwell AE, Bastani R, Thurfjell E, Ekbom A, Lambe M (2002). Sociodemographic predictors of 
non-attendance at invitational mammography screening--a population-based register study (Swe-
den). Cancer Causes Control 13: 73-82 
Lâle N, Öry F, Detmar S (2003). Factoren die geassocieerd zijn met het niet deelnemen van Turkse vrouwen 
aan screening op baarmoederhalskanker. Tijdschr Soc Geneeskd 81: 184-188 
Chapter 2.3 
 46 
McPherson K, Steel CM, Dixon JM (2000). Breast cancer – epidemiology, risk factors, and genetics. Br Med J 
321: 624-628 
Parkin DM, Pisani P, Ferlay J (1999). Estimates of the worldwide incidence of 25 major cancers in 1990. Int J 
Cancer 80: 827-841 
 Schakenraad J, Coronel C, Otter R (1995). Kankerincidentie in de Nederlandse Antillen 1982-1991. Gronin-
gen/Willemstad: Laboratorium voor de Volksgezondheid 
Seow A, Straughan PT, Ng EH, Emmanuel SC, Tan CH, Lee HP (1997). Factors determining acceptability of 
mammography in an Asian population: a study among women in Singapore. Cancer Causes Control 
8: 771-779 
StatLine. Statistics Netherlands. http://statline.cbs.nl/StatWeb/start.asp?lp=Search/Search 
Suarez L, Lloyd L, Weiss N, Rainbolt T, Pulley L (1994). Effect of social networks on cancer-screening behav-
ior of older Mexican-American women. J Natl Cancer Inst 86: 775-779 
Van der Sanden GA, Coebergh JWW, Schouten LJ, Visser O, van Leeuwen FE (1995). Cancer Incidence in 
the Netherlands in 1989 and 1990. First results of the nationwide Netherlands Cancer Registry. Eur J 
Cancer 31: 1822-1829 
Van Dijck JAAM, Hendriks JHCL, Holland R, Schouten LJ, Verbeek ALM (2000). Veranderde stadiumverdeling 
van borstkanker sinds de invoering van de landelijke screening: onderzoek over de periode 1989-
1995. Ned Tijdschr Geneeskd 144: 1119-1124 
Verbeek AL, Broeders MJ (2003). Evaluation of The Netherlands breast cancer screening programme. Ann 
Oncol 14: 1203-1205 
Visser O, Busquet EH, van Leeuwen FE, Aaronson NK, Öry FG (2003). Incidentie van baarmoederhalskanker 
naar geboorteland bij vrouwen in Noord-Holland in 1988-1998. Ned Tijdschr Geneeskd 147: 70-74 
Visser O, Van der Kooy K, Van Peppen AM, Öry FG, Van Leeuwen FE (2004). Breast cancer risk among first 
generation migrants in the Netherlands. Br J Cancer(in press). 
Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AM, West DW, Wu-Williams AH, Kolonel LN, Horn-
Ross PL, Rosenthal JF. (1993). Migration patterns and breast cancer risk in Asian-American women. J 
Natl Cancer Inst 85: 1819-1827. 
 
3 
THE ENVIRONMENT AND CANCER 
 
 
3.1 Incidence of cancer in the area around 
Amsterdam Airport Schiphol in 1988-
2003; a population-based ecological study 
Visser O, Van Wijnen JH, Van Leeuwen FE. Incidence of cancer in the area around 
Amsterdam Airport Schiphol in 1988-2003; a population-based ecological study. 
BMC Public Health (accepted for publication) 
ABSTRACT 
Background 
Amsterdam Airport Schiphol is a major source of complaints about aircraft noise, safety 
risks and concerns about long term adverse health effects, including cancer. We inves-
tigated whether residents of the area around Schiphol are at higher risk of developing 
cancer than the general Dutch population. 
Methods 
In a population-based study using the regional cancer registry, we estimated the can-
cer incidence during 1988-2003 in residents of the area surrounding Schiphol. We de-
fined a study area based on aircraft noise contours and 4-digit postal code areas, since 
historical data on ambient air pollution were not available and recent emission data did 
not differ from the background urban air quality. 
Results 
In residents of the study area 13 207 cancer cases were diagnosed, which was close to 
the expected number, using national incidence rates as a reference (standardized inci-
dence ratio [SIR] 1.02). We found a statistically significantly increased incidence of 
hematological malignancies (SIR 1.12, 95% confidence interval [CI]: 1.05, 1.19), 
mainly due to high rates for non-Hodgkin lymphoma (SIR 1.22, 95% CI: 1.12, 1.33) 
and acute lymphoblastic leukemia (SIR 1.34, 95% CI: 0.95, 1.83). The incidence of 
cancer of the respiratory system was statistically significantly decreased (SIR 0.94, 
95% CI: 0.90, 0.99), due to the low rate in males (SIR 0.89). In the core zone of the 
study area, cancer incidence was slightly higher than in the remaining ring zone (rate 
ratio of the core zone compared to the ring zone 1.05, 95% CI 1.01, 1.10). This was 
caused by the higher incidence of cancer of the respiratory system, prostate and the 
female genital organs in the core zone in comparison to the ring zone.  
Conclusions 
The overall cancer incidence in the Schiphol area was similar to the national incidence. 
The moderately increased risk of hematological malignancies could not be explained by 
higher levels of ambient air pollution in the Schiphol area. This observation warrants 
further research, for example in a study with focus on substances in urban ambient air 




Amsterdam Airport Schiphol is one of the main airports of Europe. The airport is a 
major source of complaints about aircraft noise, noise related adverse health effects 
and – especially since the crash of an airplane in a suburb of Amsterdam on October 
4th 1992 – about safety risks. A longstanding subject of concern of the surrounding 
population is the exposure to aviation fuels and their combustion products and an al-
leged increase of cancer risk. Particularly in warm summers the smell of aviation fuels 
can be distinguished outside the airport grounds. Aircraft emissions vary with the en-
gine type, the engine load and the kind of fuel. Combustion of aviation fuels results in 
CO2, CO, Ce, NOx ,particles, and a great number of other organic compounds, among 
which a number of carcinogens [1]. Among the emitted polycyclic aromatic hydrocar-
bons no compound characteristic for aircraft engines has been detected so far.  
A committee of the Health Council of The Netherlands recently reviewed the data on 
the health impact of large airports [2]. It was concluded that, generally, integrated 
health assessments are not available. In the last 30 years, several adverse health ef-
fects in relation to exposure to aircraft noise have been the subject of study, such as 
the use of tranquillizers, the prevalence of bronchitis and cardiovascular disease as 
well as child stress responses and cognition [3-6]. However, little information is avail-
able in the international literature on cancer risk in relation to airports. 
In the late 1980s, mortality due to cancer in the community of Haarlemmermeer, 
which hosts Schiphol, was investigated by the Municipal Health Service of Amsterdam 
on request of the general practitioners in the area [7]. The total cancer mortality and 
the lung cancer mortality in Haarlemmermeer during 1981-86 did not differ statistically 
significantly from the cancer mortality in the two standard populations that were used. 
The mortality due to non-Hodgkin lymphoma (NHL) was statistically significantly in-
creased, but conclusions as to the cause of the excess mortality were not possible.  
In the 1990s, we carried out a first study on the incidence of cancer in the vicinity of 
Schiphol, as part of the health surveillance of the resident population of the Schiphol 
area [8]. During 1988-1993, the incidence of cancer in the area around Schiphol was 
close to the national average. The differences in incidence of certain types of cancer in 
comparison to the national average, as well as those between two study areas charac-
terized by different levels of increased aircraft noise, were considered to be most likely 
due to differences in life style, such as smoking. In order to investigate whether cancer 
risk of the resident population of the Schiphol area (in comparison to the national av-
erage) changed since 1988-1993, we continued monitoring cancer incidence and we 
report here on the second, much larger population-based study of the cancer incidence 
around Schiphol. 
METHODS 
Definition of the study population and the study area 
When we designed our first study, relevant exposure data on the ambient air quality 
around Schiphol airport were lacking and we could not define a study population ex-
posed to increased ambient levels of aircraft emissions. The airport itself has no per-
manent residents and the most heavily exposed population – the airport personnel and 
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the travelers – cannot be defined geographically. Therefore, we defined our study 
population as the population most heavily exposed to increased levels of aircraft noise. 
Since 1994, the ambient air quality outside Schiphol has been monitored and no differ-
ences with the background urban air quality have been reported for the compounds 
that were measured [9]. Table 1 summarizes the results of the three monitoring loca-
tions in the Schiphol area. 
 
Table 1. Summary of the results in µg/m3 (except benzo(a)pyrene: ng/m3) of the air quality 
monitoring system of the Schiphol area in 2002 
Location of monitoring station Pollutant Unit Limit
Badhoevedorp Oude Meer Hoofddorp
NO2 year average 40a 38 38 31
 maximum 200b 163 544(1x>200) 124
CO P98 (8 hours) 9 000 112 100 88
 P99.9 40 000 134 165 160
O3 maximum 240c 185 174 266 (2x>240)
PM10 average (year) 40d,e 26 24 28
 maximum (24 hours) 50d,f 81 (13x>50) 81 (8x>50) 132 (22x>50)
Benzene year average 10 1.4 1.1 0.7
Black smoke P98 (24 hours) 90g 42 48 34
Benzo(a)pyrene year average 1 0.14  
 
a as of 1-1-2010; b exceeding of the limit no more than 18 times per annum; c exceeding of the limit not more 
than 48 hours; d including factor 1.3; e as of 1-1-2005; f exceeding of the limit no more than 35 times per 
annum; g the limit expired in July 2001  
PM10 = particulate matter <10 µm  
 
However, it is possible that exposure to aircraft emissions has been greater in the past 
when aircraft engines used to be technologically and ecologically less advanced. Also, 
we cannot exclude that certain carcinogenic compounds specific to aviation combus-
tion have not been monitored. Since most cancers have a long induction period and 
the noise contours are thought to reflect best the historical exposure of the surround-
ing population to aircraft emissions, we continued to use the levels of aircraft noise to 
define our study area. The aircraft noise levels of 1991 were available as so-called 
Kosten-units (Ku) [10]. We used the 35 Ku contour and extended the area with about 
2 km outside the 35 Ku contour (figure 1). This total area (surrounded by the solid 
black line in figure 1) was redefined as 4-digit postal code areas (postal code areas 
surrounded by grey lines in figure 1). The four airstrips of the airport are easily recog-
nized by noise levels over 50 Ku. We also defined a core zone for the 4-digit postal 
code areas within the 45 Ku contour (the area bordered by the blue line in figure 1), 
although we do not have empirical data showing that this zone corresponds to a zone 
with increased levels of ambient air pollution. The remaining study area surrounding 
the core zone we designated as ‘ring zone’. The location of the three air quality moni-
toring stations (Badhoevedorp, Hoofddorp, Oude Meer) is also indicated in figure 1. 
The total study area with a population of 177 000 on 31 December 2003 comprised 
(parts of) five municipalities (table 2). Table 2 also includes figures on per capita in-





Figure 1. Noise exposure (in Kosten-units) in the Schiphol area in 1991. The area sur-
rounded by the grey line indicates the core zone, the black line includes the total study 
area. The location of the three air quality monitoring stations are indicated by asterisks 
(*). 
Population data 
Annual population data covering the period 1995-2003 according to 4-digit postal 
code, 5-year age groups and sex, were available for all municipalities from Statistics 
Netherlands. For the period 1988-1994 we used data from the municipal administra-
tions. 
Cancer registry data 
The Amsterdam Cancer Registry (ACR) is a regional, population-based cancer registry 
with complete regional coverage since 1988. The ACR is part of the nation-wide Neth-
erlands Cancer Registry (NCR) [11]. Completeness of the NCR is estimated to be over 
95%. The information is extracted from the medical records by registration clerks. 
Apart from demographic data, data are collected on tumor site, morphological classifi-
cation (according to the International Classification of Diseases for Oncology [ICD-O], 
versions 1 and 2), stage of the tumor and treatment of the patients. The third version 
of the ICD-O was introduced in the NCR for cases diagnosed as of January 2001. 
Cases diagnosed in a hospital outside the ACR region but with residence in the ACR 
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region are routinely obtained from the national registry and included in our regional 
registry. Consequently, these cases could be included in the study. 
We selected from the registry all cancer cases in the period 1988-2003 with residence 
in the area around Schiphol airport at the date of diagnosis. We stratified the cases 
according to type of cancer (or group of cancers), area of residence (core zone or the 
ring zone), 5-year age group and sex.  
 
Table 2. Some characteristics of the Schiphol study area 




Core zone 30 590 31 850 €10 900† 
1161 8 300 7 820 €10 700 
1175, 1435-8, 2143 6 880 6 015 €11 000 
2132 7 815 10 965 €11 000 
Haarlemmermeer 
2153 3 520 3 310 €10 500 
Amstelveen 1182 4 075 3 740 €11 500 
Ring zone 131 210 144 870 €11 800† 
1171 10 750 11 770 €13 200 
2131 10 205 11 030 €11 400 
2151-2 11 925 22 260 €11 100 
Haarlemmermeer 
2154-8, 2165 5 585 5 940 €10 300 
Amstelveen 1181, 1183 31 145 30 385 €12 400 
Amsterdam 1067, 1081-3 34 960 35 080 €14 500 
Aalsmeer 1431-3 21 740 22 870 €11 300 
Haarlemmerliede & Spaarnwoude 1165, 2064-5 4 900 5 535 €10 800 
Total study area  161 800 176 720 €11 700† 
 
* the national average in 1998 was €10 00 
† weighed average, rounded to €100  
Statistical methods 
In our analysis, the incidence of cancer in the national population of the Netherlands 
served as the reference entity. The expected numbers of cancer (E) for the Schiphol 
area were calculated for three periods (1988-1993, 1994-1998 and 1999-2003), based 
on the population data of the Schiphol area (according to 5-year age category and 
sex) and the 5-year age category and sex-specific cancer incidence rates from the 
NCR. For the period 1988-1993 we used the average incidence rates of the NCR cover-
ing the period 1989-1993 [12], because data for 1988 were not available from the 
NCR. For the periods 1994-1998 and 1999-2003 we used NCR-data covering 1994-
1998 and 1999-2003, respectively [13]. The expected numbers were compared with 
the observed numbers (O) and standardized incidence ratios (SIRs) were calculated as 
the ratio between the observed and expected numbers. Exact 95%-confidence inter-
vals (CI) based on the Poisson distribution of O were calculated using STATA 7.0 
(STATA Corporation. College Station, Texas, USA). Rate ratios (RR) for the core zone 
were calculated by dividing the standardized incidence ratio of the core zone by the 
rate of the ring zone. Ninety five percent CIs of RRs were calculated assuming a log-
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RESULTS 
In 1988-2003, a total of 13 207 cancers (6 739 in males, 6 468 in females) were diag-
nosed among residents of the Schiphol area (table 3), which included 2 352 cases 
among residents of the core zone. Table 3 shows, that the total number of observed 
cancers was close to the expected number (SIR 1.02, 95% CI: 1.00, 1.03), in males 
(SIR 1.00, 95% CI: 0.97, 1.02) as well as in females (SIR 1.03, 95% CI: 1.01, 1.06). 
The observed number of cancers of the respiratory system (predominantly lung can-
cer) in females was increased (SIR 1.13, 95% CI: 1.03, 1.24), but the number in both 
sexes combined was statistically significantly decreased (SIR 0.94, 95% CI: 0.90, 
0.99). This was caused by a relatively low incidence in males (SIR 0.89, 95% CI: 0.84, 
0.94). A similar pattern was observed for cancer of head and neck (SIR females 1.25, 
95% CI 1.04, 1.49; SIR males 0.92, 95% CI 0.78-1.07).The incidence was statistically 
significantly increased for hematological malignancies (SIR 1.12, 95% CI: 1.05, 1.19, 
1044 cases). The raised risk was most prominent in males (SIR males 1.18, 95% CI: 
1.09, 1.28, SIR females 1.04, 95% CI: 0.95, 1.14). A statistically significantly increased 
incidence was observed for NHL (SIR 1.22, 95% CI: 1.12, 1.33, 516 cases), while the 
confidence interval for acute lymphoblastic leukemia (ALL; SIR 1.34, 95% CI: 0.95, 
1.83, 39 cases) included unity. A relatively low rate was observed for Hodgkin lym-
phoma (SIR 0.78, 95% CI: 0.58, 1.04).Classification of lymphoid malignancies accord-
ing to the WHO-classification, revealed relatively high rates for lymphoplasmocytic 
lymphoma (SIR 1.5, 95% CI: 1.1, 2.9), follicular lymphoma (SIR 1.5, 95% CI: 1.2, 
1.8), diffuse large B-cell lymphoma (SIR 1.6, 95% CI: 1.4, 1.9) and T-cell lymphoma 
(SIR 1.4, 95% CI: 1.0, 1.8). The rates for plasma cell tumors (SIR 1.1, 95% CI 0.9, 
1.3), small lymphocytic lymphoma/chronic lymphocytic leukemia (SIR 0.8, 95% CI: 
0.6, 1.0) and other & unspecified lymphoma/leukemia (SIR 1.0, 95% CI: 0.8, 1.2) 
were not increased.  
Cancer was diagnosed in 74 children up to 15 years of age, which was relatively high 
(SIR 1.26, 95% CI 0.99, 1.58), due to the higher than expected number of children 
with ALL (23 cases, SIR 1.59, 95% CI 1.01, 2.39). 
For most cancer sites, the SIRs for the periods 1988-1993, 1994-1998 and 1999-2003 
were quite similar. The increased risk of hematological malignancies was consistently 
observed in the three time periods. An increased number of breast cancer cases was 
observed in the 1994-1998 period (SIR 1.09, 95% CI 1.01, 1.18). An increased num-
ber of cancer of the bladder and other urinary organs in males was only observed in 
1988-1993 (SIR 1.24, 95% CI 1.06, 1.44). 
Cancer incidence in the core zone  
Table 4 shows that cancer incidence in the core zone was slightly increased in com-
parison to the national incidence (SIR 1.06, 95% CI 1.02, 1.10) as well as in compari-
son to the ring zone (RR 1.05, 95% CI 1.01, 1.10), mostly because of an increased 
incidence in males (SIR 1.07, 95% CI 1.01, 1.13; RR 1.09, 95% CI 1.03, 1.16). Statis-
tically significantly increased numbers in the core zone in comparison to the ring zone 
were observed for cancer of the respiratory system (RR 1.27, 95% CI 1.12, 1.45) and 
prostate (RR 1.17, 95% CI 1.02, 1.34) in males and for cancer of the genital organs in 
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(cervix 1.20, corpus 1.04, ovary 1.55, vulva & other 1.17). In comparison to the na-
tional incidence only cervical cancer and ovarian cancer were increased (SIR cervix 
1.29, corpus 1.00, ovary 1.32, vulva & other 0.98). In the core zone, the incidence 
rate of bladder cancer in males (SIR 1.26, 95% CI 1.01, 1.56; RR 1.20, 95% CI 0.94, 
1.52) was also relativity high. The incidence of hematological malignancies was higher 
in the core zone than in the to the ring zone, but the increase was not statistically 
significant (RR 1.06, 95% CI 0.91, 1.24). 
DISCUSSION 
The major finding of our study is that total cancer incidence in the area around Schi-
phol airport was almost equal to the national cancer incidence (SIR 1.02). Further-
more, the incidence of hematological malignancies was statistically significantly in-
creased, while the incidence of cancer of the respiratory system was statistically sig-
nificantly decreased. We observed an excess risk in children aged 0-14 (SIR 1.26). The 
cancer incidence in the core zone was slightly increased in comparison to the ring 
zone, due to an excess risk of cancer of the respiratory tract and prostate in males and 
cancer of the genital organs in females. 
As the overall incidence of cancer of the respiratory tract was decreased (SIR 0.94), 
this observation does not support a positive association between the airport and the 
occurrence of cancer of the respiratory tract. The incidence pattern of respiratory sys-
tem cancer in the Schiphol area, i.e. low rates in males and somewhat higher rates in 
the core zone and among females, is well within the normal regional variation in the 
Netherlands. Because smoking is the most important risk factor for lung cancer [15], 
and there is evidence of substantial regional variation in smoking habits in the Nether-
lands [16], smoking is likely to be responsible for the differences in respiratory system 
cancer (mainly lung cancer) between the Schiphol area and the Netherlands overall. 
Unfortunately, no data on smoking habits according to postal code in the Schiphol area 
are available. Lung cancer incidence in the 1990s in males was lowest in high income 
areas in the Netherlands. In females, low rates were found in rural areas, while high 
rates were observed in urban areas [17]. The slightly increased incidence of cancer of 
the respiratory system in females is in accordance with the moderately urbanized 
status of the Schiphol area. The data on per capita income (table 2) support the as-
sumption that the low incidence of cancer of the respiratory system in males is related 
to the high per capita income of the Schiphol area. However, within the Schiphol area 
only a weak association was observed between the incidence of lung cancer and per 
capita income by postal code area (data not shown). This may be due to relatively 
small numbers by postal code area and the long induction period of lung cancer as the 
regional variation in lung cancer incidence can best be explained by the smoking habits 
10 to 30 years ago.  
In a number of studies in urban areas an increase of lung cancer incidence or mortality 
was observed [18,19], mostly attributed to differences in smoking habits. However, 
there is increasing evidence for a relation between lung cancer risk and ambient air 
pollution [20,21]. Although we cannot exclude the possibility that the incidence of 
cancer of the respiratory system in the absence of the airport would even have been 
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lower than the observed incidence, the pattern of the observed incidence does not 
render this very likely.  
The statistically significantly increased rate for breast cancer in 1994-1998 (SIR 1.09 
for the total study area) is also within the observed regional variation in the Nether-
lands. Part of this variation can be explained by local variation in the start of the na-
tional screening program for breast cancer. The relatively high incidence of breast 
cancer in 1994-1998 is probably related to the start of screening in the Schiphol area 
in that period.  
We do not have an explanation for the relatively high incidence of cancer of the female 
genital organs in the core zone (RR in comparison to the ring zone 1.24). Possibly, this 
is only a chance finding, as despite the large variation in risk factors for the specific 
sites the incidence of all specific sites was increased, while the SIR in comparison to 
the general population was not statistically significantly increased. An association with 
pollution has not been described for cancer of the female genital organs. Moreover, in 
the total study area the incidence of these cancers was not increased (SIR 0.97).  
The most striking observation in our study is the increased incidence of hematological 
malignancies, which was observed consistently over three periods, mostly in males but 
also in females. The increase was more pronounced in the core zone. The increased 
incidence was mostly due to increased numbers of cases of ALL and NHL (especially 
lymphoplasmocytic lymphoma, follicular lymphoma, diffuse large B-cell lymphoma and 
T-cell lymphoma, but not small lymphocytic lymphoma/chronic lymphocytic leukemia 
[SLL/CLL]), while the incidence of Hodgkin lymphoma was decreased. However, pa-
thology could not be reviewed in this study and different classification systems of lym-
phoma have been used by pathologists during the study period.  
The moderately increased cancer incidence in children (about one supplementary case 
per year) was mainly caused by the increased number of cases of ALL, as ALL occurs 
mainly in children. 
Also from a national perspective, the number of cases of NHL was markedly increased. 
In the Netherlands in 1989-1998, the highest rate of NHL in males was found in 
Greater-Amsterdam, which includes the Schiphol area (source: the Netherlands Cancer 
Registry). In females in Greater-Amsterdam, the incidence of NHL was also relatively 
high. Chance is not a likely explanation for our finding of an increased incidence of 
NHL, since the increase was consistently observed over three time periods. The rela-
tively high incidence of NHL in the Schiphol area is also consistent with an increased 
mortality due to NHL already reported in Haarlemmermeer in 1981-1986 [7]. In sev-
eral studies, an increased risk of hematological malignancies was found for farmers, 
which is related to the use of pesticides, infectious micro-organisms or working with 
beef cattle [22-27]. However, although the Schiphol area includes a few areas with 
intensive agricultural activities, the increased risk for hematological malignancies was 
also found in areas with few agricultural activities.  
Several studies have shown that the incidence of NHL is correlated with nitrate in mu-
nicipal drinking water due to nitrogen fertilizers [28,29] and is increased in ur-
ban/industrialized areas [30,31]. Hatzissabas et al found that the incidence of large cell 
high malignancy lymphomas is highest in industrialized regions with pollution of water 
supplies by more toxic and immunosuppressive substances, while CLL is more frequent 
in areas with rather low-dose chronic influences such as from the use of fertilizers and 
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pesticides in farming [32]. The pattern of NHL in the Schiphol area -increase of follicu-
lar and diffuse large B-cell lymphoma, but not SLL/CLL- might indicate a relation with 
pollution which is also found in urban areas.  
However, an association between the incidence of hematological malignancies and the 
environment in the Schiphol area is not supported by the available data on ambient air 
quality. Measurements in 1989 at the airport grounds of Schiphol showed increased 
levels of ambient air pollutants, including polycyclic aromatic hydrocarbons which are 
probably or possibly carcinogenic according to the International Agency for Research 
on Cancer, but not in the direct vicinity outside the airport ground [33]. Morphology 
and composition of soot emitted by aircraft at Schiphol showed great similarities with 
soot emitted by the road traffic. Only different profiles of hydrocarbons in the range of 
C6–C12 in emissions from aircraft engines, aviation fuels and road traffic were re-
ported. Since 1994, three locations in the vicinity of Schiphol are part of the provincial 
monitoring network for ambient air quality measurement [34]. During 1994-2002, the 
concentrations of the air pollutants NO2, CO, O3, PM10  (particulate matter <10 µm), 
benzo(a)pyrene, benzene and black smoke at the three locations in the Schiphol area 
were stable and well comparable to urban background levels in Amsterdam [9]. A 
more detailed investigation at 59 additional locations in the Schiphol area in 2000/2001 
revealed that the average contribution of air traffic emissions and of aviation fuel stor-
age and transfer to the total concentration of volatile hydrocarbons in the area around 
Schiphol were only 3%, and up to 5-7% at individual locations [35]. Road traffic con-
tributed 28%. For CO, NO2 and PM10, no relevant influence of emissions of Schiphol 
on ambient pollutant levels could be determined. Although we cannot exclude the pos-
sibility that residents of the Schiphol area have been exposed to air pollutants that 
were not measured or that higher levels of air pollutants have existed in the past, the 
results of the ambient air quality monitoring and the source appointment of air pollut-
ants render it unlikely that aircraft emissions have contributed substantially to the total 
levels of pollutants in the ambient air of the Schiphol area. It therefore seems unlikely 
that the increased incidence of hematological malignancies is specifically related to 
ambient air pollution caused by aircraft emissions. 
Our results should be interpreted considering the strengths and limitations of the study 
design. An advantage is the availability of high quality data from a population-based 
cancer registry over a period of sixteen years. However, the use of the national cancer 
incidence as a reference has its limitations. Preferably, the cancer incidence in a popu-
lation which is comparable to the Schiphol region as far as urbanization, socio-
economic status and smoking habits, should be used. Unfortunately, such a reference 
population is not available. Another limitation of the study is that only cancer cases 
that were residents of the Schiphol area at the date of diagnosis were included in the 
study. Part of the original residents will have left the area, while others only recently 
settled in the area. The effect of migration (non-differential misclassification) usually 
results in an underestimation of the risk at study. 
CONCLUSIONS 
The overall cancer incidence in the Schiphol area was similar to the national incidence 
in the Netherlands. An association was found between residence in the Schiphol area 
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and a moderately increased incidence of hematological malignancies, especially NHL 
and ALL. However, the increased risk of hematological malignancies could not be ex-
plained by higher levels of ambient air pollution in the Schiphol area, while similarly 
increased rates were observed in Greater Amsterdam. Further studies, for example a 
study with focus on substances in urban ambient air pollution, are necessary in order 
to elucidate the causes of the observed association. 
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ABSTRACT 
Objective 
To examine the association between cancer incidence in 1989-97 in Amsterdam and 
residential traffic intensity. 
Methods 
We linked data on the daily traffic intensity for individual addresses along the main 
roads with the population-based regional cancer registry. Information on smoking hab-
its was derived from a smoking survey. 
Results 
During 1989-1997, 27 157 cancer cases were diagnosed in Amsterdam residents. Us-
ing the age group- and sex-specific cancer incidence in the population not residing 
along the main roads as a reference, the standardised incidence ratio (SIR) of the 
population residing along the main roads was 1.03, (3 384 cases), while the 95% con-
fidence interval (CI) included unity (1.00–1.07). For most cancer sites the SIR was 
close to 1, except for gastrointestinal cancer in males (SIR 1.16, CI: 1.04, 1.28), can-
cer of the respiratory tract in females (SIR 1.13, CI: 0.97, 1.31) and haematological 
malignancies in adult females (SIR 1.23, CI: 1.04, 1.44). Five cases of acute lympho-
cytic leukaemia were diagnosed in children along the main roads (SIR 2.5, CI: 0.8, 
5.9). Smoking habits did not differ between residents along the main roads and those 
living along other roads.  
Conclusions 
We found no clear evidence for an association between residence along main roads 
and the incidence of cancer in adults, but we cannot exclude an association with hae-
matological malignancies in females and children.  
ABBREVIATIONS USED 
ALL = acute lymphocytic leukaemia; CI = confidence interval; E = expected (number); 
O = observed (number); OR = odds ratio; SES = socio-economic status; SIR = stan-




In many urban areas road traffic is the major source of local air pollution. In a number 
of studies, elevated concentrations of especially black smoke and NO2 were measured 
in the ambient air near traffic routes and busy streets compared to the ambient urban 
background.1 Black smoke is indicative of diesel exhaust.2 The International Agency for 
Research on Cancer has classified the emission of diesel engines as probably carcino-
genic (2A) and the emission of gas engines as possibly carcinogenic (2B).3 
The relation between ambient air pollution and cancer has been the subject of numer-
ous studies in the general population or in occupationally exposed populations. In a 
number of studies urban air pollution was reported to be associated with (lung) can-
cer.4-8 The findings on the association between cancer risk and occupational exposure 
to vehicle exhaust related air pollution are inconclusive, mostly due to limited exposure 
information and incomplete information on confounders like smoking.9-16 Several stud-
ies have reported an increased risk for leukaemia in association with residential traffic 
density.17-19 However, this was not confirmed in a large case-control study by 
Raaschou-Nielsen et al.,20 and several other studies.21-24 The role of residential traffic 
density in childhood leukaemia remains subject of discussion.25-27 
In Amsterdam, traffic circulation is regulated by way of a network of designated roads. 
Approximately 12 percent of the addresses in Amsterdam are situated along traffic 
roads with more than 10 000 vehicle equivalents per day. Fisher et al. measured the 
largest contrasts between outdoor air concentrations in front of homes along busy and 
quiet streets in Amsterdam for carcinogenic compounds like benzo(a)pyrene, total 
polycyclic aromatic hydrocarbons and benzene.28 Similar differences were found for the 
indoor air of these homes. However, the number of measurements was small. Within 
the urban area of Amsterdam substantial differences, up to 300 percent, exist between 
ambient air black smoke concentrations at road traffic measurement sites and back-
ground sites.29 
Considering the large number of cancer cases available in the Amsterdam Cancer Reg-
istry and the unique information on residential traffic density in the city since 1986, we 
conducted a population-based study to examine the effect of residency along busy 
roads on the incidence of cancer. Because of the findings in other studies we were 
particularly interested in the incidence of cancer of respiratory tract (mainly lung can-
cer) and haematological malignancies, especially in children. 
MATERIALS AND METHODS 
Cancer registry 
The cancer registry of the Comprehensive Cancer Centre Amsterdam (‘Amsterdam 
Cancer Registry’) is population-based since 1988 and covers the province of Noord-
Holland and the larger part of Flevoland. On January 1st, 1998, the population of the 
region numbered 2.72 million, of which 718 000 with residence in Amsterdam. The 
Amsterdam Cancer Registry is part of the Netherlands Cancer Registry.30 All malignant 
tumours, with the exception of basal cell carcinomas of the skin, are registered in all 
20 hospitals in the region. Data from residents diagnosed in a hospital outside our 
region, are routinely obtained from the national registry. 




Cancer registry data are extracted directly from the medical records. Apart from 
demographic data, data are collected on the site and morphological classification (ac-
cording to the International Classification of Diseases for Oncology), stage and the 
primary treatment. Finally, the 4-digit postal code at the date of diagnosis is regis-
tered. 
For this study all cancer cases diagnosed from 1 January 1989 through 31 December 
1997 in patients residing in Amsterdam at the date of diagnosis were selected from the 
cancer registry. Borderline and non-invasive tumours were excluded. Kaposi’s sarco-
mas were also excluded, because these malignancies occurred almost exclusively 
among the members of the gay community of Amsterdam and this community is geo-
graphically unevenly distributed over the city. Cancer cases diagnosed in 1988 could 
not be included in the study, because detailed address data as necessary for this study 
were not accessible. 
Daily traffic intensity 
By means of infrastructural works and other measures taken in the past decades, the 
traffic flows in Amsterdam are primarily through the so-called ‘main road network’, 
while the other roads are mostly used by residential traffic. Consequently, the main 
roads are the most busy roads of Amsterdam. Data on the daily traffic intensity of the 
main roads in 1986, 1991 and 1993 were obtained from the Environmental Research 
Institute City of Amsterdam (OMEGAM). Traffic intensity for roads not belonging to the 
main road network is not available. Based on actual counts or interpolations, the 24-
hour numbers of passenger cars and trucks were available for all road segments of the 
main road network. There were 55 719 addresses along the main roads out of a total 
of 373 157 addresses in Amsterdam. For each address, the distance (in meters) be-
tween the road axis and the front of the house was also available. We added 5 778 
main road addresses to ‘other roads’, because that distance was more than 50 meters. 
For each of the remaining 49 941 addresses a daily traffic intensity score (TIS) was 
calculated for each of the 3 available years, passenger cars counting for 1 and trucks, 
with their larger emissions, counting for 10. An address belonged to the main road 
network if the TIS was 10 000 or higher during at least one of the three years. For 4 
077 addresses the TIS was below 10000 in all three available years. These 4 077 ad-
dresses were added to ‘other roads’, leaving 45 864 addresses (12.3 percent of the 
total number of addresses in Amsterdam), classified as ‘main road addresses’. For 25 
168 of these main road addresses the TIS was 20 000 or higher in at least one of the 
three available years. 
Population data 
Annual population data according to sex and 5-year age groups were obtained for 
each year of the study period from the Statistical Office of Amsterdam (O + S), which 
received its data from the population register of Amsterdam. Population data (date of 
birth, sex, marital status, country of birth, address, etc.) in the Netherlands are not 
census-derived, but recorded on a day-to-day basis by the municipal population regis-
ters and include detailed address data. We obtained data for ‘main roads’ (TIS ≥ 
10000), ‘other roads’, as well as separate data for main road addresses with 10 000 ≤ 
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TIS < 20 000 and TIS ≥ 20 000, respectively. The average population with residence 
along main roads was 76000 inhabitants, that is 35 000 with 10 000 ≤ TIS < 20 000 
and 41 000 with TIS ≥ 20 000, while the average population size along other roads 
was 637 000. There were on average 8 700 children with residence along main roads 
(4200 with 10 000 ≤ TIS < 20 000 and 4500 with TIS ≥ 20 000), while on average 
96000 children resided along other roads. 
Address according to population register 
A full postal code in the Netherlands consists of 4 digits followed by 2 letters. The 
combination of the full postal code and the number of the house can identify each 
individual address. Because the 4 digit postal code as available in the cancer registry 
was insufficiently accurate for defining whether a patient was living along a main road 
or not, supplementary address data were requested from the Amsterdam population 
register. By means of record linkage (using the date of birth, gender and 4 letters of 
the family name) of the cancer registry data and a data file containing address data of 
all present and former (since 1989) Amsterdam residents, supplementary address data 
(full postal code and the number of the house) were added to the cancer registry data, 
ignoring the original postal codes as available in the cancer registry. However, in 89 
percent of the cases the postal code in the cancer registry equalled the postal code in 
the population register. All cancer cases for which computerized linkage was unsuc-
cessful were extensively checked by hand. For all patients still alive and residing in 
Amsterdam we used the address data at April 1st 1998, when the data file of the 
population register was generated. For patients who had died or moved away from 
Amsterdam, we used the address data at the date of death or the last address in Am-
sterdam, respectively. Finally, cancer registry data were linked to the main road ad-
dresses (TIS ≥ 10 000), as previously defined on the basis of the daily traffic density, 
thus separating cancer cases residing along main roads and along other roads. Subse-
quently in this article, ‘main road’ cancer cases are cases with residence along the 
main road network (TIS ≥ 10 000) at April 1st 1998, at the date of death or at the 
date of departure from Amsterdam. All other cancer cases are cases with residence 
along ‘other roads’. 
Survey on smoking habits 
Smoking is an important potential confounder when examining the association be-
tween traffic density and cancer. As information on smoking was not available in the 
cancer registry we conducted a population-based survey to see whether smoking hab-
its differed between residents along main roads and other roads. A total of 5 000 ad-
dresses in Amsterdam were randomly selected from the file made available by the 
Population Register of Amsterdam. Two thousand five hundred addresses were along 
the main roads of Amsterdam. The other 2 500 were along other roads. In order to 
obtain a population sample that could easily be compared to cancer patients, the se-
lection of addresses was stratified according to the age and sex distribution of the 
latter group. One thousand extra addresses of both categories were kept standby. The 
selected addresses were approached by telephone, followed by a telephone interview 
with the main occupant or his/her partner. Children were not interviewed. Prior to the 




interview a letter was sent to all addresses by the Municipal Health Service Amster-
dam, introducing the telephone interview. It included questions on the present and 
past smoking status, present (or past) number of packs smoked weekly, the type(s) of 
tobacco (cigars, cigarillos, [hand-rolled] cigarettes, pipe-tobacco), starting age and 
time passed since giving up smoking, as well as some demographic items like age, sex, 
duration of residence at the present address, education and profession. The survey 
was performed in January - February 2000 by NIPO, a market research institute with 
ample experience regarding telephone interviews. NIPO used Computer Assisted Tele-
phone Interviewing, in which the questions appear on the screen of the interviewer 
and the answers are entered directly into the computer.  
Data analysis 
We calculated 5-year age group- and sex-specific cancer incidence rates for total Am-
sterdam, as well as for inhabitants not residing along main roads. Using the latter inci-
dence rates as a reference and the distribution according to 5-year age group and sex 
of residents along the main roads of Amsterdam, we calculated expected numbers (E) 
of cancer for residents along main roads. We calculated separate expected numbers 
for main roads with 10 000 ≤ TIS <20 000 and TIS ≥20 000 as well. Expected num-
bers were compared with the observed numbers (O) and standardised incidence ratios 
(SIR) with corresponding 95 percent confidence intervals based on the Poisson distri-
bution of O were calculated using STATA 7.0 for Windows (STATA Corporation, College 
Station, Texas, USA). 
 
Table 1. Main characteristics of cancer patients in Amsterdam according to residency, 1989-
1997 
residency 
 along main roads along other roads* total 
parameter 

























































total 3 384  23 773  27 157  
 
* including 225 cases with unknown address 
RESULTS 
Cancer incidence 
In 1989-1997 a total of 27 157 cancer cases (13 606 males, 13 551 females) were 
diagnosed among inhabitants of Amsterdam. Table 1 shows that a total of 3 384 can-
cer patients (12.4 percent of the total number) had residence along the main roads of 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































residing along other roads. Of 225 cases (0.9 percent) address data were insufficiently 
accurate to determine whether a case lived along a main road or not. On average pa-
tients with residence along the main roads were somewhat older than patients living 
elsewhere in Amsterdam. Over 70 percent of the patients were 60 years or older, while 
only 9 percent were below the age of 45.  
The age-standardized cancer incidence rate (European standardized rate31) for total 
Amsterdam was 470.7 per 100 000 males and 355.1 per 100 000 females, which was 3 
and 7 percent above the national average, respectively. Compared to the national av-
erage, rates for total Amsterdam in males were increased for cancer of the oral cavity, 
pharynx, liver, mesothelioma, urinary tract and non-Hodgkin’s lymphoma. Colorectal 
cancer, gallbladder, skin and testicular cancer were well below the national average. 
Compared to the national average, the rates for total Amsterdam in females were in-
creased for smoking-related cancers (head & neck, lung, bladder), as well as for cervi-
cal cancer and non-Hodgkin’s lymphoma. The female rates for cancer of the gallblad-
der and the skin, as well as leukaemia were below the national average. The incidence 
rates for the population not residing along the main roads were almost equal to the 
incidence rates for total Amsterdam. 
Using the age group- and sex-specific cancer incidence rates for 1989-1997 in the 
population not residing along the main roads as a reference, expected numbers of 
cancer cases in the population along the main roads were close to the observed num-
bers (table 2). For both sexes combined, the standardized incidence ratio (SIR) for 
total cancer was 1.03 (95 percent confidence interval [CI]: 1.00, 1.07). For cancer of 
the respiratory system, we calculated a SIR of 1.01 (males) and 1.13 (females, 95 
percent CI: 0.97, 1.31). The SIR of the other specific cancer sites was close to 1, with 
the exception of gastrointestinal tract in males (SIR 1.16, 95 percent CI: 1.04, 1.28) 
and haematological malignancies in children (SIR 1.35, 95 percent CI: 0.44, 3.15) and 
adult females (SIR 1.23, 95 percent CI: 1.04, 1.44). The latter increase was mainly 
caused by an increased number of cases of non-Hodgkin’s lymphoma (SIR 1.23, 95 
percent CI: 0.97, 1.54) and multiple myeloma (SIR 1.33, 95 percent CI: 0.90, 1.90) 
and a statistically significantly increased number of cases of myeloid leukaemia (SIR 
1.60, 95 percent CI: 1.01, 2.40). In both sexes combined, there were 69 adult cases of 
leukaemia (SIR 1.19, 95 percent CI 0.93, 1.51), of which 29 cases of lymphoid leu-
kaemia (SIR 1.07, 95 percent CI: 0.72, 1.54) and 40 cases of myeloid leukaemia (SIR 
1.29, 95 percent CI: 0.93, 1.76).  
The total number of 10 cancer cases in children with residence along the main roads 
was close to an expected number of 8.7 cases. All 5 children up to the age of fifteen 
with haematological malignancies were diagnosed with acute lymphocytic leukaemia 
[ALL] (SIR 2.5, 95 percent CI: 0.8, 5.9)  
In residents along the busiest main roads (TIS ≥ 20 000), the SIR for total cancer was 
0.97 (0.94 for males and 0.99 for females), while in residents along less busy main 
roads (10 000 ≤ TIS < 20 000) the SIR for all cancers combined was slightly increased 
(SIR 1.09; 95 CI: 1.04, 1.14). This latter increase was mainly caused by relatively high 
numbers of cancer of the gastrointestinal tract in males (SIR 1.23; 95 CI: 1.07, 1.41) 
as well as cancers of the respiratory tract (SIR 1.29; 95 CI: 1.06, 1.57) and haemato-
logical malignancies (SIR 1.40; 95 CI: 1.12, 1.72) in females. 
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All 5 children with ALL had residence along the busiest main roads (SIR 4.9, 95 per-
cent CI: 1.6, 11.4). 
 
Table 3. Main characteristics and smoking habits of participants of a smoking survey in Am-
sterdam, according to residency 
residency along 
 main roads 
residency along  
other roads 
total characteristics 















duration of residency at 
present address 






























































































































































































































total 1 346  1 347  2 693  
Smoking survey 
The final survey on smoking habits comprised 5 022 subjects, with whom a total of 
2693 successful interviews equally divided over both subsamples were realized (table 
3). The response rate was 53.6 percent for both subsamples combined. On average, 
participants living along main roads of Amsterdam were younger and had a higher 
socio-economic status (SES) than the participants living elsewhere in Amsterdam (table 
3). Sixty-two percent of the subjects residing along main roads had been living there 
for at least 10 years and 42 percent for at least 20 years. For subjects with residency 
along other roads these figures were 66 and 45 percent, respectively. For subjects of 




45 years or older (both subsamples combined) the figures were 75 and 53 percent, 
respectively (data not shown). The smoking history -present, past or never smoker- 
did not differ between residents along main roads and residents elsewhere in Amster-
dam. Also, the distribution of the number of pack-years of cigarettes smoked did not 
differ between the two population samples. In a multivariate logistic regression (ad-
justed for age, sex and SES) residence along the main roads was not associated with 
smoking history (OR 0.9, 95 percent CI 0.8-1.1).  
DISCUSSION 
During 1989-1997, the overall incidence of cancer among inhabitants of Amsterdam 
residing along main roads was close to that of the remaining population of Amsterdam. 
We found an increased incidence of cancer of the gastrointestinal tract in males as well 
as increased rates for haematological malignancies in adult females, cancer of the 
respiratory system in females and haematological malignancies in children. However, 
the 95 percent confidence intervals of the relative risks of the latter two diagnoses 
included unity. For cancer of the respiratory tract and haematological malignancies in 
females we found no increase among residents along the busiest main roads, while for 
cancer of the gastrointestinal tract in males the increase among residents along the 
busiest main roads was less than among residents along less busy main roads, which 
argues against a causal association. 
All types of haematological malignancies combined occurred more often among chil-
dren and females living along the main roads than among residents of the remaining 
city of Amsterdam. This was caused by an increase of acute lymphocytic leukaemia in 
children (SIR 2.8) and an increase of non-Hodgkin’s lymphoma (SIR 1.23 versus SIR 
males 0.99), multiple myeloma (SIR 1.33 versus SIR males 0.79) and myeloid leukae-
mia in adult females (SIR 1.60 versus SIR males 1.03). The male/female differences in 
excess risk in lymphoma, multiple myeloma and myeloid leukaemia, as well as the 
absence of an increased risk of haematological malignancies in females with residence 
along the busiest roads (SIR 1.03), render a causal association with residence along 
the main roads less likely. The number of cases of childhood leukaemia was small in 
our study, but we found a statistically significantly increased risk of ALL in children 
with residence along the busiest roads. It must be pointed out, however, that the con-
fidence interval surrounding the risk estimate was wide and that the risk increase re-
lates to a subgroup analysis which was done as a result of our observation of in-
creased risk for haematological malignancies. In three other studies elevated risks for 
leukaemia were also reported.17-19 Although the SIR for childhood ALL in our study 
was increased, the public health implications are relatively small. If the association 
between traffic density and childhood ALL were causal, we estimate that, based on our 
results, 1 excess case of ALL would occur every 3 years among children with residency 
along the main roads in Amsterdam. 
The incidence of cancer of the gastrointestinal tract in males residing along main roads 
was slightly increased (SIR 1.16). However, a causal association between urban air 
pollution and cancer of the gastrointestinal tract is not very plausible from a biological 
perspective. The lack of a dose-response relation (SIR in residents along the busiest 
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main roads 1.08) does not support a causal association either. More likely, this result is 
a chance finding attributable to the multiple comparisons in our analysis. 
Since tobacco smoke and ambient air pollution contain many identical toxic com-
pounds, smoking is an important potential confounder in this study. Although the 
populations compared are quite large and one would not a priori expect differences in 
the smoking habits of residents along main roads and other roads, a drawback of our 
study is the lack of information on individual smoking histories. We did, however, ob-
tain information on the smoking habits of large random samples of the populations 
involved. The results of our survey showed almost identical smoking histories among 
residents living along the main roads and the population residing elsewhere in Amster-
dam. 
We observed a slightly increased incidence of cancer of the respiratory tract in females 
(SIR 1.13), but not in males. Although this result was not statistically significant, we 
cannot exclude a weak association between residency along main roads and cancer of 
the respiratory tract in females, taking into account the fact that women used to be 
more often at home than men. Especially in the past, the proportion of employed 
women in the Netherlands was rather low. Therefore, the total exposure to traffic-
related air pollution may have been greater for women than for men. However, our 
observation that no increased incidence was present among female residents along the 
busiest main roads and that the distribution according to morphological type of cancer 
of the respiratory tract (data not shown) was similar in residents along main roads and 
other roads, both in males and in females, do not support a possible association. 
At first sight, our finding of a slightly increased cancer incidence among residents 
along less busy roads (SIR 1.09), while there was no increase among residents along 
the busiest roads (SIR 0.97) does not appear to support a causal relation between 
cancer and main roads. However, because of the municipal policy for sound insulation, 
the houses along the busiest main roads were better insulated and we cannot exclude 
the possibility that this insulation policy may have led to lower levels of pollutants in 
the houses along the busiest roads in comparison to less busy roads. We did not per-
form separate analyses for trucks and cars, although trucks may have been the main 
source of traffic-related air pollution, as the numbers of trucks and cars were highly 
correlated (correlation coefficients were as high as 0.97, 0.87 and 0.96 in 1986, 1991 
and 1993, respectively).  
A drawback of the study is the possibility of non-differential misclassification, since 
people may have moved from main roads to other roads and vice versa. However, the 
smoking survey showed comparable residence times between the two groups. More-
over, nearly two thirds of inhabitants had not changed their residency in the last 10 
years. The record linkage of cancer registry data to the data from the Amsterdam 
Population Register showed that the 4-digit postal code at the date of diagnosis in the 
cancer registry was equal to the last known address in 89 percent of the cases. Never-
theless, some random misclassification is likely to be present in this study, causing an 
attenuation of the true risk estimates towards unity. 
Less than 1 percent of the cancer cases could not be found in the Amsterdam Popula-
tion Register. Among these, people born outside the Netherlands were relatively com-
mon. Possibly, they were residing in Amsterdam illegally, or they were living temporar-
ily with relatives in Amsterdam because of cancer treatment in one of the Amsterdam 




hospitals. Because there is no reason to assume that the unclassifiable cases would 
have had residence along the main roads more often than known cases, it is unlikely 
that the very low proportion of unclassifiable cases has influenced our results. 
Finally, the differences in SES between residents along the main roads and other roads 
may have slightly influenced our results. According to the Amsterdam Bureau for Re-
search and Statistics, residents along main roads had somewhat higher levels of edu-
cation, 43 percent ‘high’ versus 39 percent ‘high’ among residents along other roads. 
Family incomes were almost equal, 12 percent ‘high’ among residents along main 
roads and 13 percent ‘high’ among residents along other roads. Among participants of 
the smoking survey, we also found a higher percentage of residents along the main 
roads in the highest SES category (26 percent versus 16 percent). However, this dif-
ference was most pronounced in younger participants. In participants of the smoking 
survey over the age of 50, the difference in SES was much smaller, 14 percent cate-
gory A in residents along main roads versus 10 percent in residents along other roads. 
As the majority of cancer patients is also older than 50, we conclude that SES is 
unlikely to have influenced our results substantially.  
In conclusion, our large population-based study does not support the association be-
tween traffic related air pollution and cancer incidence in adults as observed in some 
studies. However, an increased risk of ALL among children along the busiest roads was 
observed and this possible association should be the subject of further research. 
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ABSTRACT 
While stage is the most important factor for determining cancer survival, population-
based survival data according to stage are rarely presented. We present such data for 
a large population diagnosed with cancer in the area covered by the Amsterdam Can-
cer Registry in 1989-2001 (n=108 251). Cases were grouped according to the TNM-
Classification. For all sites, a close relation between stage at diagnosis and survival was 
observed. The stage-specific 5-year relative survival rate (RSR) ranged from close to 
100% for stage I carcinoma of the salivary glands, thyroid, colon/rectum, skin, breast, 
female genitals, prostate and urethra to ≤ 1% for stage IV carcinoma of the oesopha-
gus, stomach, liver, gallbladder, pancreas and lung. Between 1989-1991 and 1999-
2001, we observed an increase of the stage-specific RSR for carcinoma of co-
lon/rectum (stages II-IV), lung (stages I-II), breast (stages I-III) and prostate (stages 
II-IV). Changes in diagnostic (breast, prostate) and staging procedures (lung), surgery 
(rectum, prostate) and adjuvant treatment (breast, colon) are likely to have contrib-




Information on the prognosis of cancer patients is important for both patients and 
their clinicians. From the EUROCARE-3 study, age- and site-specific survival rates are 
available for many European countries [1]. However, the prognosis of a cancer patient 
is also influenced by many other factors, such as morphological type, treatment and 
co-morbidity [2,3]. For epithelial cancers, stage is the most important factor and most 
survival differences between populations can be explained by differences in stage dis-
tribution [4,5]. Moreover, stage-specific survival rates are essential for the interpreta-
tion of differences in survival rates between sexes or changes in the overall survival 
rates over time, as the overall survival will change as a result of changes in stage dis-
tribution. Unfortunately, stage-specific survival is unavailable in the majority of the 
European cancer registries, which hampers the comparison of survival rates between 
registries and the explanation of survival changes over time. 
The nation-wide Netherlands Cancer Registry collects stage information for all relevant 
cancer sites and, consequently, is uniquely positioned to examine population-based 
survival according to stage. In this paper, we present stage-specific survival rates for 
all major epithelial cancers as well as melanoma skin cancer, based on a very large 
population-based cohort of cancer patients in the north-western part of the Nether-
lands. 
2. PATIENTS AND METHODS 
2.1 The Amsterdam Cancer Registry 
The Amsterdam Cancer Registry (ACR), is a regional, population-based cancer registry 
with complete regional coverage since January 1st, 1988. The region of the ACR cov-
ers the major part of two out of twelve provinces of the Netherlands: North-Holland 
and Flevoland. Its population numbered 2.84 million on December 31st, 2001, ap-
proximately 17% of the total population of the Netherlands. The ACR is part of the 
nation-wide Netherlands Cancer Registry, whose data are included in Cancer Incidence 
in Five Continents as of volume VII [6,7]. Cases diagnosed in a hospital outside the 
ACR region but with residence in the ACR region, are routinely obtained from the na-
tional registry and included in the regional registry. 
The information for the registry is extracted from the medical records by registration 
clerks. Apart from demographic data, data are collected on tumour site and morpho-
logical classification (according to the International Classification of Diseases for On-
cology), stage of the tumour and primary treatment of the patients. For the stage of 
the tumour, TNM is registered whenever applicable. We used the 4th edition for cases 
diagnosed in 1989-92, the 2nd revision of the 4th edition in 1993-98 and the 5th edi-
tion in 1999-2001 [8,9]. 
2.2 Study population 
For this study, we selected cancer sites included in the 5th edition of the TNM Classifi-
cation [9]. Cancer sites with mainly non-epithelial cancers (bone, soft tissue, eye) were 
excluded. Skin melanoma was included. 




Stage grouping was according to the 5th edition of the TNM-classification, based on a 
combination of clinical TNM (cTNM) and pathological TNM (pTNM). If pTNM was avail-
able (61% of the cases) we used pTNM-data, otherwise cTNM-data were used. In case 
of small numbers, stages were grouped together. 
The TNM-classification for carcinoma of the small intestines was not available until the 
2nd revision of the 4th edition. We converted the extent of disease as registered in 
1989-92 to TNM-stage as follows: localised=stage I, direct extension=stage II, re-
gional lymph node metastasis=stage III, distant metastasis=stage IV. 
Between January 1st, 1989 and December 31st, 2001 a total of 130 619 first invasive 
cancers were registered. After exclusion of sites with mainly non-epithelial cancers and 
sites for which TNM was not applicable, 108 251 cancers remained (table 1).  
2.3 Follow-up 
For patients with residence in the ACR region and diagnosed in 1989-97, the vital 
status was updated by linking electronic files with deceased persons to the cancer 
registry. These files were made available in 1999/2000 by 54 municipal population 
registers (covering 90% of the population of the region) out of a total of 74 registers 
in the region. The files included all deceased residents (irrespective of cause of death) 
of those municipalities, generally covering the period 1989-99. Active follow-up was 
performed in the hospitals for all patients with residence in the remaining 20 munici-
palities and in case the datafile made available by the municipal population register 
covered only a part of the period 1989-99. In case of missing data in the hospital, the 
municipal population registers were asked for the date of death of individual patients. 
In September 2003, the vital status of all patients (diagnosed 1989-2001) still alive at 
last follow-up was updated by linkage to the electronic death register of the Central 
Bureau for Genealogy (CBG), which contains all deceased residents of the Netherlands 
as of October 1st 1994. This electronic register is updated on a daily basis with data 
from all municipal population registers in the Netherlands. Patients who probably died 
before October 1st 1994 according to hospital information, but with unknown date of 
death, were checked in the personal record card register of the CBG which contains all 
Dutch residents who died before October 1st 1994. Finally, all patients not known by 
CBG were assumed to be alive at 1 September 2003, one week before record linkage 
with the electronic death register was performed. 
Checks on the vital status of patients assumed to be alive at 1 September 2003 were 
performed in the hospitals for all patients with metastatic disease at diagnosis, patients 
over 95 years of age in 2003 and patients with cancer of the oesophagus, stomach, 
liver, gallbladder, bile ducts, pancreas, and lung. This procedure revealed that the 
number of patients assumed to be alive after record-linkage but who turned out to 
have died according to hospital information, was negligible. Overall, missing dates of 
death are estimated to be well below 0.5%. 
2.4 Statistical analysis 
Because the cause of death is not available in the population registers and conse-
quently not complete in our data set, and because linkage with the cause of death 
registration of Statistics Netherlands is not possible because of privacy regulations, we 
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were unable to calculate disease specific survival. As an alternative, we calculated 
relative survival and 95% confidence intervals using STATA 7.0 (StataCorp. Stata Sta-
tistical Software: Release 7.0. College Station, TX: Stata Corporation) with software 
written by Dickman and colleagues [10], based on a computer package developed by 
Hakulinen and Abeywickrama [11]. This method corrects observed survival for ex-
pected mortality according to annual life tables of the general population. We used 
national age-, sex- and calendar year-specific life tables from Statistics Netherlands 
[12].  
 
Table 1. Invasive cancers according to TNM-stage, North-Holland/Flevoland, the Netherlands, 










Lip/oral cavity 1 654 40% 16% 10% 29% 3% 1% 0% 
Pharynx 889 5% 10% 21% 63% 1% 1% 0% 
Larynx 1 353 39% 25% 11% 23% 1% 1% 0% 
Maxillary sinus 66 3% 6% 26% 58% 0% 5% 3% 
Salivary glands 232 38% 11% 6% 22% 11% 12% 0% 
Thyroid gland 665 43% 19% 19% 17% 2% 0% 0% 
Oesophagus 2 014 4% 12% 19% 28% 36% 0% 1% 
Stomach 4 472 15% 11% 17% 36% 16% 2% 2% 
Small intestine 305 5% 16% 12% 17% 4% 43% 4% 
Colon/rectum 15 685 17% 31% 25% 20% 3% 1% 2% 
Anal canal 238 13% 40% 25% 5% 14% 3% 1% 
Liver 581 1% 12% 14% 39% 16% 5% 13% 
Gallbladder 452 7% 11% 15% 47% 9% 0% 12% 
Extrahep. bile ducts 834 5% 5% 7% 29% 18% 1% 35% 
Pancreas 3 185 10% 6% 7% 38% 5% 1% 33% 
Lung 17 448 17% 4% 35% 32% 4% 1% 5% 
Skin**, 
non-melanoma 4 987 63% 11% 2% 0% 20% 3% 0% 
Skin, melanoma *** 4 718 53% 28% 13% 1% 4%   
Breast 21 121 34% 50% 8% 6% 2% 0% 1% 
Vulva**** 439 30% 31% 20% 12% 6% 1% 0% 
Vagina 99 25% 18% 16% 21% 7% 12% 0% 
Cervix uteri 1 835 51% 17% 22% 7% 2% 0% 0% 
Corpus uteri 2 649 70% 8% 7% 4% 2% 8% 0% 
Ovary 2 438 20% 7% 44% 17% 2% 8% 2% 
Penis**** 177 47% 21% 13% 3% 15% 0% 1% 
Prostate 12 131 4% 49% 15% 26% 4% 0% 2% 
Kidney 2 638 9% 32% 18% 23% 1% 3% 13% 
Renal pelvis/ureter 434 28% 13% 23% 26% 7% 0% 3% 
Bladder 4 471 45% 24% 12% 14% 3% 1% 1% 
Urethra 41 22% 29% 12% 20% 15% 2% 0% 
TOTAL 108251 26% 27% 18% 19% 5% 1% 3% 
* mainly carcinoid tumours of the lung and gastrointestinal tract (appendix, small intestines), mixed tu-
mours of the female genital organs and salivary glands, leiomyosarcoma of the corpus uteri, as well as 
germ cell and stromal tumours of the ovaries 
** including scrotum 
*** including melanoma of vulva (n=25), penis (n=1) and scrotum (n=2) 
**** excluding melanoma 





Out of a total of 108 251 patients with a primary cancer of one of the selected tumour 
sites (table 1), TNM-stage was available for 95% of the cases (98 210 epithelial can-
cers as well as 4 718 skin melanomas). 1 554 non-epithelial cancers (other than skin 
melanoma) of the selected tumour sites were registered (1% of the cases). A total of 
3769 cancers (3%) were not microscopically confirmed, mostly cancers of the pan-
creas (1043 cases) and the lung (925 cases). The highest percentage of non-
microscopically confirmed tumours was observed for cancers of the extrahepatic bile 
ducts (35%, 293 cases). 
Stage I was the most registered stage for carcinoma of the lip/oral cavity, larynx, sali-
vary glands, thyroid, skin, uterus, penis and bladder (table 1). For carcinoma of the 
pharynx, maxillary sinus and the digestive organs (small intestines, colon/rectum and 
anal canal excluded) stage IV was the most registered stage. The proportion of un-
known stage was particularly high for oesophageal (36%) and skin (20%) carcinoma, 
mostly due to an unknown T-category. 
Figures 1 to 5 show a clear relation between stage at diagnosis and the relative sur-
vival rate (RSR) for all cancer sites: a relatively high RSR in early stages and low RSRs 
in advanced or metastatic disease. The 5-year RSRs were almost equal for stage I and 
II pharyngeal carcinoma (69% and 70%, respectively), stage I and II thyroid carci-
noma (99% and 98%, respectively) and stage II and III prostate carcinoma (91% and 
88%, respectively). For carcinoma of the vagina and the penis the 5-year RSR was 
slightly higher in stage II than in stage I, but the 95% confidence intervals largely 
overlapped. 
For stage I carcinomas, the 5-year RSR was generally between 80 and 100%. The risk 
of dying was almost equal to the general population risk for patients with stage I car-
cinoma of the salivary glands, thyroid, colon/rectum, skin, breast, female genital or-
gans and urethra. For prostate carcinoma this figure was even above 100%. The 5-
year RSR was relatively low for stage I lung carcinoma (62% and 35% for stages Ia 
and Ib, respectively). The lowest RSR of stage I carcinoma was observed for pancreas 
(15%). 
For the most frequent cancer sites (breast, lung, colon/rectum, prostate), 1-year RSRs 
for stage IV disease were observed of 61%, 13%, 33% and 86%, respectively. For 
many sites, the 5-year RSR for stage IV disease was ≤ 1% (oesophagus, stomach, 
liver, gallbladder, pancreas, lung), but relatively high rates were observed for carci-
noma of the lip/oral cavity (36%), pharynx (31%), larynx (44%) and prostate (31%). 
The 5-year RSR for stage IV breast carcinoma was also relatively high (17%). 
Survival of cases with an unknown stage was close to stage I or stage II disease for 
cancers of the lip/oral cavity, skin, breast, vulva and penis, because these cases were 
mostly localized with an unknown T-category. For most other sites, survival of cases 
with unknown stage was intermediate to stage III and IV, because of the absence of 
apparent distant metastases.  
In general, the variation in the stage-specific RSRs 5 years after diagnosis exceeded 
the variation in stage-specific RSRs 1 year after diagnosis. For example, the absolute 
differences in RSRs between stage I and stage IV breast cancer were 38% 1 year after 
diagnosis and 80% 5 years after diagnosis. For stage I and IV prostate carcinoma 
these figures are 17% and 68%, respectively. 
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A. Lip and Oral Cavity












































Figure 1. One-year ( ) and five-year ( ) relative survival rates of patients diagnosed with head 
& neck cancer according to TNM-stage, North-Holland/Flevoland, the Netherlands, 1989-2001 
(UK=unknown). Lines represent 95% confidence intervals. 




























D. Colon and Rectum




















Figure 2. One-year ( ) and five-year ( ) relative survival rates of patients diagnosed with 
gastro-intestinal cancer according to TNM-stage, North-Holland/Flevoland, the Netherlands, 










B. Extrahep. Bile Ducts























E. Carcinoma of Skin






F. Melanoma of Skin







Figure 3. One-year ( ) and five-year ( ) relative survival rates of patients diagnosed with 
gastro-intestinal, lung or skin cancer according to TNM-stage, North-Holland/Flevoland, the 
Netherlands, 1989-2001 (UK=unknown). Lines represent 95% confidence intervals. 

















































Figure 4. One-year ( ) and five-year ( ) relative survival rates of patients diagnosed with 
breast or gynaecological cancer according to TNM-stage, North-Holland/Flevoland, the Nether-

























D. Renal Pelvis & Ureter





















Figure 5. One-year ( ) and five-year ( ) relative survival rates of patients diagnosed with 
cancer of the male genitals or urinary organs according to TNM-stage, North-
Holland/Flevoland, the Netherlands, 1989-2001 (UK=unknown). Lines represent 95% confi-
dence intervals. 




No gender differences in stage-specific survival of lung or colorectal carcinoma were 
observed (table 2). However, stage-specific survival of melanoma was more favourable 
in females, while stage-specific survival of bladder carcinoma was more favourable in 
males. Gender differences in survival for all stages combined were also observed for 
carcinoma of the larynx (higher survival in males), pharynx and thyroid (higher survival 
in females). This was mainly due to differences in stage distribution according to gen-
der and no significant differences in stage-specific survival were observed (results not 
shown). 
 
Table 2. Percentage 5-year relative survival for selected sites according to stage and gender, 
North-Holland/Flevoland, the Netherlands, 1989-2001 
Gender 
males  females 
cases  cases 
Stage at diagnosis 
n % 
% survival (95% 
confidence interval)  n % 
% survival (95% 
confidence interval) 
Colon/rectum         
stage I 1 393 18% 95 (92-98)  1 346 18% 96 (93-99) 
stage II 2 410 32% 74 (71-76)  2 507 33% 74 (72-77) 
stage III 1 900 25% 51 (48-54)  2 020 26% 48 (45-51) 
stage IV 1 631 22% 4 (3-5)  1 504 20% 4 (3-5) 
unknown 241 3% 36 (28-45)  273 4% 36 (28-44) 
all stages 7 575  55 (54-57)  7 650  56 (55-57) 
Lung          
stage Ia 722 6% 59 (55-64)  272 6% 68 (61-74) 
stage Ib 1 620 13% 34 (31-37)  414 10% 38 (33-43) 
stage II 956 8% 26 (22-29)  233 6% 28 (22-35) 
stage IIIa 1 680 14% 8 (7-10)  585 14% 9 (6-11) 
stage IIIb 2 570 21% 4 (4-5)  915 22% 5 (4-7) 
stage IV 3 999 33% 1 (1-1)  1 597 38% 1 (1-2) 
unknown 561 5% 5 (3-7)  173 4% 13 (8-19)* 
all stages 12 108  13 (12-13)  4 189  13 (12-14) 
Melanoma          
stage I 931 48% 98 (95-100)  1 561 56% 100 (98-101) 
stage II 574 30% 83 (79-87)  761 27% 91 (88-94)* 
stage III 324 17% 49 (42-56)  134 5% 61 (54-68) 
stage IV 39 2% 11 (4-24)  26 1% 0  
unknown 69 4% 79 (63-92)  132 5% 88 (78-95) 
all stages 1 937  83 (81-86)  2 781  92 (90-93)* 
Bladder          
stage I 1 644 48% 83 (80-86)  356 37% 78 (72-85) 
stage II 855 25% 45 (41-50)  240 25% 37 (29-45) 
stage III 402 12% 38 (32-44)  137 14% 20 (13-29)* 
stage IV 428 12% 8 (5-12)  185 19% 9 (5-14) 
unknown 108 3% 47 (34-60)  42 4% 29 (14-46) 
all stages 3 437   58 (56-60)  960   45 (41-48)* 
* survival in males differs from survival in females (P<0.05) 
 
The 3-year RSR for all stages combined increased significantly between 1989-91 and 
1999-2001 for carcinomas of the breast, colon/rectum and prostate, but not for lung 
carcinoma (table 3). Nevertheless, we observed an increase in the 3-year RSR for the 
lower stages of non-small cell lung carcinoma (NSCLC).  
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Table 3. Percentage 3-year relative survival according to stage and period of diagnosis, North-
Holland/Flevoland, the Netherlands 
Period of diagnosis 
1989-1991  1999-2001 
cases  cases 
Stage at diagnosis 
n % 
% survival (95% 
confidence interval)  n % 
% survival (95% 
confidence interval) 
Colon/rectum         
stage I 612 19% 96 (92-99)  624 17% 96 (93-99) 
stage II 999 31% 76 (73-80)  1 246 33% 81 (78-84) 
stage III 798 25% 57 (54-61)  1 018 27% 65 (61-69) 
stage IV 659 21% 5 (4-7)  771 20% 13 (11-16)* 
unknown 105 3% 38 (27-50)  112 3% 36 (25-49) 
all stages 3 173  59 (57-61)  3 771  64 (62-66)* 
Lung, small cell carcinoma     
stage I and II 96 12% 15 (9-24)  39 6% 24 (11-40) 
stage IIIa 121 15% 12 (7-18)  105 15% 12 (6-20) 
stage IIIb 125 15% 7 (3-13)  150 22% 9 (5-15) 
stage IV 394 49% 1 (1-3)  382 55% 2 (1-4) 
unknown 72 9% 8 (3-16)  18 3% 6 (0-25) 
all stages 808  9 (4-8)  694  6 (5-9) 
Lung, non-small cell carcinoma      
stage Ia 229 8% 66 (59-73)  195 7% 86 (79-92)* 
stage Ib 481 16% 39 (35-44)  326 11% 54 (48-60)* 
stage II 288 10% 29 (24-35)  214 7% 42 (34-50) 
stage IIIa 434 14% 13 (10-17)  354 12% 18 (13-22) 
stage IIIb 602 20% 6 (6-9)  664 23% 9 (6-11) 
stage IV 769 26% 2 (1-3)  1 074 37% 3 (2-4) 
unknown 210 7% 11 (7-17)  62 2% 16 (8-28) 
all stages 3 013  19 (17-20)  2 889  20 (19-22) 
Breast          
stage I 1 166 29% 97 (96-99)  2 023 36% 100 (99-101) 
stage IIa 1 296 32% 91 (89-93)  1 724 31% 97 (95-98)* 
stage IIb 817 20% 84 (81-87)  1 032 19% 89 (87-92) 
stage IIIa 157 4% 62 (54-70)  184 3% 69 (60-76) 
stage IIIb 189 5% 58 (50-66)  261 5% 60 (52-67) 
stage IV 268 7% 32 (26-38)  296 5% 28 (23-34) 
unknown 128 3% 89 (80-95)  58 1% 76 (61-88) 
all stages 4 021  85 (83-86)  5 578  90 (89-91)* 
Prostate          
stage I 91 4% 104 (91-114)  75 2% 99 (86-107) 
stage II 887 43% 92 (86-95)  1 716 54% 99 (96-101) 
stage III 216 10% 92 (79-95)  667 21% 97 (94-101) 
stage IV 670 32% 47 (32-41)  685 22% 60 (55-64)* 
unknown 215 10% 72 (54-72)  40 1% 64 (40-85) 
all stages 2 079   76 (68-74)  3 183   90 (88-92)* 
* survival in 1999-2001 differs from survival in 1989-1991 (P<0.05) 
 
The 3-year RSR for stage Ia increased from 66% to 86%, for stage Ib from 39% to 
54% and for stage II from 29% to 42%. This increase in RSR for the lower stages of 
NSCLC coincided with a decrease in the proportion of early stages of NSCLC. The pro-
portion of stage I decreased from 24% in 1989-91 to 18% in 1999-2001, stage II de-




creased from 10% to 7% and stage IIIa from 14% to 12%. The proportions of stages 
IIIb and IV increased.  
The 3-year RSR increased for all stages of colorectal carcinoma, except for stage I. 
The largest increase was observed for stages III and IV (7% and 8%, respectively). 
The increase for stage II was 5%. The stage distribution of colorectal cancer hardly 
changed between 1989-91 and 1999-2001. 
For breast carcinoma, the largest increases in 3-year RSR were observed for stages II 
and IIIa (5-7%). The increase was statistically significant for stage IIa only. The 3-
year RSR of stage I breast carcinoma increased by 3% to reach 100% in 1999-2001, 
while no increase was observed for stage IV breast carcinoma. 
For stage I to III prostate carcinoma the 3-year observed survival in 1999-2001 almost 
equalled expected survival (RSR 97-99%), but the largest increase was observed for 
stage IV (47% in 1989-91, 60% in 1999-2001). 
4. DISCUSSION 
The Amsterdam Cancer Registry is one of few population-based cancer registries 
worldwide collecting data on stage and follow-up. The excellent population registers in 
the Netherlands enabled us to obtain near complete data on the vital status of 108 000 
cancer patients diagnosed in 1989-2001. Stage-specific 5-year RSRs ranged from close 
to 100% for stage I carcinoma of the salivary glands, thyroid, colon/rectum, skin, 
breast, female genital organs, prostate and urethra to 1% or less for stage IV carci-
noma of the oesophagus, stomach, liver, gallbladder, pancreas and lung. Although the 
poor survival for metastatic disease may be somewhat disappointing, it reflects com-
mon knowledge and is an indication for a high level of completeness of follow-up in 
our data. 
Comparison to other registries is hampered by a variety of factors. The observed RSRs 
were generally equal to the rates from another Dutch registry with similar methods as 
our registry, the Eindhoven Cancer Registry [13], but table 4 shows that our rates are 
generally lower than in the USA according to SEER Program data [14,15]. This differ-
ence might be real, but could also be caused by a lower level of completeness of fol-
low-up in SEER-data, as suggested by relatively high RSRs for stage IV disease in the 
USA. Differences in staging procedures also might influence stage-specific RSRs. For 
example, in endometrial carcinoma the stage-specific RSRs are lower in our data than 
in SEER-data, but the difference for all stages combined is only 1%. As survival of 
cases with unknown stage is rather high according to SEER, these cases also comprise 
many cases with localised disease, while in our data the cases with unknown stage are 
mostly cases with advanced disease. This implies that the level of certainty of the re-
ported TNM-stage differs considerably between our data and the SEER-data. Screening 
procedures may also influence stage-specific survival. Although screening for prostate 
specific antigen (PSA) also occurred in our region to some extent, prostate cancer 
incidence in the USA is twice as high [16] and the vast majority of localised prostate 
cancers in the USA is detected by PSA-screening. These cases have a survival which 
equals or even exceeds the survival of the general population, which was also ob-
served for stage I prostate carcinoma in our region. A higher socio-economic status of 
patients with prostate carcinoma detected by PSA-screening might contribute to this 
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observation. Finally, more aggressive treatment regimens in the USA may have caused 
a better survival in the USA than in the Netherlands [17,18]. 
 
Table 4. Five-year relative survival rates for selected cancer sites according to stage in the
Netherlands (1989-2001) and the United States of America (1990-1999) 
cancer registry   cancer registry 
ACR*  SEER**  ACR*  SEER** 
Cancer site/ stage 
% survival % survival 
Cancer site/ 
stage 
% survival % survival 
Colon and rectum    Breast    
stage I 95  95  stage I 97  100 
stage II 74  82  stage II 83  85 
stage III 50  57  stage III 52  58 
stage IV 4  7  stage IV 17  19 
unknown 36  61  unknown 80  80 
all stages 56  62  all stages 82  86 
Lung     Corpus uteri    
stage I 44  56  stage I 93  98 
stage II 26  32  stage II 78  82 
stage III 6  9  stage III 43  62 
stage IV 1  2  stage IV 13  28 
unknown 7  16  unknown 27  71 
all stages 13  15  all stages 83  84 
Prostate     Ovary    
stage I 96  100  stage I 88  94 
stage II 91  100  stage II 49  78 
stage III 88  100  stage III 23  45 
stage IV 39  53  stage IV 7  19 
unknown 63  100  unknown 16  49 
all stages 76   96   all stages 37   53 
* The ACR (Amsterdam Cancer Registry) covers 17% of the population of the Netherlands 
** Based on 9 SEER (Surveillance, Epidemiology, and End Results) Registries which cover approximately
9.5% of the population of the United States 
 
Gender differences in stage-specific survival were confined to melanoma and bladder 
carcinoma, probably caused by differences in distribution according to subsite (mela-
noma) and anatomical dissimilarities (bladder).  
Although the overall survival of patients with lung cancer was poor and no significant 
increase in overall survival was observed over time, the increase in survival of the 
lower stages of NSCLC was remarkable. As this increase in survival coincided with a 
decrease in the proportion of lower and unknown stages, while the proportion of the 
higher stages increased, this phenomenon (stage migration) is probably caused by 
improved staging procedures for lung cancer, as described earlier by Feinstein and 
colleagues [19]. In 1999, imaging with positron emission tomography (PET) was intro-
duced in our region for preoperative staging of NSCLC patients. Consequently, the 
total number of thoracotomies and the number of futile thoracotomies decreased [20], 
while the patients without lymph node metastasis who remained eligible for a thora-
cotomy, experienced an improved survival. 
Stage-specific survival of breast cancer patients increased for stages I-IIIb. Although 
the stage distribution of patients with breast cancer changed between 1989-91 and 
1999-2001, improved staging procedures are less likely to have caused the improved 




survival. Axillary lymph node dissections were routinely performed throughout the 
study period and no stage migration towards higher stages was observed. To the con-
trary, the proportion of lower stages increased between 1989-91 and 1999-2001, due 
to the start of the breast cancer screening in 1990. Because the overall incidence of 
breast cancer increased by 25% between 1990 and 2000 and even by 40% for women 
between 50 and 70 years of age [21], overdiagnosis of screen-detected breast cancers 
may have occurred. This phenomenon may have contributed to improved survival in 
early stage breast cancer. It is likely that adjuvant treatment of breast cancer with 
hormones and/or chemotherapy also has contributed to improved survival [22], as its 
application gradually increased between 1989-91 and 1999-2001 in our region, from 
11% to 24% in stage I, from 35% to 75% in stage IIa and from 70% to 90% in stage 
IIb. In a study of Vervoort and colleagues, the increased adjuvant treatment in the 
Netherlands is predicted to reduce breast cancer mortality in women aged 55-74 years 
by 7% in the year 2007 [23]. Finally, stage migration within stages may have contrib-
uted to improved survival. For example, in stage I the proportion of tumours with a 
diameter of 1 cm or less (T1a/b) increased from 23% in 1989-91 to 32% in 1999-2001 
and in stage IIa the proportion of tumours with a diameter of 2 cm or less (T1) in-
creased from 38% in 1989-91 to 55% in 1999-2001. 
Overdiagnosis of previously unnoticed cases may have contributed to improved sur-
vival of localised prostate cancer. Between 1989-91 and 1999-2001, the number of 
localised carcinomas doubled (mostly due to PSA screening), while the number of 
stage IV carcinomas hardly increased. However, the increase in the RSR for stage IV 
prostate carcinoma cannot be attributed to effects of early detection and a more likely 
explanation relates to changes in the hormonal treatment of stage IV carcinoma. In 
localised prostate carcinoma, treatment may also have improved survival, as the per-
centage of patients with wait-and-see policy decreased in favour of the percentage of 
patients who underwent a prostatectomy or curative radiotherapy. 
The stage distribution of colorectal cancer hardly changed in the 1990s. So, the in-
crease in survival of colorectal cancer cannot be attributed to improved staging proce-
dures or early detection. Most likely, changes in treatment practices have contributed 
to an improved stage-specific survival of colorectal cancer. Between 1989-91 and 
1999-2001, the proportion of patients with stage III colon carcinoma who received 
adjuvant chemotherapy increased from 5% to 49% and the application of radiotherapy 
for stage II/III rectal carcinoma changed from post-operative to pre-operative. Also, 
the surgical procedures for rectal surgery improved by the introduction of the total 
mesorectal excision in 1996/97. As the survival of colorectal carcinoma mainly in-
creased in stages II and III, and the largest increase was observed for rectal carci-
noma (results not shown), the above changes in the treatment of colorectal cancer are 
likely to have caused the improvement in survival [24]. In stage IV colorectal carci-
noma, the increased application of metastasectomy (in 3% and 6% of patients in 
1989-91 and 1999-2001, respectively) and increased treatment with chemotherapy 
(15% and 42% in 1989-91 and 1999-2001, respectively) may have contributed to an 
increased survival. 
In conclusion, in comparison to 1989-91 improved stage-specific RSRs were observed 
for the most common cancers diagnosed in 1999-2001, probably related to screening 
(breast, prostate), treatment (breast, colon/rectum, prostate) and staging procedures 
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(lung). Improved stage-specific RSRs may contribute to an overall improvement of the 
survival of specific cancers and, in the end, a decreased mortality due to these can-
cers, but, as the results for lung cancer show, this is not necessarily so. 
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One-, five- and ten-year relative survival of patients in North-Holland/Flevoland, the Nether-
lands, in 1989-2001, according to site and TNM-stage 
Site and      Number 
stage         of cases








10-year relative survival 
(95% CI) 
Lip and Oral Cavity 
I 655 100% (98% - 101%)  91% (87% - 95%)  80% (73% - 88%) 
II 271 95% (91% - 98%)  80% (72% - 87%)  63% (51% - 74%) 
III 171 75% (67% - 81%)  49% (40% - 58%)  31% (21% - 42%) 
IV 483 65% (60% - 69%)  36% (31% - 41%)  25% (20% - 32%) 
unknown 57 91% (79% - 97%)  81% (64% - 94%)  71% (47% - 93%) 
Pharynx             
I 45 94% (81% - 100%)  69% (50% - 84%)  45% (24% - 66%) 
II 86 91% (82% - 96%)  70% (57% - 81%)  46% (29% - 64%) 
III 185 81% (74% - 86%)  61% (52% - 69%)  46% (35% - 56%) 
IV 559 71% (67% - 75%)  31% (27% - 35%)  24% (19% - 30%) 
unknown 8 51% (15% - 79%)  39% (9% - 70%)  20% (1% - 58%) 
Larynx             
I 527 100% (98% - 101%)  92% (87% - 96%)  83% (74% - 91%) 
II 338 94% (90% - 97%)  71% (64% - 77%)  56% (48% - 65%) 
III 153 86% (79% - 91%)  58% (48% - 67%)  35% (24% - 47%) 
IV 312 72% (66% - 77%)  44% (38% - 50%)  36% (28% - 45%) 
unknown 11 68% (32% - 90%)  41% (10% - 77%)  28% (3% - 72%) 
Maxillary Sinus            
I/II 6 74% (22% - 100%)  54% (3% - 122%)  54% (2% - 122%) 
III 17 98% (68% - 103%)  37% (13% - 64%)  40% (15% - 70%) 
IV 38 60% (42% - 74%)  24% (11% - 40%)  28% (13% - 47%) 
unknown             
Salivary Glands            
I 88 101% (94% - 102%)  97% (87% - 103%)  104% (89% - 113%) 
II 26 96% (76% - 102%)  68% (42% - 88%)  55% (28% - 79%) 
III 14 99% (63% - 105%)  43% (14% - 76%)  47% (15% - 83%) 
IV 52 68% (53% - 80%)  27% (14% - 43%)  9% (1% - 30%) 
unknown 25 79% (56% - 92%)  63% (37% - 84%)  54% (22% - 88%) 
Thyroid Gland            
I 285 99% (97% - 100%)  99% (96% - 100%)  99% (95% - 101%) 
II 125 99% (94% - 101%)  98% (90% - 103%)  95% (81% - 105%) 
III 125 87% (79% - 92%)  77% (66% - 86%)  68% (53% - 82%) 
IV 114 37% (28% - 46%)  12% (6% - 20%)  9% (3% - 19%) 
unknown 15 69% (38% - 88%)  64% (30% - 91%)  54% (15% - 100%) 
Oesophagus            
I 72 95% (85% - 100%)  82% (67% - 93%)  86% (67% - 102%) 
IIa 155 75% (67% - 82%)  32% (24% - 41%)  18% (9% - 29%) 
IIb 84 63% (52% - 73%)  26% (16% - 37%)  21% (10% - 35%) 
III 385 37% (32% - 42%)  8% (5% - 11%)  7% (4% - 11%) 
IV 559 16% (13% - 19%)  1% (0% - 3%)     
unknown 728 33% (29% - 37%)  5% (3% - 7%)  5% (3% - 8%) 
 




One-, five- and ten-year relative survival of patients in North-Holland/Flevoland, the Nether-
lands, in 1989-2001, according to site and TNM-stage (continued) 
Site and      Number 
stage         of cases








10-year relative survival 
(95% CI) 
Stomach             
Ia 253 85% (79% - 89%)  82% (74% - 89%)  76% (63% - 87%) 
Ib 431 85% (81% - 89%)  60% (53% - 66%)  50% (41% - 60%) 
II 499 72% (68% - 76%)  33% (28% - 38%)  28% (23% - 35%) 
IIIa 538 53% (49% - 57%)  15% (12% - 19%)  10% (7% - 15%) 
IIIb 138 56% (47% - 64%)  10% (6% - 17%)  5% (2% - 14%) 
IV 1695 13% (11% - 15%)  1% (1% - 2%)     
unknown 733 24% (21% - 27%)  5% (3% - 7%)  3% (1% - 7%) 
Small Intestines            
I 14 74% (42% - 91%)  65% (31% - 90%)  60% (26% - 89%) 
II 49 68% (52% - 80%)  38% (22% - 55%)  45% (26% - 65%) 
III 37 69% (51% - 82%)  29% (14% - 47%)  29% (12% - 50%) 
IV 51 26% (15% - 39%)  7% (2% - 18%)  4% (0% - 17%) 
unknown 13 16% (2% - 41%)         
Colon and Rectum            
I 2739 97% (96% - 98%)  95% (93% - 97%)  91% (87% - 95%) 
II 4917 89% (88% - 90%)  74% (72% - 76%)  70% (67% - 73%) 
III 3920 85% (84% - 86%)  50% (48% - 52%)  44% (42% - 47%) 
IV 3135 33% (31% - 35%)  4% (3% - 5%)  3% (2% - 4%) 
unknown 514 58% (53% - 63%)  36% (30% - 42%)  30% (23% - 38%) 
Anus             
I 30 99% (80% - 102%)  83% (59% - 97%)  87% (58% - 106%) 
II 95 88% (79% - 94%)  68% (54% - 80%)  64% (45% - 81%) 
III 60 89% (77% - 96%)  39% (25% - 53%)  25% (10% - 44%) 
IV 11 28% (6% - 56%)         
unknown 33 87% (68% - 97%)  59% (34% - 82%)  37% (11% - 74%) 
Liver             
I/II 72 48% (36% - 60%)  22% (12% - 35%)  16% (5% - 33%) 
III 84 41% (30% - 52%)  13% (5% - 24%)  9% (2% - 22%) 
IV 228 14% (10% - 19%)  1% (0% - 4%)  1% (0% - 4%) 
unknown 92 12% (6% - 20%)  2% (1% - 8%)     
Gallbladder             
I 31 91% (72% - 99%)  68% (43% - 88%)  61% (30% - 92%) 
II 49 60% (44% - 73%)  18% (7% - 33%)  16% (5% - 37%) 
III 68 35% (24% - 47%)  5% (1% - 14%)  6% (1% - 24%) 
IV 212 6% (3% - 10%)  1% (0% - 4%)  1% (0% - 4%) 
unknown 39 16% (6% - 30%)  8% (2% - 20%)  9% (2% - 21%) 
Extrahepatic Bile Ducts           
I 40 85% (69% - 94%)  56% (36% - 74%)  49% (25% - 74%) 
II 45 73% (57% - 84%)  40% (23% - 57%)  46% (27% - 66%) 
III 60 59% (45% - 70%)  13% (5% - 25%)  4% (0% - 16%) 
IV 242 27% (22% - 33%)  3% (1% - 7%)  3% (1% - 7%) 
unknown 147 43% (35% - 51%)  5% (2% - 11%)  5% (1% - 12%) 
Pancreas             
I 163 40% (32% - 48%)  15% (9% - 22%)  10% (4% - 22%) 
II 176 28% (22% - 35%)  1% (0% - 5%)  1% (0% - 4%) 
III 215 34% (28% - 40%)  6% (3% - 10%)  6% (3% - 11%) 
IVa 210 24% (18% - 30%)  2% (1% - 5%)     
IVb 1161 5% (4% - 7%)  0% (0% - 1%)     
unknown 171 18% (13% - 24%)  4% (2% - 8%)  5% (2% - 11%) 
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One-, five- and ten-year relative survival of patients in North-Holland/Flevoland, the Nether-
lands, in 1989-2001, according to site and TNM-stage (continued) 
Site and      Number 
stage         of cases








10-year relative survival 
(95% CI) 
Lung             
Ia 994 89% (87% - 91%)  62% (58% - 66%)  43% (37% - 48%) 
Ib 2034 67% (64% - 69%)  35% (32% - 37%)  27% (24% - 31%) 
II 1189 60% (58% - 63%)  26% (23% - 29%)  17% (13% - 20%) 
IIIa 2265 47% (45% - 49%)  7% (6% - 9%)  4% (3% - 6%) 
IIIb 3485 31% (29% - 33%)  5% (4% - 6%)  3% (2% - 3%) 
IV 5596 13% (12% - 14%)  1% (1% - 1%)  1% (0% - 1%) 
unknown 734 34% (30% - 38%)  7% (5% - 9%)  4% (2% - 6%) 
Carcinoma of Skin            
I 3144 101% (100% - 102%)  98% (95% - 100%)  98% (93% - 103%) 
II 538 96% (93% - 99%)  84% (77% - 91%)  90% (77% - 104%) 
III 105 82% (72% - 90%)  64% (50% - 78%)  53% (33% - 74%) 
IV 21 15% (3% - 34%)  16% (3% - 43%)     
unknown 1022 99% (97% - 101%)  94% (89% - 98%)  95% (87% - 104%) 
Melanoma of Skin            
I 2492 100% (100% - 101%)  99% (98% - 100%)  99% (97% - 101%) 
II 1335 100% (99% - 101%)  88% (85% - 90%)  81% (77% - 85%) 
III 625 89% (86% - 92%)  55% (50% - 60%)  43% (36% - 50%) 
IV 65 28% (18% - 40%)  8% (3% - 17%)  8% (3% - 17%) 
unknown 201 96% (91% - 99%)  85% (77% - 92%)  77% (66% - 86%) 
Breast             
I 7111 100% (100% - 100%)  97% (96% - 98%)  91% (89% - 93%) 
IIa 6518 99% (99% - 99%)  88% (87% - 89%)  78% (75% - 80%) 
IIb 3969 98% (97% - 99%)  76% (74% - 78%)  59% (56% - 61%) 
IIIa 760 95% (93% - 97%)  58% (54% - 62%)  40% (35% - 45%) 
IIIb 913 88% (85% - 90%)  47% (43% - 51%)  28% (23% - 33%) 
IV 1216 61% (58% - 64%)  17% (15% - 20%)  5% (3% - 7%) 
unknown 365 95% (92% - 97%)  80% (74% - 85%)  74% (67% - 82%) 
Vulva             
I 132 97% (91% - 100%)  97% (86% - 105%)  87% (67% - 105%) 
II 135 88% (80% - 94%)  76% (64% - 87%)  88% (68% - 106%) 
III 87 78% (67% - 86%)  53% (39% - 67%)  59% (39% - 79%) 
IV 54 47% (33% - 60%)  21% (10% - 35%)  8% (1% - 24%) 
unknown 27 96% (75% - 104%)  94% (61% - 118%)  90% (45% - 129%) 
Vagina             
I 25 94% (73% - 100%)  78% (54% - 93%)  81% (53% - 99%) 
II 18 87% (59% - 98%)  84% (53% - 102%)  73% (24% - 109%) 
III 16 65% (35% - 85%)  57% (26% - 84%)  65% (29% - 95%) 
IV 20 67% (42% - 84%)  26% (8% - 49%)  28% (9% - 53%) 
unknown 7 74% (24% - 98%)  43% (6% - 86%)  51% (7% - 102%) 
Cervix Uteri            
I 938 99% (98% - 100%)  95% (93% - 97%)  91% (88% - 94%) 
II 312 89% (85% - 92%)  61% (54% - 67%)  53% (45% - 62%) 
III 407 78% (73% - 82%)  48% (43% - 53%)  39% (33% - 46%) 
IV 134 42% (33% - 50%)  18% (11% - 26%)  19% (12% - 28%) 
unknown 32 57% (37% - 73%)  28% (12% - 48%)  28% (10% - 53%) 
 




One-, five- and ten-year relative survival of patients in North-Holland/Flevoland, the Nether-
lands, in 1989-2001, according to site and TNM-stage (continued) 
Site and      Number 
stage         of cases








10-year relative survival 
(95% CI) 
Corpus Uteri            
I 1864 99% (98% - 100%)  93% (91% - 95%)  94% (90% - 98%) 
II 223 95% (90% - 98%)  78% (70% - 85%)  70% (57% - 82%) 
III 175 71% (63% - 78%)  43% (34% - 52%)  41% (31% - 51%) 
IV 111 35% (26% - 44%)  13% (7% - 21%)  11% (5% - 19%) 
unknown 41 61% (43% - 77%)  27% (12% - 48%)  34% (14% - 63%) 
Ovary             
I 489 96% (94% - 98%)  88% (84% - 91%)  80% (74% - 85%) 
II 164 79% (72% - 85%)  49% (40% - 58%)  35% (26% - 46%) 
III 1067 63% (60% - 66%)  23% (20% - 26%)  15% (12% - 18%) 
IV 422 44% (39% - 49%)  7% (4% - 10%)  4% (2% - 7%) 
unknown 58 31% (19% - 44%)  16% (7% - 28%)  14% (5% - 27%) 
Penis             
I 84 94% (84% - 100%)  82% (65% - 96%)  76% (51% - 100%) 
II 37 95% (78% - 102%)  88% (65% - 105%)  95% (65% - 119%) 
III 23 74% (50% - 90%)  50% (23% - 77%)  31% (6% - 71%) 
IV 6 18% (1% - 56%)         
unknown 26 99% (78% - 105%)  101% (69% - 121%)  89% (40% - 134%) 
Prostate             
I 1820 100% (99% - 101%)  96% (92% - 99%)  105% (90% - 119%) 
II 4550 99% (98% - 100%)  91% (89% - 93%)  76% (72% - 81%) 
III 1868 100% (99% - 101%)  88% (85% - 91%)  69% (62% - 76%) 
IV 3185 86% (84% - 87%)  39% (37% - 41%)  24% (21% - 27%) 
unknown 427 87% (82% - 91%)  63% (56% - 70%)  54% (44% - 66%) 
Kidney             
I 234 101% (98% - 102%)  95% (85% - 102%)  75% (52% - 95%) 
II 856 96% (94% - 97%)  84% (80% - 87%)  70% (64% - 75%) 
III 483 89% (85% - 92%)  66% (60% - 71%)  56% (48% - 64%) 
IV 599 33% (29% - 37%)  10% (7% - 13%)  7% (5% - 10%) 
unknown 33 49% (30% - 66%)  47% (26% - 69%)  54% (23% - 93%) 
Renal Pelvis and Ureter           
I 123 99% (93% - 101%)  80% (68% - 90%)  60% (44% - 77%) 
II 55 93% (81% - 99%)  62% (44% - 78%)  37% (18% - 60%) 
III 100 68% (57% - 77%)  36% (25% - 48%)  35% (22% - 49%) 
IV 111 22% (15% - 30%)  9% (4% - 17%)  7% (2% - 17%) 
unknown 29 73% (52% - 87%)  65% (40% - 86%)  32% (7% - 71%) 
Bladder             
I 2000 97% (96% - 98%)  82% (79% - 85%)  72% (67% - 77%) 
II 1095 74% (71% - 77%)  43% (39% - 47%)  35% (30% - 40%) 
III 539 60% (55% - 64%)  33% (28% - 38%)  26% (19% - 33%) 
IV 613 33% (29% - 37%)  9% (7% - 12%)  6% (4% - 9%) 
unknown 150 56% (47% - 64%)  42% (32% - 53%)  35% (22% - 50%) 
Urethra             
I 9 105%    95% (36% - 120%)  43% (5% - 99%) 
II 12 88% (51% - 101%)  73% (27% - 107%)     
III 5 62% (13% - 91%)  35% (1% - 84%)     
IV 8 25% (3% - 56%)  13% (1% - 44%)     
unknown 6 85% (28% - 99%)  38% (5% - 77%)  49% (7% - 99%) 
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ABSTRACT 
Background 
Carcinoid tumours are rare malignant neuro-endocrine tumours. In 1992 octreotide 
was introduced in The Netherlands as a palliative treatment for the carcinoid syndrome 
in metastatic carcinoid disease. The aims of this epidemiological study were to evalu-
ate epidemiological data and the impact of octreotide on survival in metastatic carci-
noid disease.  
Methods 
Between 1989 and 1996, 2391 patients with carcinoid disease were diagnosed in the 
Netherlands. Survival data from two Registries were available in 619 patients, diag-
nosed between 1980 and 1997. 
Results 
Between 1989-1996, incidence was 1.95/100 000 population. Under the age of 50 
years a significant female predominance was observed. Under the age of 35 years, 
appendiceal carcinoid was the most frequently diagnosed primary site. Incidence of 
distant metastases at diagnosis for appendix and lung primary sites was 1.6% and 
5.5%, compared to 40% in the other primary sites. Multivariate analysis of 619 pa-
tients revealed that age, stage and appendix localization independently predicted sur-
vival, however, only year of diagnosis after 1992 independent predicted survival 
(p=0.012). 
Conclusions 
The female predominance found under the age of 50 years suggests hormonal influ-





In 1907 Oberndorfer1 investigated tumours originating in the ileum of six patients who 
died from other causes in a necropsy study. He proposed the name “Karzinoid” (carci-
noma-like), as he did not find any infiltration in surrounding tissues or distant metasta-
ses in these specimens. However, in 1890 Ransom2 described a patient with a carci-
noid syndrome and liver metastases: pain after food intake followed by diarrhoea, 
attacks of dyspnoea, a grossly enlarged liver with numerous cancerous nodules and a 
polypoid growth in the ileum of the size of a walnut. 
As carcinoid tumours arise from cells of the diffuse neuro-endocrine system, almost 
any site can be affected. However, most carcinoid tumours originate from the gastro-
intestinal tract or the lungs. Peptide production is the hallmark of the disease3, result-
ing in substantial morbidity (i.e. flushing, diarrhoea and/or wheezing, known as the 
carcinoid syndrome) in approximately 10% of the patients (mostly with liver metasta-
ses). The most frequently detected peptide responsible for the carcinoid syndrome is 
serotonin, described by Lembeck4 in 1953. Serotonin is synthesized by the decarboxy-
lation of 5-hydroxytryptophan, a derivative of tryptophan. Serotonin is subsequently 
metabolized by monoamine oxidase to 5-hydroxy indole acetic acid (5-HIAA) and ex-
creted in the urine. 
Carcinoid tumours are rare and the incidence is approximately 5% of the incidence of 
cancer of the colon5. Carcinoid tumours are malignant, but even in the presence of 
metastatic disease these tumours often have an indolent nature. When metastatic 
disease is present, treatment is primarily aimed at palliation of the incapacitating 
symptoms of the carcinoid syndrome with somatostatin analogues, interferon-α or 
MIBG6. Surgery is indicated for the primary tumour in case of obstruction. However, in 
metastatic disease of the liver palliative resection is usually not feasible due to in-
volvement of both liver lobes. 
The aim of this study was to evaluate epidemiological data of carcinoid tumours in the 
Netherlands and to investigate whether survival has improved since 1992, when oc-
treotide became available nationwide. 
PATIENTS AND METHODS 
The Netherlands Cancer Registry (NCR), which has been operating since 1989, is a 
population-based cancer registry, with systematic collection of data on all malignant 
neoplasms. The NCR consists of nine regional registries, each part of a comprehensive 
cancer centre. In all Dutch hospitals, pathologists enter their coded histological diag-
noses in a computer system, which notifies one of the regional cancer centres 5. The 
cancer registries do not register patients treated by a general practitioner only. This 
well known systematic under-registration for all cancers is estimated to be 1.3% for 
the registry of the Comprehensive Cancer Centre Zuid-Nederland and at 1.6% in the 
registry of the Comprehensive Cancer Centre Limburg7,8. Due to occasional errors and 
shortcomings in notification procedures, additional incompleteness is possible. 
The database of the NCR was searched for patients with carcinoid tumours, i.e. all 
ICD-O M-8240/* codes (thus excluding argentafinomas, Goblet cell carcinoids, APU-
Domas and patients with mixed tumours), diagnosed from 1989 until 1996. To com-
pare incidence rates between different populations, age-adjusted incidence rates were 




calculated. For the calculation of the European standardised rates (ESR), the European 
Standard Population was used 9. For estimation of survival, only data from two regions 
(Comprehensive Cancer Centre South 1980-1992 and Comprehensive Cancer Centre 
Amsterdam 1988-1997) were available. Unfortunately cause of death was not avail-
able. Survival was calculated as crude and as relative survival, using a computer pro-
gram from the Finnish cancer registry 10. Statistical analysis, including the Kaplan-
Meier estimates of survival and the Cox multivariate regression analysis were per-
formed using Stata 6.0 for Windows. To detect survival differences that could relate to 
the use of somatostatin analogues since 1992, patients with metastatic disease from 
primary midgut, lung and unknown primary site were selected for their probability of 
displaying the carcinoid syndrome, excluding patients with primary rectal and GIT 
foregut tumours. For this purpose only, patients that died within 3 months after diag-
nosis were excluded from this analysis, as they probably did not receive (long-term) 
octreotide therapy.  
RESULTS 
Incidence data 
The total number of patients registered from 1989 until 1997 was 2391. The annual 
total number of new patients with carcinoid disease ranged from 218 to 331. Discard-
ing the first year of registration, European Standardised Incidence Rates remained 
stable at 1.95/100 000, evenly distributed between both sexes (Table 1).  
 
 
Table 1. Incidence of carcinoid tumours in the Netherlands, 
1989-1996 
Men    Women  Women 
 n ESR   n ESR  n ESR 
1989  95 1.4  124 1.5  219 1.4
1990 134 1.9  170 2.0  304 2.0
1991 138 2.0  153 1.8  291 1.9
1992 145 2.0  172 2.1  317 2.0
1993 136 1.9  168 2.0  304 1.9
1994 136 1.8  169 1.9  305 1.9
1995 167 2.2  175 2.0  342 2.1
1996 133 1.8  176 2.0  309 1.9
 
Source: Netherlands Cancer Registry 
ESR = European Standardised Rate 
 
Two peaks could be identified in the age-specific incidence rates: a small one 
(±1.5/100000) between 15 and 25 years, consisting of considerably more women than 
men, and a large one (± 7.5-9.5/100 000) between 65-75 years, with a male predomi-
nance. Under the age of 50 a female predominance could be observed, both for the 
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Figure 1. Age-specific incidence of carcinoid disease in the Netherlands according to gender and 
localisation of the primary tumour, 1989-1996 (n=2391). 
Source: Netherlands Cancer Registry 
 
Table 2. Carcinoid tumours in the Netherlands according to primary site and age group, 1989-
1996 
Age group (years) 
  < 30 30-44 45-59 60-74 > 74 
Total 






























































































Breasts - 2 1 4 10 17 






















Other sites - - - - 1 1 
Unknown primary site 1 19 66 136 67 289 
Total 375 355 499 769 393 2 391 
       
Source: Netherlands Cancer Registry 
 




The main primary sites were: appendix (27%) and lung (22%). In 12% the site of the 
primary tumour was unknown. Of all 2391 carcinoid tumours, 1492 (62%) were lo-
cated in the gastro-intestinal tract. In only 68 cases (3%) a primary site outside the 
gastro-intestinal tract or the bronchopulmonary tree was identified. Appendiceal carci-
noid was more frequent in young people: 72% was younger than 45 years (Table 2). 
Presentation with distant metastases was found in 22%; in 11% stage of disease was 
unknown. The distribution of patients with an unknown stage between the various 
subgroups was similar. In lung or appendiceal primary site presentation with distant 
metastases was seen in only 4.8% and 1.5%. Among all patients with distant metasta-
ses a primary site was identified in only 45% (Table 3).  
 









Head and neck     
Larynx 1 8 1 10 
Middle ear - 5 4 9 
Other - 4 - 4 
Gastro-intestinal     
Stomach 9 69 26 104 
Small bowel 90 197 62 349 
Appendix 10 575 69 654 
Large bowel (excl. appendix) 44 81 10 135 
Rectum 10 118 8 136 
Pancreas 29 28 11 68 
Liver - 6 3 9 
Other 10 17 10 37 
Lung-mediastinum     
Lung 25 456 44 525 
Thymus/mediastinum 1 11 5 17 
Breasts 2 15 - 17 
Urogenital     
Ovaries 3 12 2 17 
Prostate 1 3 - 4 
Other - 6 - 6 
Other sites - 1 - 1 
Unknown primary site 289   289 
Total 524 1612 255 2 391 
     
Source: Netherlands Cancer Registry 
Survival data 
Stage of disease influenced prognosis significantly: overall relative five-year survival 
rates for local disease was 93%, for regional disease 74% and for distant metastases 
19%, differences between stages were statistically significant (p<0.05, using the log-
rank test). For localised disease relative 5-year survival rates were not significantly 
different between the different primary sites, (table 4).  
Using the Cox multivariate regression analysis for 619 cases and six co-variates (age, 
gender, stage of disease, primary localisation [appendix, lung, midgut, unknown], 
period of diagnosis [before or after 1992] and cancer centre [Comprehensive Cancer 
Centre South 1980-1992 and Comprehensive Cancer Centre Amsterdam 1988-1997]), 
Chapter 4.2 
 104 
age (p=0.000), stage (p=0.000), gender (p=0.001) and a primary appendix localiza-
tion (p=0.012) were independent predictors of survival.  
 
Table 4. Relative survival of carcinoid tumours according to stage and primary site, Amster-
dam Cancer Registry (1988-1997) and Eindhoven Cancer Registry (1980-1992) 
Stage Primary site Cases Five-year survival (%) 95% CI 
All 694 72 68-77 
Appendix 198 95 91-99 
GIT, appendix excl. 227 61 53-70 
Lung 159 80 71-88 
Other 29 67 43-91 
All 
Unknown 81 19 6-32 
All 387 93 89-97 
Appendix 186 96 92-100 
GIT, appendix excl. 71 88 76-100 
Lung 116 92 84-100 
Localised 
Other 14 85 53-100 
All 63 74 60-88 
Appendix 8 100 100 
GIT, appendix excl. 33 85 66-100 
Lung 17 45 17-73 
Regional 
Other 5 65 15-100 
All 164 19 11-28 
Appendix 2 0 0 
GIT, appendix excl. 67 21 8-33 
Lung 10 0 0 
Other 4 43 0-100 
Distant 
Unknown 81 19 6-33 
All 80 63 50-77 
Appendix 2 55 0-100 
GIT, appendix excl. 56 61 44-78 
Lung 16 77 50-100 
Unknown 
Other 6 56 13-98 
     




In patients with distant metastases from lung, midgut or unknown primary (n=107), 
crude survival was clearly affected by period of diagnosis (log-rank test: p=0.007, 
figure 2). Median survival increased from 24 to 43 months. Three-year survival in-
creased significantly from 29% to 66%. In the Cox multivariate analysis, assembled 
from 5 parameters (age in 5y cohorts, gender, primary site [appendix, lung, un-
known], year of diagnosis [before 1992, from 1992] and cancer centre), only period of 
diagnosis was an independent predictor of survival (p=0.012). 
DISCUSSION 
In The Netherlands, between 1990 and 1996 European Standardised incidence Rates 
(ESR) for carcinoid tumours remained stable at 1.95/100 000, with an equal distribu-
tion between the sexes. Six other reports concerning incidence revealed incidence 




rates between 0.79 (per 100 000 in England) and 1.88 (per 100 000 in African Ameri-
cans), with a slight female predominance11,12,13,14,15,16. An explanation for this differ-
ence could be that in The Netherlands all carcinoids, including benign appendiceal 
carcinoids, were entered in the database of the NCR, resulting in higher incidence 
rates compared to the SEER database (0.54 vs. 0.10 per 100 000). As all appendiceal 
carcinoids were entered in the database of the NCR, only 1.5% metastatic disease was 
found in patients with appendiceal carcinoid at diagnosis, compared to 8.5% found in 
the SEER database. In a large (n=16 294) autopsy study from in Sweden between 
1958 and 1969, representing 63% of the people who died in that area, a total of 201 
carcinoid tumours were found, resulting in an incidence of 8.4/100 000 population17.  
 
Figure 2. Overall survival in 107 carcinoid patients with distant metastases from a midgut, lung 
or unknown primary site, according to year of diagnosis. Univariate analysis was performed 
using log-rank test. 
Source: Amsterdam Cancer Registry (1988-1997) and Eindhoven Cancer Registry (1980-1992). 
 
In the present study stage of disease was unknown in 11%. This was mainly due to 
insufficient information in the medical records on T- and N-stage of the TNM-
classification. Moreover, many carcinoid tumours were found at sites where the TNM-
classification is not applicable. Although in many of those cases the extent of disease 
was registered, information on the extent of disease was not always available. 
The overall incidence was equally distributed between the sexes. However, for the two 
most frequent primary sites (appendix and lung), in patients under the age of 50 
years, women were affected twice as often as men (for the other primary sites differ-
ences did not reach statistical significance). For appendiceal carcinoid this might be 
explained by a diagnostic bias, because women have a higher rate of abdominal pro-
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cedures than men: incidental appendectomy is approximately five times more often 
performed in females compared to men throughout the reproductive years 16,18 19 20. In 
contrast, the higher incidence of lung carcinoids under the age of 50 cannot be ex-
plained by the same diagnostic bias as in appendiceal carcinoids and suggests a com-
mon (hormonal) etiologic factor for all primary sites. In addition, a female predomi-
nance was also reported for gastric, colonic, and bronchopulmonary carcinoids during 
the first 50 years of life16, and in the SEER database a significantly higher female/male 
ratio for carcinoid lesions of the appendix was observed than for malignant non-
carcinoid lesions of the appendix (2.12 vs. 0.89)21.  
Not surprisingly we found that stage did matter for prognosis; five-year survival rates 
between stages were significantly different. These findings were in line with other 
reports. Modlin and Sandor presented five-year survival rates: 75-80% for localised 
disease, 30-35% for primary midgut carcinoid with liver metastases and 15-20% for 
patients with liver metastases of a hindgut or foregut primary14.  
Differences in five-year relative survival rates for localised disease between appen-
diceal and other gastro-intestinal carcinoids (96% vs. 88%) were not statistically sig-
nificant. In contrast Sandor and Modlin found their differences (94% vs. 73%) to be 
significant and their result could be extended to other stages.  
Treatment of patients with the carcinoid syndrome is aimed at a reduction of the inca-
pacitating symptoms, as cure is almost never a feasible option. Since 1992, octreotide 
has become the main therapeutic regimen for carcinoid syndrome-related complaints 
in The Netherlands. Octreotide is often suggested to prolong survival but this has 
never been confirmed. Results from the present study might suggest that octreotide 
could have been a contributor to the increased survival in patients with distant metas-
tases from midgut, lung or unknown primary site diagnosed since 1992. Virtually all 
patients with the carcinoid syndrome exhibit distant metastases and the majority of 
patients with liver metastases from midgut, lung or unknown primaries present with, 
or will eventually develop, the carcinoid syndrome. Therefore, patients with distant 
metastases from midgut, lung or unknown primary site were the best substitute for 
patients with the carcinoid syndrome, as expression of the carcinoid syndrome was not 
an item in the database of the NCR.  
Treatment strategies for carcinoid disease were comparable throughout the country. 
The two regions with available survival data were considered representative. Multivari-
ate analysis further emphasised the absence of regional differences in treatment 
strategies. Interferon-alpha was used sporadically and in trials, therefore not thought 
to play a major role in overall survival. As the improvement in survival in patients with 
metastatic carcinoid disease could also reflect a general improvement in all patients 
with carcinoid disease, we verified that there was only a minor, non-significant, im-
provement in patients with non-metastatic carcinoid disease. The study design was 
incapable to detect and to exclude the possible influence of earlier disease detection, 
stage migration, the effect of a more adequate therapy of carcinoid heart disease and 
the prevention of a carcinoid crisis on survival.  
Improved survival in patients with metastatic disease after 1992 (confirmed by multi-
variate analysis) could relate to the use of octreotide and should implicate further in-
vestigation of the role of octreotide in tumour growth suppression, not only in patients 
with the carcinoid syndrome but also in patients with metastatic disease without the 




carcinoid syndrome and, maybe, even in patients without evidence of metastatic dis-
ease. 
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4.3 Incidence and survival rate of women 
with cervical cancer in the Greater Am-
sterdam area 
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women with cervical cancer in the Greater Amsterdam area. 
Br J Cancer. 2003 Sep 1;89(5):834-9. 
ABSTRACT 
Background 
To evaluate the effect of population-based cervical cancer screening on the occurrence 
of cervical cancer in The Netherlands, we investigated the incidence and survival of 
cervical cancer registered by a cancer registry in the Greater Amsterdam area. 
Results 
The incidence rate of squamous cell carcinoma decreased significantly from 9.2/100 
000 women in 1988 to 5.9/100 000 in 2000 (P<0.001). The incidence rate of adeno-
carcinomas remained stable. After adjustment for age, stage and lymph node involve-
ment, the relative risk of death was 1.6 times higher for patients with adenocarcino-
mas than for patients with squamous cell carcinoma (95% CI 1.2–2.1). The decreased 
survival was related to histological type, as the effect remained significant after correc-
tion for confounding factors. Over time, the prognosis of women with squamous cell 
carcinoma improved significantly. No significant change was observed for women di-
agnosed with adenocarcinoma. 
Conclusions 
These results suggest that the screening programme in The Netherlands as executed 
in the Greater Amsterdam area is associated with a decreased incidence and increased 
survival of patients with squamous cell carcinoma, but fails to detect (pre)malignant 
lesions of adenocarcinoma. Since more than 92% of adenocarcinomas and its precur-
sors contain high-risk HPV, adding HPV testing to cytological screening might improve 






Population-based cervical cancer screening has led to a decrease in the incidence of 
cervical cancer (Gustafsson et al, 1997; Vizcaino et al, 2000). However, recent data 
suggest that the decrease in incidence is caused by a decrease of squamous cell carci-
noma, while the incidence of adenocarcinoma of the cervix shows no 
change or sometimes even an increase (Anttila et al, 1999; Bergstrom et al, 1999; 
Hemminki et al, 2001; Liu et al, 2001). 
It has been suggested that the unchanged or even increased incidence of adenocarci-
noma of the cervix is the result of systematic underscreening of cervical smears for 
(pre)malignant changes of adenocarcinoma of the cervix (Parkin et al, 1985; Mitchell 
et al, 1995; Stockton et al, 1997). Moreover, patients with adenocarcinomas of the 
cervix are considered to have a decreased survival compared to patients with 
squamous cell carcinomas (Hopkins and Morley, 1991; Lai et al, 1999; Nakanishi et al, 
2000; Grisaru et al, 2001). It has been suggested that this decreased survival is asso-
ciated with higher stages of disease with which patients with adenocarcinomas are 
detected. 
Here, we report on the incidence and survival rates of cervical cancer cases registered 
by a cancer registry in a large geographically defined region of The Netherlands, the 
Greater Amsterdam area. Special attention was paid to trends in incidence and survival 
rates for cases of squamous cell carcinoma and adenocarcinoma. 
MATERIALS AND METHODS 
Data collection 
The cancer registry of the Comprehensive Cancer Centre Amsterdam (CCCA, ‘Amster-
dam Cancer Registry’) is a population-based cancer registry since 1988, and part of the 
nationwide Netherlands Cancer Registry as of 1989. It covers two out of 12 Dutch 
provinces: Noord-Holland and the major part of Flevoland. The population of the CCCA 
region increased from 2.50 million on 1 January, 1988 to 2.80 million on 1 January, 
2001. All malignant tumours were registered in all 20 hospitals in the region, compris-
ing two university hospitals and a specialised cancer 
hospital (where cancer patients are treated). Clinical information and pathology data 
were extracted from the medical records. Apart from demographic data, data were 
collected on tumour site, morphological classification (according to the 
International Classification of Diseases for Oncology) and stage of the tumour. The 
fourth edition of the TNM-classification was used whenever applicable (Hermanek and 
Sobon, 1987). In 1988–1993, the FIGO stage was registered separately, and after 
1993 the FIGO stage was derived from TNM stage. Data concerning participation in 
cervical cancer screening programmes were not available. 
For this study, all cervical cancer cases diagnosed between 1 January, 1988 and 31 
December, 2000 were selected from the cancer registry. The following tumours were 
excluded: non-invasive tumours and tumours diagnosed in patients living outside the 
CCCA region. Patients diagnosed in a hospital outside the region, but living in the 
CCCA region were included. Information on the vital status of all patients was collected 




in the hospitals and from general practitioners. However, the majority of the informa-
tion on vital status was obtained from record linkage of computerised data on all de-
ceased persons in the study period that were made available by 51 of the 74 munici-
palities in the CCCA region (covering more than 85% of the population). Inquiries 
about the vital status of patients living in the other 23 municipalities were made at the 
municipal population registers and at the Central Office for Genealogy of The Nether-
lands, The Hague. Less than 1% of the cases were lost to follow-up. In the survival 
analyses, cases diagnosed in 1998–2000 were excluded, because of the short period of 
follow-up. Tumours first diagnosed at autopsy, second (or third, etc.) tumours and 
non-carcinomas were also excluded from the survival analyses. Follow-up of the pa-
tients diagnosed in 1988–1997 was complete until at least 1 January, 1999. 
Population data of The Netherlands were obtained from Statistics Netherlands (CBS, 
Voorburg/Heerlen, The Netherlands). Data from Statistics Netherlands were also ob-
tained with respect to the survival of the general Dutch population. 
Statistical analysis 
Incidence of cervical cancer was calculated per 100 000 person years. Direct stan-
dardisation was used for age adjustment with respect to the European standard popu-
lation, and the European standardised rates (ESRs) were calculated. Trends in the 
incidence of the ESR were investigated by calculating the estimated annual percent 
change (EAPC) (Visser et al, 2001). For the analyses, cases were divided into 
squamous cell carcinoma, adenocarcinoma including adenosquamous carcinoma and 
other histological type (i.e., other and unspecified carcinomas, sarcomas and unde-
fined tumours). Age was divided into 15-year categories. However, age categories of 
15–29 and 30–44 years were analysed jointly in the survival analyses, based on the 
low number of cases (n=90) in the category of 15–29 years. Differences in distribution 
over stage and age categories were assessed with X2 statistics. 
Relative survival and 95% confidence intervals (CIs) were calculated as a measure of 
disease-specific survival (Hakulinen and Abeywickrama, 1985). The relative survival is 
the ratio between crude and expected survival and is close to disease-specific survival. 
We did not calculate disease-specific survival, because the cause of death was not 
available as linkage with the death registry in The Netherlands is not possible. 
The Cox multivariate regression analysis for survival was performed to investigate sur-
vival. Associations were examined for all cases, and for cases of squamous cell carci-
noma and adenocarcinoma separately. In the analyses, the FIGO classification was 
used to adjust for stage. Lymph node status is not considered in the FIGO classifica-
tion for cervical carcinoma, and therefore it was introduced in the analyses as a sepa-
rate variable. For cases diagnosed in 1988, TNM was not registered, so these cases 
were classified as ‘nodal involvement unknown’. Age, stage and nodal involvement 
were divided into categories and entered into the model as dummy variables. P-values 
of 0.05 or less were considered statistically significant. Using STATA 6.0 for Windows, 




From 1988 up to 2000, 1925 patients were diagnosed with invasive cervical cancer 
(Table 1). The annual number of incident cases of cervical cancer decreased from 157 
patients registered in 1988 to 135 patients in 2000. The ESR decreased from 
11.8/100000 women in 1988 to 8.2/100 000 women in 2000. The total ESR decreased 
by 2.7% annually (P<0.001). This decrease in incidence was mainly caused by a de-
crease in the incidence of squamous cell carcinoma cases, as the EAPC in ESR for 
squamous cell carcinomas was -3.2% (P<0.001). For adenocarcinomas, there was no 
statistically significant trend in the incidence (EAPC -1.1%, P=0.54). The incidence of 
other cervical malignancies decreased with 1.4% annually (P=0.74). During the study 
period, the contribution of adenocarcinomas to the total number of malignancies in-
creased from 16% in 1988–1990 to 18% in 1998–2000. 
 
Table 1. Incidence of cervical cancer in the Greater Amsterdam area, the Netherlands, 1988–
2000 
 SCC  AdCx  Other  Total 
Year Cases ESR   Cases ESR  Cases ESR  Cases ESR 
1988 128 9.7  22 1.6  7 0.5  157 11.8 
1989 129 9.5  24 1.8  2 0.2  155 11.5 
1990 125 8.8  29 2.2  4 0.3  158 11.3 
1991 111 7.6  19 1.2  4 0.3  134 9.0 
1992 134 9.5  28 1.9  6 0.4  168 11.9 
1993 126 8.9  30 2.1  2 0.2  158 11.1 
1994 114 7.5  26 1.8  4 0.3  144 9.6 
1995 120 7.8  25 1.7  3 0.2  148 9.7 
1996 107 6.8  18 1.2  7 0.4  132 8.5 
1997 117 7.4  32 2.1  4 0.2  153 9.6 
1998 118 7.5  33 2.1  2 0.1  153 9.6 
1999 108 6.8  17 1.1  5 0.3  130 8.2 
2000 100 6.1  26 1.6  9 0.6  135 8.2 
EAPC  -3.2%   -1.1%   -1.4%   -2.7% 
P-value  <0.001  0.54 0.74  0.001 
            
SCC=squamous cell carcinoma; AdCx=adeno(squamous)carcinoma; ESR=European standardised rate; 
EAPC=estimated annual percent change 
 
The median age of patients with adenocarcinoma was 3 years below the median age 
of patients with squamous cell carcinoma, that is 44 years (range: 18–92) and 47 
years (range: 19–98), respectively (P<0.05). Age-specific incidence was highest in age 
groups 35–39 and 70–84 years for squamous cell carcinoma patients, and the age-
specific incidence was highest in the age group 35–49 years for adenocarcinoma pa-
tients (Figure 1). 
Younger patients were more often diagnosed in early stages of cancer than older pa-
tients (Figure 2). Of women 15–29 years, 82% were diagnosed with FIGO stage I dis-
ease, while only 15% of patients 75 years and over were diagnosed with FIGO stage I 
disease. Only 2% of the patients in the age category 15–29 years were diagnosed in 
stage IV, while 14% of the oldest patients were diagnosed in this stage. Figure 3 
shows that 55% of squamous cell carcinomas and 65% of patients with adenocarci-




nomas were diagnosed in FIGO stage I (P=0.003). However, adenocarcinomas were 
diagnosed less often in the microinvasive (i.e., Ia) stage of the disease than squamous 
cell carcinomas (15 and 22%, respectively) (P<0.0001). The percentage of cases diag-
nosed in FIGO stage IV did not differ statistically significantly between squamous cell 
carcinomas (7%) and adenocarcinomas (6%) (P=0.71). During the study period, there 
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Figure 7. Stage at diagnosis by 15-year age category of patients in the Greater Amsterdam 
area, the Netherlands, 1988–2000. 
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During 1988–1997, there were 1441 patients with cervical carcinoma in the region of 
the CCCA, 480 of whom died (33.3%). The median follow-up time was 56 months 
(range: 0–165 months). The overall 5-year relative survival of cervical carcinoma was 
71% (Table 2). Relative survival decreased from 85% for women o45 years to 41% for 
women of 75 years and over. Patients with FIGO stage I had a relative survival of 91% 
decreasing to 16% for tumours diagnosed in FIGO stage IV. Relative survival of 
squamous cell carcinomas was 72% (95% CI: 69–75%), and somewhat lower for 


























Figure 8. Stage at diagnosis by histological type of patients in the Greater 
Amsterdam area, the Netherlands, 1988-2000 
 
Table 2. Relative survival of patients with cervical carcinoma in the Greater Amsterdam area, 
the Netherlands in 1988-1997 
Variable Category Cases 5-year survival (%) 95% CI (%) 
All cases  1 441 71 68-74 
Age <45 665 85 82-88 
 45-59 321 72 66-77 
 60-74 285 54 47-60 
 75+ 170 41 31-52 
FIGO stage I 831 91 88-93 
 II 304 57 50-64 
 III 168 35 27-43 
 IV 99 16 9-24 
 Unknown 39 44 27-61 
Histology SCC 1 169 72 69-75 
 AdCx 244 66 59-72 
 Other/unspecified carcinoma 28 60 38-78 
 
CI=confidence interval; SCC=squamous cell carcinoma; AdCx=adeno(squamous)carcinoma 




Table 3 displays the results of the multivariate analysis of survival for all types of cervi-
cal cancer. Compared to FIGO stage I, all other stages had significantly increased HRs. 
Lymph node status is not considered in the FIGO classification for cervical carcinoma. 
For cases diagnosed in 1988, TNM was not registered and these cases were classified 
as ‘nodal involvement unknown’. However, nodal involvement appeared to be associ-
ated with an increased risk of death (HR 2.1, 95% CI 1.6–2.7). Tumour histology was 
investigated with squamous cell carcinoma cases as reference category. Univariately, 
the HR of adenocarcinomas was slightly increased (HR 1.1), while other/unspecified 
carcinomas were associated with a significant increase in risk. The increased risk for 
other/unspecified carcinomas disappeared with multivariate adjustment, indicating that 
the increase in risk was caused by confounding by age and stage. After adjustment, 
the HR for adenocarcinomas was significantly increased (HR 1.6, 95% CI 1.3–2.1). 
Over time, the prognosis of patients with cervical cancer improved, as the multivariate 
HRs were decreased for the periods 1991–1993 and 1994–1997 as compared to the 
reference period 1988–1990. Adjustment for stages 1a and 1b separately did not alter 
these findings substantially (data not shown).  
 
Table 3. Relative risk of death for patients in the Greater Amsterdam area, The Netherlands, 
with cervix carcinoma diagnosed in 1988–1997 (n=1441) 
   Univariate  Multivariatea 
Factor Cases  Hazard ratio 95% CI  Hazard ratio 95% CI 
FIGO stage      
I 831 1 Reference  1 Reference 
II 304 4.9* 3.8-6.3  3.3* 2.6-4.7 
III 169 10* 7.9-13  6.4* 4.7-8.5 
IV 99 19* 14-25  11* 7.6-15 
Unknown 39 9.2* 5.9-14  5.7* 3.6-9.1 
Nodal involvement      
No 563 1 Reference  1 Reference 
Yes 668 3.2* 2.5-4.1  2.1* 1.6-2.7 
Unknownb 210 1.6* 1.3-2.0  1.4* 1.1-1.8 
Morphological type      
SCC 1 169 1 Reference  1 Reference 
AdCx 244 1.1 0.9-1.4  1.6* 1.3-2.1 
Other/unspecified carcinoma 28 1.7 1.0-3.0  0.7 0.4-1.2 
Year of diagnosis      
1988/1990 451 1 Reference  1 Reference 
1991/1993 442 0.7* 0.6-0.9  0.8* 0.6-1.0 
1994/1997 548 0.8 0.7-1.1  0.8* 0.6-1.0 
 
a Adjusted for age category and all other factors in the table. 
b Cases diagnosed in 1988 were all classified as unknown. 
*P<0.05. CI=confidence interval; SCC=squamous cell carcinoma; AdCx=adeno(squamous)carcinoma. 
 
Squamous cell carcinoma cases and adenocarcinoma cases were also analysed sepa-
rately (Table 4). Both for squamous cell carcinomas and adenocarcinomas, survival 
decreased with increasing age, higher FIGO stage and positive lymph nodes at diagno-
sis (data not shown). The improvement in survival of women with cervical cancer dur-
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ing the period 1988–1997 was associated with cases of squamous cell carcinoma only. 
Survival of women with cervical adenocarcinoma did not improve during the study 
period (Table 4). 
 
Table 4. Relative risk of death for patients in the Greater Amsterdam area, The Netherlands, 
with cervix carcinoma diagnosed in 1988–1997 (n=1441). Year of diagnosis as an indicator of 
survival, separately for patients with squamous cell carcinoma and adenocarcinoma 
  Univariate  Multivariatea 
Factor   Hazard ratio 95% CI  Hazard ratio 95% CI 
Year of 1988/1990 1 Reference  1 Reference 
diagnosis 1991/1993 0.9 0.5-1.5  0.8 0.5-1.5 
AdCx 1994/1997 1.0 0.6-1.6  1.2 0.7-2.0 
Year of 1988/1990 1 Reference  1 Reference 
diagnosis 1991/1993 0.7* 0.6-0.9  0.8* 0.6-1.0 
SCC 1994/1997 0.8 0.6-1.0  0.8* 0.6-1.0 
 
aAdjusted for age, stage and nodal involvement. 
*P<0.05. CI=confidence interval; SCC=squamous cell carcinoma; AdCx=adeno(squamous)carcinoma. 
DISCUSSION 
Our results show that the incidence of cervical cancer has decreased significantly dur-
ing the period 1988–2000, and that this decrease is caused by a decrease in the inci-
dence of squamous cell carcinomas. In multivariate analyses, survival for patients di-
agnosed with adenocarcinoma of the cervix was significantly lower than survival for 
patients with squamous cell carcinoma. This indicates that women with adenocarci-
noma of the uterine cervix have an intrinsically increased risk of death compared with 
women with squamous cell carcinoma independent of stage, age and nodal involve-
ment. 
We studied patients with cervical cancer who were all diagnosed within a geographi-
cally defined region in The Netherlands: the Greater Amsterdam area. As data were 
obtained by the Regional Cancer Registry, we were able to study an unbiased popula-
tion of women with different histological types of cervical cancer for factors associated 
with survival. In this study, the histological verification rate was 99.8%. Nationally, the 
histological verification-rate for cervical cancer is 99.7%, indicating a high accuracy 
rate of the Dutch Cancer Registries (Visser et al, 1997). 
In this study, knowledge of participation in cervical cancer screening preceding the 
diagnosis of cancer may have been relevant. We did not have data on either individual 
Pap smear taking or participation in the nationwide screening programme in this group 
of women with cervical carcinoma. Cytological screening on an individual basis has 
been available for women in this region of The Netherlands since the 1970s. A nation-
wide screening programme aimed at specific age categories was initiated in 1988. 
Between 1988 and 1996, women aged 34–54 years were screened triannually, and 
from 1996 onwards, women aged 30–60 years are screened every 5 years. Overall, 
the coverage of cervical cancer screening activities over a period of 5 years is ap-
proximately 80% (van Ballegooijen and Hermens, 2000). However, regional participa-
tion in each screening round of the population-based programme is lower (60–70%). 
Even without data on screening participation, some findings do suggest the efficacy of 




screening in this region of The Netherlands. The incidence of cervical squamous cell 
carcinoma decreased significantly, while no statistically significant change in the inci-
dence of adenocarcinoma was found. Previous studies have reported that cervical ade-
nocarcinoma and its preinvasive stages are diagnosed less efficiently by Pap smear 
screening than squamous cell lesions (Mitchell et al, 1995; Stockton et al, 1997). In 
some countries, not only the absence of a decrease in incidence (Sigurdsson, 1993; 
Nieminen et al, 1995), but also increases in the incidence of cervical adenocarcinoma 
have been described in the presence of a screening programme (Bergstrom et al, 
1999; Hemminki et al, 2001; Liu et al, 2001). One study even suggested an increase in 
incidence especially in younger women (Anttila et al, 1999), whereas older women 
were not affected by increases in the incidence rate of cervical cancer. Our data do not 
support this trend. Our findings suggest a positive effect of the screening programme 
as shown by the decrease in cervical carcinoma incidence. Increasing screening par-
ticipation to obtain an even higher degree of coverage will most likely increase the 
efficacy of the screening programme in decreasing the incidence of cervical cancer. In 
our analyses, patients with cervical adenocarcinoma had a worse prognosis than pa-
tients with squamous cell carcinoma after correction for confounders such as age, 
stage and nodal involvement. Previous studies either usually lacked sufficient numbers 
of patients with adenocarcinomas (Pilch et al, 2001), or were not population-based 
(Hopkins and Morley, 1991; Nakanishi et al, 2000), or did not make direct comparisons 
between patients with squamous cell carcinoma and adenocarcinoma (Benedet et al, 
1998). Some studies attributed the decreased survival of women with adenocarcinoma 
to differences in histological type (Lai et al, 1999; Grisaru et al, 2001). In our study, 
patients with adenocarcinoma presented with more advanced stage I tumours than 
patients with squamous cell carcinomas. Still, patients with cervical adenocarcinoma 
were slightly younger at diagnosis than patients with squamous cell carcinoma, 48 and 
50 years, respectively. As the association between adenocarcinomas and a worse 
prognosis increased after correction for confounding factors, this indicates that women 
with cervical adenocarcinoma have an inherently worse prognosis than women with 
squamous cell carcinoma. The main causal factor for the development of both 
squamous cell carcinoma and adenocarcinoma of the uterine cervix is infection with 
high-risk types of the human papillomavirus (hrHPV) (Walboomers et al, 1999; Bosch 
et al, 2002). There are substantial differences with respect to the exact type of hrHPV 
and the histological diagnosis. Adenocarcinomas are more often associated with HPV 
type 18 than squamous cell carcinomas (Bosch et al, 1995, 2002; Andersson et al, 
2001; Clifford et al, 2003). Moreover, HPV 18 has been shown to be associated with a 
worse prognosis than other HPV types (Hildesheim et al, 1999; Schwartz et al, 2001), 
but this finding has been challenged (Pilch et al, 2001). An intrinsic difference between 
neoplasically converted squamous and cylindrical epithelium might also be the cause of 
the difference in prognosis, independent of HPV infection. 
The survival of patients with squamous cell carcinoma increased during 1988–1997, 
while the survival of patients with adenocarcinomas did not change significantly. Dur-
ing the study period, there were no large changes in treatment of patients with cervi-
cal cancer in any stage of the disease. The nationwide screening programme was in-
troduced in 1988. Theoretically, an improvement in the prognosis of patients with 
squamous cell carcinomas might have been caused by a major change in stage at di-
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agnosis during the study period. We did not observe such a change in stage at diagno-
sis over time (data not shown). However, we cannot exclude an effect of subtle 
changes within broad stages, such as a shift from FIGO 1b to FIGO 1a. Screening, 
leading to an earlier detection of cervical cancer even without significant changes in 
broad FIGO stage distribution, may contribute to such an effect. We were not able to 
find a trend over time in histological lymph node positivity over all stages of disease, 
as lymph node sampling is dependent on stage at diagnosis. In this study, in 31% of 
women with adenocarcinoma and 43% of women with squamous cell carcinoma, 
lymph node status was not determined histologically. Stage migration due to improved 
staging procedures might also have contributed to the increased survival. Still, the 
statistically significant difference in survival was based on small numbers of adenocar-
cinoma cases compared to squamous cell carcinoma cases. Therefore, caution should 
be taken into account when interpreting trends in the survival of adenocarcinoma 
based on these data. 
The overall 5-year survival rate was 71%. Compared to other countries in Europe, this 
is a high survival rate, with only the Nordic countries having comparable survival rates 
(Berrino et al, 1999). Other studies have also shown that within Europe, The Nether-
lands have a very low incidence, and a very high survival compared with other coun-
tries (Levi et al, 2000). It is reasonable to attribute these findings to the presence of a 
nationwide screening programme, as similar effects on incidence have been described 
in other countries with a screening programme (Gustafsson et al, 1997). Whether the 
effect on survival in the absence of changes in treatment can be exclusively attributed 
to the cervical cancer screening programme, remains a question of debate (Quinn et 
al, 1999; Sasieni and Adams, 1999). 
Our study suggests that the present screening programme for cervical cancer is effi-
cient in detecting (pre) malignant stages of squamous cell carcinoma, but fails to de-
tect (pre) malignant stages of adenocarcinoma (Sasieni and Adams, 2001). Since more 
than 92% of the adenocarcinomas and its precursors contain hrHPV (Pirog et al, 2000; 
Pilch et al, 2001), adding hrHPV testing to conventional cytological screening might 
improve the present screening programme in detecting adenocarcinoma and its pre-
cursor lesions. This should be a focus of further research concerning the functioning of 
the screening programme for cervical cancer. 
In conclusion, in the Greater Amsterdam area, the incidence of squamous cell carci-
nomas has decreased while there were no changes in the incidence of adenocarcinoma 
of the uterine cervix. Cases of adenocarcinoma of the uterine cervix are associated 
with a decreased survival rate compared to patients with squamous cell carcinoma. 
This decreased survival is related to tumour histology itself, since after correction for 
factors such as age, stage and lymph node status, the survival of adenocarcinoma 
patients is still lower compared with squamous cell carcinoma patients. 
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ABSTRACT 
Objectives 
To determine retrospectively in a population based study the survival of patients with 
bladder cancer and the local recurrence rate (LRR) after cystectomy. 
Methods 
All bladder cancer cases diagnosed between 1988 and 2001 (vital status updated until 
September 2003) were selected from the Amsterdam Cancer Registry, which covers a 
population of 2.84 million people. For all patients who underwent a cystectomy be-
tween 1988 and 1997 in 18 participating hospitals, information on local recurrence and 
the vital status was collected from the medical records.  
Results 
Five-year relative survival for all bladder cancer cases combined (n=8 321) was 75%. 
For clinical stage 0-a this was 99%, decreasing to 85% for stage 0-is and 82% for 
stage I, and to 44%, 28% and 9% for stages II, III and IV, respectively. Five-year 
relative survival after cystectomy was 81%, 44% and 23% for stages II, III and IV, 
respectively. The LRR after cystectomy (n=566) was 19% for all cases and institutions 
combined. The LRR increased with higher pT-stages and reached 11%, 23% and 31% 
for stage II, III and IV respectively, and was slightly lower in oncological centers 
(18%) than in community hospitals (20%) (not significant).  
Conclusions 
Survival is higher than the European average, but below the figure for the United 
States. Only one in three stage II-III patients was treated with cystectomy. A relatively 
high stage-specific survival is experienced after cystectomy, in spite of a local recur-




Bladder cancer is the sixth cancer in the Netherlands.1 Compared to other European 
countries, the incidence of bladder cancer is relatively low.2 In the Netherlands, more 
than two-thirds of all new bladder cancer patients present with superficial disease3, 
which can be sufficiently treated with (repeated) local treatments. A cystectomy is 
usually offered as treatment of first choice to patients presenting with muscle invasive 
bladder cancer and to patients in whom local treatment of superficial bladder cancer is 
unsuccessful. Studies on the local recurrence after cystectomy are often hospital-based 
and local recurrence rates (LRR) have been reported from 7% to 25%.4-7  
This study aims to investigate in a population-based setting the survival of bladder 
cancer patients and the LRR after cystectomy in the region of the Comprehensive Can-
cer Centre Amsterdam (CCCA). 
MATERIALS AND METHODS 
Cancer registry data 
All primary bladder tumors diagnosed in patients with residence in the CCCA-region 
(population: 2.84 million) between January 1st 1988 and December 31st 2001 were 
selected from the Amsterdam Cancer Registry, a population-based cancer registry with 
complete regional coverage. Registration clerks extract information for the registry 
from detailed hospital records. Apart from demographic data, data are collected on 
morphology, stage and primary treatment. Stage grouping in this study was according 
to the 5th edition of the TNM-classification (table 1).8 cTNM was used for the survival 
analysis which included all patients, pTNM was used in a subset analysis of cystectomy 
cases. We converted older TNM-data to the 5th edition. All T4-tumors were classified as 
stage IV, because the sub-classification into T4a/b was not available for all cases. 
 
Table 1. Stage grouping according to the 5th edition of the 
TNM-classification 
Stage tumour lymph nodes metastasis 
0-a Ta N0 M0 
0-is Tis N0 M0 
I T1 N0 M0 
II T2a, b N0 M0 
III T3a, b N0 M0 
 T4a N0 M0 
IV T4b N0 M0 
 Any T N1, N2, N3 M0 
 Any T Any N M1 
 
Follow-up 
The vital status of all patients was updated by linking files with deceased persons to 
the cancer registry. These electronic data files, covering 1988-1999, were made avail-
able by the majority of the municipal population registers and included all deceased 
residents (irrespective of cause of death). Active follow-up in the hospitals was per-
formed for patients residing in the remaining municipalities and if electronic data did 
not fully cover 1988-1999. Subsequently, the vital status of all patients still alive at last 




follow-up was updated until September 1st 2003 by linkage to the electronic death 
register of the Central Office for Genealogy (COG), which contains all deceased Dutch 
residents from October 1st 1994. This register is updated on a daily basis with data 
from all municipal population registers in the Netherlands. Patients whose follow-up 
ended before October 1st 1994 were checked in the personal record card register of 
the CBG, containing all deceased Dutch residents before October 1st 1994. Finally, 
patients not known by COG were assumed to be alive at September 1st 2003. Com-
pleteness of follow-up is estimated to be over 99.5%.9 
Cystectomy 
A subset of patients was defined by selecting patients from the cancer registry who 
underwent cystectomy during 1988-1997. Data from two small hospitals (out of 20) 
could not be included, because one hospital refused permission to extract data from 
the medical records, and because many patient-files had been destroyed in another. 
Patients referred to the oncological centers from outside the CCCA-region were ex-
cluded to keep data population based. Patients for whom cystectomy was not the pri-
mary treatment were included, but in several hospitals these cases could not be in-
cluded because of missing data in the medical records department.  
A supplementary data set including date of surgery, intent of the surgery (curative or 
palliative), presence of residual disease after surgery, and the occurrence and date of 
local recurrence (i.e. recurrence in the soft tissue within the true pelvis) was extracted 
from medical records. In case the cystectomy was not the primary treatment, TNM and 
morphology at date of cystectomy were also registered. Patients were followed at least 
5 years after cystectomy. 
Statistical methods 
Because the cause of death is not available in the population registers, we were unable 
to calculate disease specific survival. Instead, we calculated relative survival using 
STATA according to Dickman et al.10 This method corrects crude survival for expected 
mortality according to annual life tables of the general population. 
For the comparison of LRR between hospitals a standardized LRR was calculated. 
Based on the stage-specific LRR for all hospitals combined and the stage distribution in 
a specific hospital, an expected number of local recurrences was calculated for each 
hospital. The expected numbers were compared with the observed numbers and a 
stage-standardized local recurrence ratio (SLRR) was calculated as the ratio between 
the observed and expected numbers. Exact 95% confidence intervals (CI) based on 
the Poisson distribution of O, and Kaplan-Meier survival curves were calculated using 
STATA. 
RESULTS 
Primary treatment of patients with primary bladder cancer 
A total of 8 321 patients with primary bladder cancer were diagnosed between 1988-
2001. About three quarters of all patients received local treatment only as primary 
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treatment (table 2). Of the patients presenting with clinical stage II and III, 33% and 
24% received local treatment. In clinical stage II and III, more patients underwent 
radiotherapy (36% and 40%, respectively) than cystectomy (30%). Patient of 75 years 
or older underwent cystectomy less often than younger patients (chi2-test: p<0.001). 
 
Table 2. Primary treatment of primary bladder cancer in Greater Amsterdam, 1988-2001 
Primary treatment (%) cTNM-stage*/ 
 age group 
Number of 
patients Local treatment 
only 
Cystectomy 
(with or without 
radiotherapy) 
Radiotherapy Other 
0-a 3 698 98% <1% <1% 2% 
0-is 191 88% 2% 1% 9% 
I 1 914 90% 3% 5% 2% 
II 
< 75 years 

















< 75 years 
















IV 572 42% 11% 29% 18% 
Unknown 240 31% 24% 13% 33% 
Not applicable 79 28% 4% 3% 66% 
Total 8 321 76% 8% 11% 5% 
 
* stage grouping according to the 5th edition of the TNM Classification [8], but T4 classified as stage IV 
 
 
Figure 1. Crude survival according to clinical stage at diagnosis of bladder cancer patients in 

















Years after diagnosis 




Survival for all patients 
One- and five-year crude survival of all patients combined was 83% and 58%. Crude 
survival according to stage is shown in figure 1. The one- and five-year relative sur-
vival rate (RSR) was 87% and 75% (table 3). The ten-year RSR was 67% (95% CI: 
65-70%). The RSRs decrease with increasing age. 
 
Table 3. Relative survival (%) of bladder cancer patients in Greater Amsterdam, 1988-2001 
Parameter Years after diagnosis (95% confidence interval) 
 
Number 
of cases 1 5 10 
Period of diagnosis     
- 1988-1991 2 182 88 (86-90) 75 (72-77) 67 (63-70) 
- 1992-1995 2 453 86 (85-88) 76 (74-79) 69 (65-72) 
- 1996-1998 1 809 86 (84-88) 73 (71-76)  
- 1999-2001 1 877 88 (86-90)   
Sex     
- Males 6 560 89 (88-90) 76 (75-78) 69 (66-71) 
- Females 1 761 80 (78-82) 70 (67-73) 63 (58-67) 
Age group*     
- 15-44 251 95 (92-97) 90 (85-93) 86 (80-90) 
- 45-54 738 94 (92-96) 86 (83-88) 80 (75-83) 
- 55-64 1 690 92 (90-93) 79 (77-81) 73 (70-76) 
- 65-74 2 905 88 (87-89) 76 (73-78) 67 (63-70) 
- 75+ 2 733 80 (78-82) 66 (63-70) 56 (49-63) 
cTNM- stage**     
- 0-a 3 698 101 (100-101) 99 (97-101) 92 (88-95) 
- 0-is 191 99 (95-102) 85 (75-94) 78 (61-93) 
- I 1 914 97 (95-98) 82 (79-85) 73 (68-78) 
- II 1 170 74 (71-77) 44 (40-48) 36 (31-41) 
- III 457 56 (51-61) 28 (23-34) 21 (16-28) 
- IV 572 30 (26-34) 9 (6-12) 6 (3-9) 
- Unknown 240 68 (61-75) 49 (40-57) 37 (26-49) 
- TNM not applicable 79 37 (26-48) 22 (12-34) 14 (6-28) 
Morphological type 
- Transitional cell ca. 7 973 89 (88-90) 77 (76-79) 70 (67-72) 
- Squamous cell ca. 113 38 (29-47) 23 (14-32) 18 (8-31) 
- Adenocarcinoma 76 70 (58-80) 38 (26-51) 21 (10-36) 
- Undifferentiated ca. 82 37 (27-48) 14 (6-25) 11 (3-25) 
- Sarcoma 19 65 (39-83) 29 (10-53) 22 (6-47) 
- Unknown*** 58 27 (16-40) 18 (8-32) 15 (5-31) 
Morphological grade 
- Grade 1 1 626 101 (99-101) 101 (98-103) 94 (89-99) 
- Grade 2 2 594 96 (95-97) 88 (86-90) 80 (76-84) 
- Grade 3 2 858 75 (73-77) 52 (50-55) 43 (39-47) 
- Grade 4 191 44 (37-52) 26 (19-34) 19 (11-29) 
- Grade unknown 1 052 84 (82-87) 73 (69-77) 66 (61-72) 
Total 8 321 87 (86-88) 75 (74-76) 67 (65-70) 
 
* 4 cases 0-14 year 
** stage grouping according to the 5th edition of the TNM Classification [8], but T4 classified as stage IV  




For females, the RSR after five and ten years was 6% lower than for males. This was 
caused by a less favorable stage distribution in females (14% of all females were diag-
nosed as clinical stage II, 7% stage III, and 10% stage IV, compared to 14% stage II, 
5% stage III, and 6% stage IV in males). Stage-specific RSRs in females (five-year 
RSRs of 79%, 42% and 16% for stage I, II and III, respectively) were also lower than 
in males (five-year RSRs of 83%, 44% and 33% for stage I, II and III). Survival for 
patients diagnosed between 1999-2001 was almost equal to survival of patients diag-
nosed about 10 years earlier (1988-1991). 
Up to five years after diagnosis, patients with stage 0-a bladder cancer experienced a 
survival almost equal to the general population (RSR: 99%, CI: 97-101%), but the ten-
year RSR was 92% (CI: 88-95%). For patients with stage 0-is and stage I five-year 
RSRs (85% and 82%, respectively) and ten-year RSRs (78% and 73%) were almost 
equal. 
Patients with muscle-invasive bladder cancer experienced five-year survival decreasing 
from 44% for stage II, to 28% for stage III, and 9% for stage IV. The ten-year RSR 
was 36%, 21% and 6% for stage II, III and IV. Adenocarcinoma, squamous cell carci-
noma and undifferentiated carcinoma of the bladder resulted in lower survival figures 
than transitional cell carcinoma (table 3). The five-year RSR for grade I tumors was 
101%, decreasing to 88% for grade II, 52% for grade III and 26% for grade IV.  
 
Table 4. Local recurrence rate after cystectomy for bladder cancer in Greater Amsterdam, 
1988-1997 (cystectomies with palliative intent and/or macroscopic residual disease ex-
cluded) 
Local recurrence Parameter Number of 
cystectomies Yes (%) Odds Ratio No (%) Unknown (%) 
Sex      
- Males 448 85 (19) 1 (Ref.) 355 (79) 8 (2) 
- Females 118 25 (21) 1.0 (0.6-1.8) 88 (75) 5 (4) 
Morphological type      
- Transitional cell ca. 214 97 (19) 1 (Ref.) 406 (79) 11 (2) 
- Squamous cell ca. 27 3 (11) 0.4 (0.1-1.4) 22 (81) 2 (7) 
- Adenocarcinoma 18 7 (39) 2.4 (0.8-6.7) 11 (61) - 
- Undifferentiated ca. 7 3 (43) 2.4 (0.5-11) 4 (57) - 
pTNM- stage*      
- 0 (Ta/Tis) 22 1 (5) 21 (95) - 
- I 74 11 (15) }1 (Ref.) 63 (85) - 
- II 123 13 (11) 0.8 (0.4-2.0) 110 (89) - 
- III 258 59 (23) 2.2 (1.1-4.4) 189 (73) 10 (4) 
- IV 83 26 (31) 3.0 (1.4-6.7) 54 (65) 3 (4) 
- Unknown 6 -  6 (100) - 
Residual disease**      
- R0 490 90 (18) 1 (Ref.) 395 (81) 5 (1) 
-  R1 42 13 (31) 1.4 (0.7-2.9) 27 (64) 2 (5) 
- RX 34 7 (21) 1.0 (0.4-2.3) 21 (62) 6 (18) 
Hospital      
- Community hospital 458 91 (20) 1 (Ref.) 354 (77) 13 (3) 
- Oncological centre 108 19 (18) 0.8 (0.5-1.5) 89 (82) - 
Total 566 110 (19)  443 (78) 13 (2) 
 
* stage grouping according to the 5th edition of the TNM Classification [8], but T4 classified as stage IV 
** R0 = no residual disease; R1 = microscopic residual disease; RX = unknown 




Local recurrence after cystectomy 
577 patients underwent a cystectomy between 1988-1997 (number of cystectomies 
per hospital/year: 0-12), of whom eleven had macroscopic residual disease (three 
stage III, eight stage IV tumors). In 110 (19%) of the remaining 566 patients a local 
recurrence occurred (table 4). Of thirteen patients medical records were not accessible 
and it could not be established whether a local recurrence had occurred. Most of them 
died within a year after cystectomy. 
There was little difference in the LRR between males and females (19% and 21%, 
respectively). The LRR was decreased for squamous cell carcinoma compared to tran-
sitional cell carcinomas. For adenocarcinomas and undifferentiated carcinomas the LRR 
was increased (not significant). For the lower stages, the LRR was 5% in stage 0-a/0-
is, 15% in stage I, and 11% in stage II. For stage III (LRR 23%, odds ratio 2.2, CI 
1.1–4.4) and stage IV bladder cancer (LRR 31%, odds ratio 3.0, CI 1.4–6.7) the LRRs 
were significantly increased. The presence of microscopic residual disease after cystec-
tomy was an unfavorable factor (odds ratio 1.4, CI 0.7-2.9). In patients who under-
went cystectomy in an oncological centre the LRR was lower than for patients from 
community hospitals, but the difference was not statistically significant. Figure 2 shows 
that the SLRR for the various hospitals ranged from 0 to 1.7 (all hospitals combined: 
1), but for all hospitals the CI included 1.  
Figure 3 shows survival of patients after cystectomy. Crude 5-year survival of patients 
with local recurrence was 11% (median 15 months), without local recurrence 63% 
(log-rank: p<0.0001). The difference in survival between patients with and without 
local recurrence was mainly caused by the poor survival after local recurrence: median 




























Figure 2. Stage standardized local recurrence ratio after cystectomy for bladder cancer in 
Greater Amsterdam, 1988-1997 (hospitals are sorted according to the number of cystectomies; 





Figure 3. Crude survival after cystectomy for bladder cancer in Greater Amsterdam, 1988-1997 
(excluding cases dying within 3 months after cystectomy) 
 
Figure 4. Crude survival according to after local recurrence following cystectomy for bladder 
cancer in Greater Amsterdam, 1988-1997 
 Fraction surviving 
Months after local recurrence 








Months after cystectomy 

















Figure 5. Local recurrence free survival according to pathological stage after cystectomy for 
bladder cancer in Greater Amsterdam, 1988-1997. Log-rank test: stage III versus stage 0-II: 
p<0.0001; stage IV versus stage 0-II: p<0.0001; stage III versus stage IV: p=0.07 
 
Local recurrence free survival decreased with increasing stage (figure 5). There was 
little difference between the lower stages (stage 0-II). However, in stage III (log-rank 
versus stage 0-II: p<0.0001) and stage IV (log-rank versus stage 0-II: p<0.0001) the 
risk of local recurrence was higher than in lower stages. 
 
Table 5. Relative survival (%) after cystectomy of bladder cancer patients in Greater Amster-
dam, 1988-1997 
years after diagnosis (95% confidence interval) pTNM- stage* Number of 
cases 1 5 10 
0 / I 96 91 (82-96) 81 (68-92) 78 (59-95) 
II 123 92 (84-96) 81 (70-89) 69 (54-82) 
III 261 67 (61-73) 44 (37-51) 25 (17-35) 
IV 91 60 (49-70) 23 (14-34) 22 (12-33) 
Total** 577 76 (72-79) 55 (50-60) 44 (37-50) 
 
* stage grouping according to the 5th edition of the TNM Classification [8], but T4 classifies as stage IV 
** Including 6 cases with unknown stage 
 
The stage-specific RSR of patients who underwent a cystectomy (table 5) was higher 
than for the total group of bladder cancer patients, which comprises all treatments 
(table 3), with the exception of superficial bladder cancer. For stage II, the 5-year RSR 
 Fraction local recurrence free 
Months after cystectomy 













was 81% for cystectomy patients (pTNM), compared to 44% for all patients combined 
(cTNM). For stage III, these rates were 44% and 28%, respectively. 
DISCUSSION 
In this study we evaluated survival and treatment outcomes of patients with bladder 
cancer. The five-year RSR of patients diagnosed with bladder cancer between 1988-
2001 was 75%.  
Survival after five years for patients with non-invasive papillary bladder cancer equals 
survival in the general population (RSR 99%). Between five and ten years after diag-
nosis survival figures decreased (10-year RSR 92%), but this should be interpreted 
with caution. These patients are at higher risk to develop invasive bladder cancer than 
the general population and other factors (e.g. smoking with associated co-morbidity) 
may also be of importance. 
According to the EUROCARE-study on survival of cancer patients in Europe, survival of 
bladder cancer patients in the Netherlands is among the highest in Europe.11 The 
EUROCARE-study reports equally high rates for Germany, Austria, Spain and Sweden. 
In the EUROCARE-study no data are available on stage distribution, so it is unknown 
whether this result is due to a more favorable stage distribution or to other factors. 
In the USA, the reported bladder cancer survival rates from the SEER-Program are 
higher than in Europe.12 Five-year relative survival rates from the SEER-Program for 
1990-1999 are 97%, 65%, 56% and 22% for stage I, II, III and IV, respectively, 
compared to 82%, 44%, 28% and 9% in our study. Although the lower survival in our 
study may be influenced by differences in staging procedures between the USA and 
the Netherlands, differences in treatment practices may also have influenced the re-
sults. Of all patients who initially presented with clinical stage II-III bladder cancer 
only 30% underwent a cystectomy. Of the patients <75 years old (probably appropri-
ate candidates) only 44% underwent cystectomy. These percentages are remarkably 
low in view of the consensus in the Netherlands that cystectomy is the preferred 
treatment for stage II-III bladder cancer. In our study, survival of patients with stage 
II-III bladder cancer who underwent a cystectomy was much higher than for all pa-
tients combined, but comparison between these patient groups is biased by factors 
such as age, co-morbidity, and physician’s preference. Development of local recur-
rence in patients undergoing cystectomy has been reported at rates from 7% to 
25%.4-7 Sengelov already demonstrated that intensified examination resulted in more 
sites of metastases,13 and local recurrence rates are probably under-reported, as the 
finding of distant metastases decreases the need for intensified local follow up when 
local recurrences are asymptomatic. After cystectomy, the tumor recurred locally in 
one out of five patients in our study, so our results are not among the most favorable 
when compared to other studies. This might be related to the fact that many other 
studies were performed in oncological centers, while our study comprised a large 
number of community hospitals in addition to three oncological centers. No statistically 
significant difference in SLRR between the various hospitals, nor a relation between 
the number of cystectomies per hospital and the SLRR could be demonstrated. The 
LRR in the oncological centers combined was lower, but the difference was not statisti-
cally significant. However, the annual number of cystectomies by hospital was rather 




low in all hospitals. For oncological centers this was due to the exclusion of referred 
patients from outside the CCCA region. In recent years, a tendency towards centraliza-
tion of cystectomies has occurred in our region and future studies should demonstrate 
whether this has improved the results. 
Stage and grade are known prognostic indicators for local failure.14,15 In contrast to 
what we expected, no significant difference was found between LRRs after a R0-
dissection (no residual tumor after cystectomy) and R1-dissection (microscopic residual 
tumor). This might be explained by the higher death rates shortly after resection for 
patients with residual microscopic disease. These patients might not have lived long 
enough to develop clinical detectable local recurrences. In other series, margin status 
was a predictor for local recurrence, although no distinction between microscopic or 
macroscopic residual tumor was made.16 Furthermore, the use of peri-operative che-
motherapy might be of influence. In the time period of our study however, peri-
operative chemotherapy was not standard practice. Consequently, only 17 patients 
underwent this multimodality treatment. This small number does not enable separate 
analysis and conclusions. 
Patients who recur locally usually do so within the first 2 years after treatment, which 
is consistent with our findings7,14,17,18.  
Differences in LRRs may be influenced by differences in definition. Mostly, local recur-
rence is defined as bladder cancer recurrence in the soft tissue within the true pelvis, 
while tumor outside the pelvis is considered as distant metastases. Some authors, 
however, define a combination of both local and distant recurrence as distant recur-
rence only, as patient outcome appears to be dictated by concomitant systemic metas-
tases.17,19 Urethral or upper tract recurrences are sometimes considered as a local 
recurrence also. However, they represent a different biological process of recurrence, 
and both treatment and prognosis differ greatly from true pelvic recurrences.20  
The aggressive natural behavior of local recurrences after cystectomy results in poor 
prognosis in many series,14,18 and our data confirm this experience. No data were 
available about the therapy following local recurrences, but the final outcome of pa-
tients with a local recurrence appears to be poor, regardless of treatment. Despite the 
availability of chemotherapeutic regimens long-term survival is achieved in less than 
10% of these patients.17,18 
CONCLUSIONS 
The five-year RSR of all patients combined was 75%, which is slightly better than 
European figures, but the stage-specific rates are worse than American figures. 
Of all patients with stage II-III bladder cancer, only 30% underwent cystectomy. Cys-
tectomy patients experienced a relatively high stage-specific survival. After cystectomy, 
a local recurrence occurred in one out of five patients, and prognosis for these patients 
is poor. We found no difference in the LRR between the various hospitals. 
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In this thesis, a number of descriptive, etiological and prognostic studies are presented 
which were performed with the population-based cancer registry of the Comprehensive 
Cancer Centre Amsterdam. The migrant studies show that the cancer risk of migrants 
from non-western countries differs considerably from the risk of persons who were 
born in the Netherlands. On the other hand, as is shown in the environmental studies, 
the influence of air pollution due to air and road traffic on the overall cancer risk 
seems to be limited. The prognostic studies show that stage is the most important 
factor to determine survival and that considerable improvement in the prognosis of 
cancer patients has been achieved for a number of cancers. Not only was this im-
provement achieved by earlier diagnosis, but also by improved treatment regimens. 
The studies in this thesis illustrate the multiple uses of a population-based cancer reg-
istry. In this chapter, the results of the studies in the different areas will be put into 
perspective. In the last section of this chapter prospects for further use of the cancer 
registry will be discussed. 
INTERNATIONAL VARIATION IN CANCER INCIDENCE AND EFFECT OF MIGRATION 
Worldwide there are large variations in cancer incidence.1,2 In general, cancer inci-
dence is much higher in developed countries than in developing countries. However, 
certain cancer types, such as liver cancer or cervical cancer, are more common in de-
veloping countries. There are two main reasons for the worldwide variation in cancer 
incidence: differences in exposure to environmental and lifestyle factors, such as 
smoking, diet, radiation, viruses, sexual behaviour, physical activity, etc. and differ-
ences in the genetic susceptibility of individuals. Although the risk of cancer for indi-
viduals with increased genetic susceptibility may also be influenced by environmental 
and lifestyle factors,  susceptibility for the presently known cancer genes generally 
increases the life-time risk for a certain cancer much more than any known exposure 
to environmental or lifestyle factors. For example, cigarette smoking increases the 
relative risk to die from lung cancer more than 20 times,3 but nevertheless only a mi-
nority of tobacco smokers develop lung cancer¶,4 whereas the lifetime risk to develop 
cancer for carriers of breast cancer genes (BRCA) may be as high as 60-80 percent.5,6 
Probably, there are also (still undiscovered) genes which cause more subtle excess 
cancer risks. 
During the last decades, more and more genes predisposing for cancer have been 
discovered. Based on present knowledge, the strong susceptibility genes are still 
thought to be responsible for only a small proportion of cancer cases (5-8%), because 
the prevalence of these genes in the population is rather low.7 Migrant studies have 
contributed to this knowledge. As during migration no change in the genetic composi-
tion of a population occurs, changes in cancer incidence after migration are most likely 
due to environmental and lifestyle factors. For example, studies of Asian migrants to 
the United States of America have shown that the cancer incidence of the migrant 
                                               
¶ In a recent review, it has been estimated that every other smoker will be killed by tobacco. Apart from lung 
cancer tobacco may cause a large variety of other cancers, including cancer of the oral cavity, pharynx, 
larynx, oesophagus, pancreas, urinary bladder and renal pelvis, nasal cavities and paranasal sinuses, stom-
ach, liver, kidney (renal cell carcinoma), uterine cervix and myeloid leukaemia. Besides, tobacco increases 
coronary artery disease, cerebrovascular disease, and atherosclerotic peripheral vascular disease. Because of 





population (Asians) gradually approaches the incidence of the native population (white 
Americans) within two generations, with incidence of the first generation closest to the 
incidence in the country of origin and the incidence of the second generation closest to 
the incidence of the native population.8,9 In our study among women with residency in 
Northwest-Netherlands (chapter 2.2), we found that the standardised incidence ratio 
(SIR) for breast cancer was statistically significantly reduced for women born in Suri-
nam (0.56), Turkey (0.29) and Morocco (0.22). For women from the latter two coun-
tries, the SIR was considerably higher in women below the age of 50 (Turkey 0.35; 
Morocco 0.33) in comparison to women of 50 years or older (Turkey 0.22; Morocco 
0.10). Although our data all relate to the first generation, a change of the breast can-
cer risk in migrants is already observed for women below the age of 50. These women 
experience a breast cancer risk which is intermediate to the breast cancer risk of older 
migrants and women born in the Netherlands. 
The low breast cancer risk in women born in Turkey and Morocco can probably be 
attributed to differences in risk factors for breast cancer in comparison to native 
women, especially in relation to reproduction. Compared to women of Dutch descent, 
women born in Turkey and Morocco have more children and have their first child at an 
earlier age. Due to the fact that these women came to the Netherlands as partners of 
(male) migrant workers, the percentage of unmarried women without children is negli-
gible. The higher breast cancer risk in younger women (below the age of 50) born in 
Morocco or Turkey, when compared to older women, is probably caused by a change 
in risk factors in younger women, such as lower parity. As a further change in risk 
factors (lower parity, increase of age at first child birth) is already observed in second 
generation migrants,10 a further change of the breast cancer risk towards the risk in 
native women seems plausible for second generation migrants in the Netherlands. 
Another migrant study (chapter 2.1) revealed that the incidence of cervical cancer 
among women in North-Holland was significantly higher than the incidence for the 
nation as a whole (SIR 1.2; 95% CI 1.1-1.2). 11 In particular, the incidence of cervical 
cancer for women living in Amsterdam (SIR 1.5; 95% CI 1.4-1.6), and for women born 
in Morocco (SIR 2.1; 95% CI 1.4-3.1) or Surinam (SIR 1.5; 95%CI 1.1-2.0) was much 
higher. Comparison of the incidence rates for migrant women in North-Holland with 
the rates in their country of origin revealed that the rates in North-Holland were inter-
mediate to the rate in the country of origin and the rate for native women in the Neth-
erlands. Consequently, a further downward change of the cervical cancer risk in sec-
ond generation migrants seems likely. Cervical cancer screening might contribute to an 
acceleration of the decrease in cervical cancer risk of first and second generation mi-
grants.  
Therefore, the data on cancer risk among migrants in the Netherlands are not only of 
epidemiological interest, but they are also relevant from a perspective of public health. 
As screening programmes are available in the Netherlands both for cervical and for 
breast cancer, knowledge of the relative risk of subpopulations is essential. Participa-
tion of migrant women in these two screening programmes is relatively low, especially 
the participation of older women from Turkey and Morocco in the breast cancer 
screening programme is very low. Our study of breast cancer screening attendance 
(chapter 2.3) showed an overall (age adjusted) attendance of 76 percent for women 
aged 50-69. Attendance was significantly lower for women born in non-western-
Chapter 5 
 136 
countries (Surinam 59%, Turkey 44%, Morocco 37%) and for native women with resi-
dence in Amsterdam (68%). Referral and detection rates for women from non-western 
countries were 5.1 and 2.2 per 1000 screened women, respectively, compared to 8.8 
and 4.0 for women born in the Netherlands (p<0.05). As migrant women from non-
western countries have a very low breast cancer risk, a passive attitude of the screen-
ing organisation with regard to the low participation is justified. On the other hand, 
efforts should be made to increase the low participation of migrant women in the cer-
vical cancer screening, as the risk of cervical cancer for these women is relatively high. 
In the Netherlands, migrant studies are hampered by the unavailability of data on eth-
nic descent. However, for all Dutch residents the country of birth and the country of 
birth of the parents are available in the municipal population registers. Since 1995, 
these data are also available electronically and, potentially, facilitate the study of can-
cer in migrants, because annual age- and sex-specific population data of first and sec-
ond generation migrants are available. Unfortunately, in the cancer registry only in-
complete information on the country of birth of cancer patients is available, due to 
incomplete information in the hospitals. Second generation migrants cannot be identi-
fied in the cancer registry at all, because information on the country of birth of the 
parents is lacking. Consequently, for migrant studies extra efforts have to be made to 
complete the available cancer registry data with regard to the country of birth of can-
cer patients. For the studies in this thesis, we could use information from the breast 
cancer screening organisation, as most women who participate in the breast cancer 
screening had agreed to record linkage with the cancer registry. As many women with 
breast or cervical cancer are referred to another hospital for (part of ) the treatment, 
we could also use the available information in those hospitals. For males, we could not 
use these sources and the proportion of registered males with unknown country of 
birth is higher than for females. 
In other European countries, with the exception of Sweden, only few migrant studies 
were performed, because, like in the Netherlands, only limited information on the mi-
grant status is available in cancer registries. In Sweden, the nationwide Swedish Fam-
ily-Cancer Database enabled numerous migrant studies, both in first- and second gen-
eration migrants. A study among first-generation migrants revealed that among indi-
vidual cancer sites and immigrant countries, 110 comparisons were significant, 62 
showing a decreased risk compared to Swedes and 48 an increased risk.12 Most of the 
differences between the rates in immigrants and Swedes could be ascribed to the 
variation of cancer incidence in the countries of origin. The high lung cancer risk (SIR 
2.4) among Dutch males in Sweden is noteworthy. Breast cancer incidence was at or 
below the Swedish level for all immigrant groups. A study among second-generation 
migrants and comparison with the results among first-generation migrants suggests 
that the first two decades of life are important in setting the pattern for cancer devel-
opment in subsequent life.13 Birth in Sweden sets the Swedish pattern for cancer inci-
dence, irrespective of the nationality of descent, while entering Sweden in the 20s is 
already too late to influence the environmentally imprinted programme for the cancer 
occurrence. 
In Saarland, Germany, Razum et al successfully tried to identify Turks with a name-
based algorithm.14 However, distinction of first and second generation is not possible 





may be difficult to determine. In the Dutch situation, the total size of the “Turkish-
named” population cannot be determined anymore, because many Turks changed 
their nationality and census data of the number of people who consider themselves as 
Turkish are not available in the Netherlands, since the last census was held in 1971. 
In a study by Bouchardy et al, the cancer mortality among North African migrants in 
France was studied.15 Although this study offers useful information concerning cancers 
for which mortality is relatively high, the value of this study is limited for cancers such 
as testicular cancer, which have a good prognosis. Generally, a low cancer mortality 
(including mortality due to breast cancer) was observed in North African migrants in 
comparison to local-born, with the exception of mortality due to cancer of the naso-
pharynx and gallbladder. Mortality due to cervical cancer was increased in Moroccan 
women, but not in other North African women.  
The excellent information regarding country of birth and country of birth of the parents 
as available in the municipal population registers in the Netherlands is a worthwhile 
source of data for future research among migrants in the Netherlands. However, this 
data source can only be exploited by linkage to the cancer registry. Unfortunately, 
privacy regulations hamper such linkage under the present circumstances.  
ENVIRONMENTAL STUDIES  
The environmental studies in this thesis (chapter 3) show that a population-based 
cancer registry is a useful tool for studies which investigate the cancer risk of a popula-
tion with residence in certain well-described geographical entities. In the first study, 
we estimated the cancer incidence during 1988-2000 in residents of the area sur-
rounding Schiphol. We defined an exposed study area based on aircraft noise contours 
and 4-digit postal code areas. The second study examined the association between 
cancer incidence in 1989-97 in Amsterdam and residential traffic intensity. For this 
study, we linked data on the daily traffic intensity for individual addresses along the 
main roads of Amsterdam with the population-based regional cancer registry. Informa-
tion on smoking habits was derived from a smoking survey. In both studies, the overall 
cancer incidence was not increased, but certain cancer types were less common than 
expected, while the incidence rates of other cancers were increased. In particular, the 
increased incidence of haematological malignancies in the Schiphol area was remark-
able. 
The cancer registry can be relatively easily used for environmental studies, with the 
additional advantages that it is virtually complete and offers an unselected study popu-
lation16. Yet, there are also several limitations regarding the use of the cancer registry 
in environmental studies. Firstly, the geographical entity of study and the available 
exposure data may not coincide with the 4-digit postal code as available in the cancer 
registry. For example, a study at street-level is not possible with the available cancer 
registry data and for the study of residential traffic density and cancer incidence in 
Amsterdam (chapter 3.2), record linkage with the population register of Amsterdam 
was necessary to obtain the required detailed address information. 
Secondly, in the cancer registry the only geographical information that is available 
relates to the date of diagnosis of cancer. As people may have moved from and to the 
study area before they were diagnosed with cancer, a proportion of the observed can-
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cers is misclassified. This proportion will be larger if mobility in a certain area is higher 
or if the period of study extends to a prolonged time period. The latter is often neces-
sary to acquire a sufficiently large number of cancer cases. On the other hand, migra-
tion after the diagnosis is not relevant in a registry-based study. The problem of mis-
classification could be solved if historical address and exposure data prior to the diag-
nosis of cancer were available. For the study of residential traffic density and cancer 
risk in Amsterdam, historical address data were made available by the population reg-
ister of Amsterdam and they will be used in a future study. 
Thirdly and most importantly, no information is available in the cancer registry about 
confounding factors such as smoking habits, occupation, socio-economic status, alco-
hol use, diet, sexual behaviour, etc. Consequently, an observed difference in cancer 
incidence in the study area in comparison to the reference population, such as the 
increased incidence of haematological malignancies in the Schiphol area, is difficult to 
interpret. Especially the interpretation of the observed incidence of cancers of the res-
piratory tract, which may be caused by air pollution,17,18 as well as by smoking,19 is 
difficult in the absence of information on smoking habits of the study population.  
Finally, the (un)availability of measurement data regarding relevant environmental 
exposures may greatly influence the outcome and interpretation of an environmental 
study. In this respect, there are large differences between the two studies in chapter 
3. Although we did not use actual measurements of air pollution in the study of resi-
dential traffic density and cancer risk in Amsterdam, the relation between road traffic 
intensity and air pollution is well-known and detailed measurements of road traffic 
intensity were available for this study. However, in the study of cancer incidence in the 
Schiphol area, which was initiated because of serious health concerns of the surround-
ing population, the available data on air quality did not enable us to define a study 
area. The noise contours that were used instead, are in fact only a weak surrogate for 
air pollution. Therefore, the results of the Schiphol study are more difficult to interpret 
than the results of the study of residential traffic density and cancer risk in Amster-
dam. 
Because of the inherent limitations of a registry-based environmental study, the finding 
of an increased cancer incidence in such a study should be followed by a subsequent 
study in which much more detailed information is available on risk factors, for example 
a case-control study. On the other hand, if no increased cancer incidence is observed 
in a population with an allegedly increased cancer risk, a registry-based study is a 
powerful instrument to refute the alleged increase of cancer risk. 
Finally, the registry-based study as a tool for environmental studies would increase its 
power if there were more possibilities for linkage with other data sources containing 
information on potential confounding factors, such as socioeconomic status, occupa-
tion or smoking habits. Privacy regulations are among the issues which limit the possi-
bilities for such linkage. 
PROGNOSTIC STUDIES  
Information on the prognosis of cancer patients is important for both patients and 
their clinicians. Although ample survival data are available from many different studies, 





chapter 4 show that stage is a major prognostic factor for the survival of patients with 
epithelial cancers and skin melanoma (chapter 4.1). The same result was observed for 
patients with carcinoid tumours (chapter 4.2). Therefore, the availability of site- and 
stage-specific survival data from the Amsterdam Cancer Registry is a major step for-
ward. For non-epithelial cancers such as sarcomas, neuro-epithelial tumours and hae-
matological malignancies, stage is of less relevance for the prognosis, which is primar-
ily determined by the morphological type and grade of malignancy of the tumour.20,21,22 
The prognosis of a cancer patient is also influenced by a variety of other factors, such 
as treatment and co-morbidity.23,24 
In 1989-2001, stage-specific 5-year relative survival rates (RSR) ranged from close to 
100% for stage I carcinoma of the salivary glands, thyroid, colon/rectum, skin, breast, 
female genital organs, prostate and urethra to 1% or less for stage IV carcinoma of 
the oesophagus, stomach, liver, gallbladder, pancreas and lung (chapter 4.1). Between 
1989-1991 and 1999-2001, we observed an increase of the stage-specific RSR for car-
cinoma of colon/rectum (stages II-IV), lung (stages I-II), breast (stages I-III) and 
prostate (stages II-IV). We also observed an increase in survival of metastatic carci-
noid tumours between 1980-1991 and 1992-1997 (chapter 4.2), a decrease in the risk 
of dying of patients with cervical cancer during 1988-1997 (chapter 4.3), but no 
change in survival of bladder cancer patients during 1988-2001 (chapter 4.4). 
Because near complete stage information is available for all relevant sites, we were 
able to demonstrate that improved survival over time was not merely an effect of 
changes over time in the stage distribution of newly diagnosed cancer cases. More-
over, because treatment data are available in the cancer registry, we were also able to 
observe an effect of changes in treatment regimens on stage-specific survival. Al-
though these effects are mostly known already from clinical trials or hospital-based 
studies, a major drawback of clinical trials and single centre studies is that they only 
include selected patients, often with a relatively favourable prognosis. Consequently, 
the results of these studies cannot always be extended to all cancer patients. On the 
other hand, the results of a cancer-registry based (population-based) survival analysis 
are based on all cancer patients and thus reflect the results for all cancer patients 
combined. In interpreting our population-based results, it should be taken into account 
that individual patients who participate in clinical trials or are treated in specialised 
cancer hospitals where many hospital studies are performed, may have a more favour-
able prognosis. 
A major drawback of our survival data is that the cause of death is lacking. Conse-
quently, disease-specific survival could not be calculated. Although the relative survival 
(the ratio between observed and expected survival) is close to the disease-specific 
survival, the expected survival is calculated with life tables for the general population 
which include deaths due to cancer. If deaths due to cancer would be excluded from 
the general life tables, the expected survival would be slightly higher and relative sur-
vival slightly lower. As for most cancer sites mortality due to the cancer site concerned 
only accounts for a small fraction of the total mortality, the effect on the calculated 
relative survival is very small. The effect is largest for lung cancer in males (in 2001, 
9.4% of all deaths in males were due to lung cancer), as well as for all cancer sites 
combined (in 2001, 30% of all deaths in males were due to cancer, compared to 24% 
in females). Nevertheless, we estimate that the overestimation of the 5-year relative 
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survival is less than 0.5% for lung cancer in males, approximately 3% in males for all 
sites combined and approximately 1% in females for all sites combined. 
Although the cause of death is available at Statistics Netherlands for all deceased 
Dutch residents, this information has not been easily accessible for research due to the 
very strict privacy regulations of Statistics Netherlands. However, a recent adaptation 
of the law might broaden the possibilities to use this information source in the future. 
PROSPECTS FOR FURTHER USE OF A POPULATION-BASED CANCER REGISTRY: 
QUALITY INDICATORS IN ONCOLOGICAL PRACTICE  
In recent years, there has been a tendency in Dutch society towards an increased 
transparency of publicly financed institutions as far as their results are concerned. This 
applies to schools, universities, hospitals, etc. However, the results of hospitals are not 
easily determined. The outcome of a patient’s treatment is influenced by a variety of 
factors, many of which are not related to the medical treatment as such. For example, 
patient behaviour (e.g. adherence to prescribed medication), co-morbidity, socio-
economic status or genetic susceptibility may influence the outcome of a medical 
treatment. Besides, depending on specific treatments available, specialised hospitals 
may attract specific subpopulations of cancer patients, for example patients with a 
poor prognosis who seek specialised treatment, or, on the other hand, patients with a 
high socio-economic status and a relatively favourable prognosis, who prefer treatment 
in a specialised hospital. The variation of the patient populations between hospitals 
may seriously hamper the comparison of treatment outcome of various hospitals and, 
consequently, the interpretation of possible differences in treatment outcome has to be 
performed with the utmost care. 
Although the regional cancer registry collects data in all hospitals, the data can only be 
used to map certain aspects of the treatment and its outcome of cancer patients. 
Hospital volume 
The determination of the number of patients with a specific cancer type that is treated 
in each hospital in a certain time period can easily be determined by the cancer regis-
try. This number is hardly subject to confounding factors and can be compared to the 
number that is generally considered necessary to establish and maintain experience in 
the diagnosis and/or treatment of that type of cancer. The relation between volume 
and treatment outcome has been the subject of many studies.25 Although hospital 
volume has been found to be associated with treatment outcome in a number of stud-
ies, for example in studies regarding surgical treatment of oesophageal and pancreatic 
cancer26 or treatment of metastatic non-seminomatous germ cell cancer,27 no associa-
tion was found in other studies.28,29 Also in our study of bladder cancer (chapter 4.4), a 
relation between hospital volume and the risk of local recurrence was not found. Con-
sequently, for each separate cancer, the pros and cons of centralisation of cancer 





Adherence to guidelines 
For many cancers, guidelines for diagnostic and treatment procedures have been or 
are being developed in the Netherlands, as a result of a cooperation of the Association 
of Comprehensive Cancer Centres, the Dutch Institute for Healthcare Improvement 
and the Order of Medical Specialists.30 The cancer registry can be used to evaluate the 
adherence to these guidelines at the hospital-level. For example, the percentage of 
breast cancer patients that received adjuvant treatment according to the guidelines 
can be determined. If supplementary data have to be collected, this is preferably done 
for a limited number of cases for a limited time period in a so-called ‘documentation 
project’. 
Recurrence 
Although recurrence (local, regional and/or distant) is not (yet) part of the standard 
item set that is collected by the Amsterdam Cancer Registry, recurrence has been col-
lected additionally for colorectal cancers diagnosed 1988-1991, rectal cancers diag-
nosed 1998-2000 and bladder cancers diagnosed 1988-1997 (chapter 4.4). The study 
of bladder cancer shows that local recurrence occurred in one out of five patients and 
that survival after recurrence was poor. Therefore, the monitoring of the occurrence of 
(local) recurrence is a good indicator for oncological practice. Unfortunately, the collec-
tion of recurrence is very time consuming and cannot (yet) be performed on routine 
basis. 
The recurrence rate can be calculated for all hospitals combined and compared to the 
rate as known from other studies in the international literature. Moreover, the rate can 
be calculated for each separate hospital and compared between hospitals. However, 
the comparison between hospitals is often hampered by the relatively low absolute 
number of recurrences, which results in large confidence intervals, and the variation in 
the patient populations of the different hospitals.  
An option for future research in the field of recurrence and adherence to guidelines 
would be a case-control study in which adherence to diagnostic and treatment guide-
lines in cases with a recurrence would be compared to adherence to the guidelines in 
controls who did not develop a recurrence while having similar follow-up time. Such a 
design is efficient since data collection is only needed for a sample of all patients. It 
requires, however, that the notification of recurrence is performed efficiently, for ex-
ample by means of the national pathology database (‘PALGA’) or the hospital discharge 
registry. 
Survival 
Like the recurrence rate, survival can be calculated for each individual hospital. How-
ever, while recurrence is always cancer-related, overall (and relative) survival is also 
influenced by mortality due to other causes than cancer. Therefore, in the comparison 
between hospitals the use of disease-specific survival is preferred. Even if disease-
specific survival is available a comparison between hospitals should be made with care, 
as in certain hospitals patients with a worse/better than average prognosis may be 
more common than in other hospitals. This may be due to differences in age, sex, co-
morbidity, socio-economic status, presence of family cancer clinic or other (partially 
Chapter 5 
 142 
unknown) determinants. Of course, it is possible to adjust the results for a number of 
co-variates (age, sex and stage, at the least), but since not all co-variates are avail-
able, residual confounding may play a role and, consequently, the results still have to 
be interpreted with caution. 
Occurrence of second or subsequent cancers 
As the population-based cancer registry records all primary tumours occurring in a 
patient, it is an ideal tool for the monitoring of the occurrence of second or subsequent 
cancers. Most of the second or subsequent cancers share etiological factors with the 
first primary, such as smoking-related cancers (e.g. lung cancer and head & neck can-
cer), or occur in one patient by coincidence (e.g. prostate cancer and skin cancer). 
However, a (relatively small) proportion of second or subsequent cancers are a (late) 
effect of the treatment of the first primary. Over the past decades, treatment-related 
second cancers have been demonstrated in, for example, patients treated for Hodgkin 
lymphoma, testicular cancer and breast cancer.31,32,33,34 In the future, the population-
based cancer registry can make an important contribution to the elucidation of pres-
ently unknown associations between various cancers and the influence of treatment 
factors. As with the years the number of registered patients with prolonged follow-up 
continues to increase, the power of the cancer registry to detect such associations will 
also increase. An advantage of the NCR, as compared to registries in many other coun-
tries, is that treatment data are available. In general, further, more detailed, studies 
will be necessary to elucidate the nature of the observed associations. 
Other indicators 
There are many other possible indicators of oncological care, for example psychosocial 
indicators (patient satisfaction, adequate information, etc), indicators of the hospital 
process (waiting lists, time interval between first hospital visit and diagnosis or be-
tween diagnosis and start of treatment, etc), morbidity or adverse effects of the 
treatment. For such indicators a population-based cancer registry is a less useful in-
strument, since either the registration process is too slow, patient contact is essential, 
or the collection of the data would be too time-consuming. However, if certain indica-
tors were to be collected for a limited number of patients and for a limited time period, 
the infrastructure of the cancer registry could be used for the collection of the re-
quested information in the framework of a ‘documentation project’. 
 
Due to their limitations and the difficult interpretation of differences between hospitals, 
recurrence or survival rates are not suitable for distribution among the general public. 
These rates should rather be used as internal information for the hospital or as infor-
mation for the medical professionals concerned, e.g. for the Tumour Working Groups. 
By contrast, there are few drawbacks with regard to the publication of hospital vol-
umes for specific cancers, waiting lists or duration of the diagnostic process. 
As in the past, the cancer registry will continue to submit the available information to 
the hospitals and their medical specialists. It is up to them to separate this information 






The announced introduction of a personal identification number (‘Burger Service 
Nummer’) in all public services (including the health sector), when included in the can-
cer registry, will increase the efficiency of the follow-up procedures of the cancer regis-
try substantially. Because such a number enables anonymous record linkage with other 
registries (preferably through a trusted third party in order to protect the privacy of 
those registered), it will also offer new perspectives for future etiological studies with 
the cancer registry, including second generation migrant studies. 
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Since 1989, the Netherlands has a nation-wide population-based cancer registry, which 
is composed of nine regional registries. The Amsterdam Cancer Registry (ACR) is one 
of these regional registries, which started its activities in 1984 and reached region-
wide coverage in 1988. All hospitals in North-Holland and Flevoland (twenty in 2005) 
participate in the ACR. The population size of the region amounted to 2.9 million on 
January 1st 2004, including 14 percent first generation migrants and 12 percent sec-
ond generation migrants. 
 
The number of registered cancers in the region of the ACR increased from 9 500 in 
1988 to 12 000 in 2002 (+26%), but the age-standardised incidence rate per 100 000 
persons only slightly increased (from 377 in 1988 to 389 in 2002). The male/female 
ratio decreased from 1.4 in 1988 to 1.2 in 2002. 
Cancers of the breast, lung, colon & rectum and prostate account for 50 percent of all 
cancers. In 1988, lung cancer was the most common cancer, but since 1991, breast 
cancer is the most common cancer. Other common cancer sites are the bladder, stom-
ach, head & neck, bone marrow and lymphatic tissues. Of all registered invasive can-
cers in 1988 7 percent concerned a second or subsequent cancer. This percentage 
increased to more than 10 percent in 2002. 
The number of cancer deaths has been rather stable during 1988-2002, but the age-
standardised mortality rate per 100 000 persons decreased by 16 percent, mainly due 
to a decrease in lung cancer mortality in males, but also mortality due to stomach 
cancer, prostate cancer, breast cancer and ovarian cancer decreased. 
Cancer prevalence in North-Holland/Flevoland numbered 61 100 persons in 2003, 
mostly breast cancer (16 300), skin cancer (7 700), colorectal cancer (7 500) and pros-
tate cancer (6 600). Cancer prevalence comprises a large variety of patients, including 
patients in the diagnostic phase or in the primary treatment phase, cured patients and 
patients in the terminal phase, with different needs for care in each phase. 
Follow-up of vital status has been performed for all incident cases diagnosed 1988-
2001, which enabled the calculation of cancer survival rates. During 1988-2001, sur-
vival slightly improved for all cancer sites combined. This is due to improved survival of 
some common cancers (breast cancer, colorectal cancer, prostate cancer) as well as 
changes in cancer incidence: the proportion of several cancers with poor survival (lung 
cancer, stomach cancer) has decreased between 1988 and 2001, while the proportion 
of cancers with a relatively favourable prognosis (breast cancer, prostate cancer, skin 
cancer) has increased. 
 
Apart from the use of a cancer registry for the calculation of cancer incidence rates, 
there are numerous possibilities for research with population-based cancer registries, 
ranging from descriptive epidemiological studies and health care planning to aetiologi-
cal and clinical research. In this thesis, the various uses of a population-based cancer 
registry are illustrated by migrant studies (chapter 2), etiologic studies of the associa-
tion between environmental factors and the occurrence of cancer (chapter 3) and re-
search on prognosis and survival of cancer patients (chapter 4). 
 
The first migrant study (chapter 2.1) is a descriptive epidemiological study and de-





The number of cases of cervical cancer in North-Holland for the period 1988-1998, by 
country of birth, was determined on the basis of data available from the ACR. Based 
on data from the Netherlands Cancer Registry, a comparison was made between the 
observed and the expected number of cases by area of residence (i.e., Amsterdam 
versus the rest of North-Holland) and by country of birth. In the period 1988-1998, the 
incidence of cervical cancer among women living in North-Holland was significantly 
higher than the national rate (standardised incidence ratio [SIR] 1.2; 95% confidence 
interval [CI] 1.1-1.2). In particular, the incidence of cervical cancer for women living in 
Amsterdam (SIR 1.5, CI 1.4-1.6), and for women born in Morocco (SIR 2.1, CI 1.4-3.1) 
or Surinam (SIR 1.5, CI 1.1-2.0) was much higher. With the exception of Turkish 
women, the incidence rate among migrant women in the North-Holland was below the 
rate in their country of origin. The percentage of patients with higher stages (TNM-
stages II-IV) did not differ between women born in the Netherlands and those born 
abroad. In conclusion, the incidence of cervical cancer during the period 1988-1998 
was significantly higher for women living in Amsterdam and for women born in Mo-
rocco or Surinam than that for the Netherlands as a whole. No significant difference in 
stage of disease at diagnosis was observed between women born in the Netherlands 
versus those born abroad. 
The second migrant study (chapter 2.2) is also a descriptive epidemiological study and 
describes the incidence of breast cancer in North-Holland and The Hague according to 
country of birth. In 1988-1998, the SIR for breast cancer was statistically significantly 
reduced for women born in Surinam (0.56), Turkey (0.29) and Morocco (0.22). For 
women from the latter two countries, the SIR was considerably higher below the age 
of 50 (Turkey 0.35; Morocco 0.33) in comparison to older women (Turkey 0.22; Mo-
rocco 0.10). In women born in Indonesia, the opposite was found (<50 years 0.83; 50 
years or older 1.03). The proportion of women with advanced stages (III and IV) did 
not differ significantly between migrants and women born in the Netherlands. Although 
the risk of breast cancer among women resident in the Netherlands but born in Suri-
nam, Turkey and Morocco is still close to the risk in their country of origin, the higher 
risk in younger women compared to older women from Turkey and Morocco indicates 
that a change in the breast cancer risk profile (e.g. lower parity) towards the risk pro-
file of native women is already occurring in first generation migrants. 
For the third migrant study (chapter 2.3) we did not use cancer registry data, but this 
study was based on data from the regional breast cancer screening organisation, in 
order to determine breast cancer screening results according to country of birth. Over-
all (age adjusted) attendance of the breast cancer screening was 76 percent for 
women aged 50-69. Attendance was significantly lower for women born in non-
western-countries (Surinam 59%, Turkey 44%, Morocco 37%) and also for women 
with residence in Amsterdam in general (68%). Referral, detection and interval carci-
noma rates for women from non-western countries were 5.1, 2.2 and 1.2 per 1000 
screened women, respectively, compared to 8.8, 4.0 and 2.2 for women born in the 
Netherlands (p<0.05). The positive predictive value was 45 percent for women born in 
the Netherlands and western countries and 43 percent for women born in non-western 
countries. Although women born in non-western countries attend breast cancer 
screening less frequently than women born in the Netherlands, they also have a low 
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detection rate and a low interval carcinoma rate. The latter findings justify a passive 
attitude towards the low attendance. 
 
The first study in chapter 3 is an example of an ecological (correlation) study (chapter 
3.1). The reason for this study was that Amsterdam Airport Schiphol has long been a 
major source of complaints about aircraft noise, safety risks and noise- and pollution-
related adverse health effects, including cancer. We estimated the cancer incidence 
during 1988-2003 in residents of the area surrounding Schiphol. As the available expo-
sure data on air pollution did not enable us to define a study area, we based the study 
area on aircraft noise contours and 4-digit postal code areas. In residents of the study 
area 13 207 cancer cases were diagnosed, which was close to the expected number, 
using national incidence rates as a reference (SIR 1.02). When examining the individ-
ual cancer sites, for most sites no increased or decreased risks were observed. The 
incidence of cancer of the respiratory system was statistically significantly decreased 
(SIR 0.94, CI 0.90-0.99), due to the low rate in males (SIR 0.89). We also found a 
statistically significantly increased incidence of haematological malignancies (SIR 1.12, 
CI 1.05-1.19), mainly due to high rates for non-Hodgkin lymphoma (SIR 1.22, CI 1.12-
1.33) and acute lymphocytic leukaemia (SIR 1.34, CI 0.95-1.83). In the core zone of 
the study area, where aircraft noise levels were highest, cancer incidence was slightly 
higher than in the remaining ring zone (rate ratio of the core zone compared to the 
ring zone 1.05, CI 1.01-1.10). This was caused by a relatively high incidence of cancer 
of the respiratory system, prostate and female genital organs in the core zone in com-
parison to the ring zone. 
In this study no individual data regarding the exposure to aircraft-related air pollution 
were available. Besides, neither information on migration to and from the study area, 
nor on confounding factors such as smoking habits, occupation, socio-economic status, 
alcohol use, diet, sexual behaviour, etc. was available. Consequently, the interpretation 
of the results of this ecological study is difficult. Therefore, although the overall cancer 
incidence was not increased, further research is necessary to elucidate the cause of 
the relatively high incidence of haematological malignancies. 
The second environmental study (chapter 3.2) differs from the first one with regard to 
the availability of individual exposure data in the second study. In this study, we exam-
ined the association between residential traffic intensity and cancer incidence in 1989-
97 in Amsterdam. We linked data on the daily traffic intensity for individual addresses 
along the main roads with the population-based regional cancer registry. Information 
on smoking habits was derived from a smoking survey. During 1989-1997, 27 157 
cancer cases were diagnosed in Amsterdam residents. Using the age group- and sex-
specific cancer incidence in the population not residing along the main roads as a ref-
erence, the SIR of the population residing along the main roads was 1.03, (3 384 
cases), while the 95% confidence interval included unity (1.00–1.07). For most cancer 
sites the SIR was close to 1, except for gastrointestinal cancer in males (SIR 1.16, CI 
1.04-1.28), cancer of the respiratory tract in females (SIR 1.13, CI 0.97-1.31) and 
haematological malignancies in adult females (SIR 1.23, CI 1.04-1.44). Five cases of 
acute lymphocytic leukaemia were diagnosed in children along the main roads (SIR 
2.5, CI 0.8-5.9). Smoking habits did not differ between residents along the main roads 





ciation between residence along main roads and the incidence of cancer in adults, we 
cannot exclude an association with haematological malignancies in females and chil-
dren.  
 
Chapter 4 includes a number of prognostic studies which made use of the follow-up 
data of  the cancer registry. While stage is the most important factor for determining 
cancer survival, population-based survival data according to stage are rarely pre-
sented. In chapter 4.1 we present such data for a large population diagnosed with 
cancer in the area covered by the Amsterdam Cancer Registry in 1989-2001 
(n=108251). Cases were grouped according to the TNM-Classification. For all sites, a 
strong influence of stage at diagnosis on survival was observed. The stage-specific 5-
year relative survival rate (RSR) ranged from close to 100% for stage I carcinoma of 
the salivary glands, thyroid, colon/rectum, skin, breast, female genitals, prostate and 
urethra to ≤ 1% for stage IV carcinoma of the oesophagus, stomach, liver, gallblad-
der, pancreas and lung. Between 1989-1991 and 1999-2001, we observed an increase 
of the stage-specific RSR for carcinoma of colon/rectum (stages II-IV), lung (stages I-
II), breast (stages I-III) and prostate (stages II-IV). Analysis of trends in stage distri-
bution and treatment practices support the assumption that changes in diagnostic 
(breast, prostate) and staging procedures (lung), new/improved surgical techniques 
(rectum, prostate) and adjuvant treatment (breast, colon) are likely to have contrib-
uted to the observed increase in the stage-specific RSRs. 
In chapter 4.2, we studied the incidence and survival of carcinoid tumours. Carcinoid 
tumours are rare malignant neuro-endocrine tumours. In 1992, octreotide was intro-
duced in the Netherlands as a palliative treatment for the carcinoid syndrome in me-
tastatic carcinoid disease. The aims of this descriptive study were to evaluate epidemi-
ological data (age-, sex-, site- and stage-specific incidence) and the impact of octreo-
tide on survival in metastatic carcinoid disease. As carcinoid tumours are rare, we used 
incidence data from the Netherlands Cancer Registry. Survival data from two registries 
(the ACR and the Eindhoven Cancer Registry) were available for 619 patients, diag-
nosed between 1980 and 1997. Between 1989-1996, the incidence of carcinoid tu-
mours in the Netherlands was 1.95/100 000 population (2 391 patients). Under the 
age of 50 years a significant female predominance was observed. Under the age of 35 
years, appendiceal carcinoid was the most frequently diagnosed primary site. The oc-
currence of distant metastases at diagnosis for appendiceal and lung carcinoids was 
1.6% and 5.5%, respectively, compared to 40% in carcinoids at other primary sites. 
The 5-year RSR was 72% for all carcinoids combined, and ranged from 93% for local-
ised disease, 74% for regional extension, to 19% in case of distant metastasis. Multi-
variate analysis revealed that older age and higher stage were independent predictors 
of worse survival, while appendix localisation predicted better survival. In a sub-group 
analysis of metastatic disease, year of diagnosis after 1992 was the only predictor of 
better survival (p=0.012). The female predominance found under the age of 50 years 
suggests hormonal influence. Improved survival in metastatic carcinoid disease might 
be related to the use of octreotide. 
In order to evaluate the effect of population-based cervical cancer screening, which 
restarted after a reorganisation in 1995, on the occurrence of cervical cancer in the 
region of the ACR, we investigated the incidence and survival of cervical cancer in 
Chapter 6 
 150 
chapter 4.3. In this descriptive study, we observed a significant decrease in the age-
standardised incidence rate of squamous cell carcinoma from 9.2/100 000 women in 
1988 to 5.9/100 000 in 2000 (p<0.001). The incidence rate of adenocarcinomas re-
mained stable (incidence rate 1.6 in 1988 and 2000). After adjustment for age, stage 
and lymph node involvement, the relative risk of death was 1.6 (CI 1.3-2.1) times 
higher for patients with adenocarcinomas than for patients with squamous cell carci-
noma. The decreased survival was related to histological type, as the effect remained 
significant after correction for confounding factors. Over time, the prognosis of women 
with squamous cell carcinoma improved significantly. No significant change was ob-
served for women diagnosed with adenocarcinoma. These results suggest that the 
screening programme in The Netherlands as executed in the region of the ACR is asso-
ciated with a decreased incidence and increased survival of patients with squamous 
cell carcinoma, but fails to detect (pre)malignant lesions of adenocarcinoma. Since 
more than 92% of adenocarcinomas and its precursors contain high-risk HPV, adding 
HPV testing to cytologic screening might improve the present screening programme in 
detecting adenocarcinoma and its precursor lesions. 
In the fourth study of chapter 4, we determined retrospectively, in a population-based 
study, the survival of patients with bladder cancer and the local recurrence rate (LRR) 
after cystectomy (chapter 4.4). All bladder cancer cases diagnosed between 1988 and 
2001 were selected for this study from the ACR. For all patients who underwent a cys-
tectomy between 1988 and 1997 in 18 participating hospitals, information on local 
recurrence and vital status was collected from the medical records. Five-year relative 
survival for all bladder cancer cases combined (n=8 321) was 75%. For clinical stage 
0-a this was 99%, decreasing to 85% for stage 0-is and 82% for stage I, and to 44%, 
28% and 9% for stages II, III and IV, respectively. Five-year relative survival after 
cystectomy was 81%, 44% and 23% for stages II, III and IV bladder cancer, respec-
tively. The LRR after cystectomy (n=566) was 19% for all cases and institutions com-
bined. The LRR increased with higher pT-stages and reached 11%, 23% and 31% for 
stage II, III and IV respectively, and was slightly lower in oncological centres (18%) 
than in community hospitals (20%) (not significant). Survival was higher than the 
European average, but below the figure for the United States. Only one in three stage 
II-III patients was treated with cystectomy. A relatively high stage-specific survival 
was experienced after cystectomy, in spite of a local recurrence in 1 out of 5 patients.  
 
In chapter 5 (the general discussion) the results of the various studies are discussed. 
Also, prospects for further use of a population-based cancer registry are presented. 
Apart from studies as already presented in this thesis, there are possibilities to use the 
cancer registry as a tool for the measurement of quality in oncological practice, for 
example with respect to adherence to guidelines, recurrence, disease-specific survival 
(for the whole region or by hospital) or other indicators (e.g. waiting lists, morbidity or 
adverse effects of the treatment, co-morbidity). If supplementary data have to be col-
lected, this should preferably be done for a limited number of cases for a limited time 
period in a so-called ‘documentation project’. Finally, as the population-based cancer 
registry records all primary tumours occurring in a patient, it is an ideal tool for the 
monitoring of the occurrence of second or subsequent primary cancers. In the future, 





dation of presently unknown associations between various cancers and the influence of 
treatment factors. As with the years the number of registered patients with long fol-
low-up continues to increase, the power of the cancer registry to detect such associa-
tions will also increase. 
 
The announced introduction of a personal identification number (‘Burger Service 
Nummer’) in all public services (including the health sector), when included in the can-
cer registry, will increase the efficiency of the follow-up procedures of the cancer regis-
try substantially. Because such a number enables anonymous record linkage with other 
registries (preferably through a trusted third party in order to protect the privacy of 
those registered), it will also offer new perspectives for future etiological studies with 








Sinds 1989 beschikt Nederland over een landelijk dekkende (‘population-based’) kan-
kerregistratie die is samengesteld uit negen regionale registraties. De kankerregistratie 
van het Integraal Kankercentrum Amsterdam (IKA) is een van deze negen regionale 
registraties. De IKA-kankerregistratie begon in 1984 en is regiodekkend vanaf 1988. 
Alle ziekenhuizen in Noord-Holland en Flevoland (twintig in 2005) nemen deel aan de 
IKA-kankerregistratie. De regio had een inwonertal van 2,9 miljoen op 1 januari 2004, 
waaronder veertien procent eerste generatie allochtonen en twaalf procent tweede 
generatie allochtonen. 
Het aantal geregistreerde gevallen van kanker in de regio van het IKA nam toe van 
9500 in 1988 tot 12 000 in 2002 (+26%), maar het naar leeftijd en geslacht gestan-
daardiseerde incidentiecijfer per 100 000 personen vertoonde slechts een kleine stij-
ging (van 377 in 1988 naar 389 in 2002). De verhouding tussen het incidentiecijfer bij 
mannen en dat bij vrouwen daalde van 1,4 in 1988 naar 1,2 in 2002. 
Kanker van de borst, long, darm en prostaat vormen ongeveer de helft van alle kan-
kers. In 1988 kwam longkanker nog het meeste voor, maar sinds 1991 is borstkanker 
de meest voorkomende vorm van kanker. Andere veel voorkomende vormen van kan-
ker zijn blaaskanker, maagkanker, kanker van hoofd & hals en kanker van de lymfati-
sche en bloedvormende weefsels. Van alle in 1988 geregistreerde maligniteiten was 7 
procent een tweede of latere maligniteit. In 2002 was dit aandeel gestegen tot 10 
procent. 
Het aantal sterfgevallen ten gevolge van kanker veranderde niet veel in de periode 
1988-2002, maar het naar leeftijd en geslacht gestandaardiseerde sterftecijfer per 
100000 personen daalde met 16 procent, vooral door een daling van de sterfte ten 
gevolge van longkanker bij mannen. Er deed zich echter ook een daling voor van de 
sterfte ten gevolge van maagkanker, prostaatkanker, borstkanker en eierstokkanker. 
Het totale aantal (ex-)kankerpatiënten (‘prevalentie’) in Noord-Holland/Flevoland be-
droeg in 2003 61 100 personen, waaronder 16 300 met borstkanker, 7 700 met huid-
kanker, 7 500 met darmkanker en 6 600 met prostaatkanker. Kankerprevalentie omvat 
een zeer diverse groep personen, zoals patiënten bij wie onderzoek wordt gedaan om 
de ziekte in kaart te brengen, patiënten die voor hun ziekte behandelingen ondergaan, 
patiënten in de terminale fase en personen die genezen zijn. In elke fase van het ziek-
teproces is er andere zorgbehoefte. 
Van alle patiënten bij wie voor het eerst kanker was vastgesteld in 1988-2001 is er 
vervolgonderzoek gedaan naar de vitale status (al dan niet overleden). Op basis van 
dit gegeven konden overlevingskansen worden berekend. In de periode 1988-2001 
verbeterden de overlevingskansen licht voor alle vormen van kanker samen. Dit komt 
enerzijds door hogere overlevingskansen van enkele veel voorkomende vormen van 
kanker (borstkanker, darmkanker, prostaatkanker), anderzijds door veranderingen in 
incidentie: het aandeel van enkele vormen van kanker met een slechte prognose 
(longkanker, maagkanker) daalde tussen 1988 en 2001, ten gunste van het aandeel 





Behalve dat de kankerregistratie gebruikt kan worden voor berekening van incidentie-
cijfers, zijn er talloze mogelijkheden voor onderzoek met ‘population-based’ kankerre-
gistraties, variërend van beschrijvende epidemiologische studies en planning van ge-
zondheidsvoorzieningen tot etiologisch (gericht op de oorzaak van ziekten) en klinisch 
onderzoek. In dit proefschrift wordt het gebruik van de kankerregistratie geïllustreerd 
met behulp van migrantenstudies (hoofdstuk 2), etiologische studies naar het verband 
tussen omgevingsfactoren en het optreden van kanker (hoofdstuk 3) en onderzoek 
naar de overlevingskansen van kankerpatiënten (hoofdstuk 4). 
De eerste migrantenstudie (hoofdstuk 2.1) beschrijft de incidentie van baarmoeder-
halskanker in Noord-Holland naar land van geboorte. Het aantal gevallen van baar-
moederhalskanker in Noord-Holland gedurende de periode 1988-1998, per geboorte-
land, werd vastgesteld op basis van gegevens uit de IKA-kankerregistratie. Met behulp 
van gegevens van de Nederlandse Kankerregistratie werd een verwacht aantal geval-
len van baarmoederhalskanker berekend per geboorteland en per woonregio (Amster-
dam versus de rest van Noord-Holland) en vergeleken met het waargenomen aantal. 
In de onderzochte periode bleek de incidentie van baarmoederhalskanker in Noord-
Holland significant hoger (gestandaardiseerde incidentie ratio [SIR§§] 1,2; 95% be-
trouwbaarheidsinterval [BI] 1,1-1,2) dan het landelijke gemiddelde. Vooral bij vrouwen 
woonachtig in Amsterdam (SIR 1,5, BI 1,4-1,6), en bij vrouwen geboren in Marokko 
(SIR 2,1, BI 1,4-3,1) en Suriname (SIR 1,5, BI 1,1-2,0) was de incidentie hoog. Het 
incidentiecijfer bij allochtone vrouwen in Noord-Holland was lager dan in hun land van 
herkomst, met uitzondering van Turkse vrouwen. Het aandeel van patiënten bij wie de 
ziekte in een vergevorderd stadium (TNM-stadium II-IV) was vastgesteld, verschilde 
niet tussen autochtone en allochtone vrouwen. Concluderend was de incidentie van 
baarmoederhalskanker significant verhoogd bij vrouwen woonachtig in Amsterdam en 
bij vrouwen geboren in Marokko of Suriname. Er werd tussen autochtone en allochto-
ne vrouwen geen significant verschil gevonden in het stadium bij diagnose. 
De tweede migrantenstudie (hoofdstuk 2.2) beschrijft de incidentie van borstkanker 
naar land van geboorte bij vrouwen woonachtig in Noord-Holland en Den Haag. In 
1988-1998 bleek de SIR significant verlaagd voor vrouwen die waren geboren in Suri-
name (0,56), Turkije (0,29) en Marokko (0,22). Bij vrouwen afkomstig uit de laatste 
twee landen was de SIR minder laag onder de 50 jaar (Turkije 0,35; Marokko 0,33) 
dan boven de 50 jaar (Turkije 0,22; Marokko 0,10). Bij vrouwen die in Indonesië gebo-
ren waren was het juist andersom (<50 jaar 0,83; 50 jaar of ouder 1,03). Het aandeel 
van vrouwen bij wie de ziekte in een vergevorderd stadium (III en IV) werd vastge-
steld verschilde niet significant tussen allochtone en autochtone vrouwen. Hoewel het 
risico op borstkanker bij allochtone vrouwen in Nederland nog weinig verschilt van het 
risico op borstkanker bij vrouwen in het land van herkomst, is het hogere risico van 
jongere vrouwen in vergelijking met oudere vrouwen een aanwijzing dat een verande-
ring van het risicoprofiel voor borstkanker (bijv. een lager gemiddeld kindertal) naar 
het risicoprofiel van autochtone vrouwen al gaande is in eerste generatie allochtonen. 
Voor de derde migrantenstudie (hoofdstuk 2.3) is geen gebruik gemaakt van gegevens 
van de kankerregistratie, maar van gegevens van de regionale organisatie voor borst-
kankerscreening. Deze gegevens zijn gebruikt om de screeningsresultaten per land van 
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geboorte te bepalen. De totale (naar leeftijdsgroep gestandaardiseerde) opkomst bij 
het bevolkingsonderzoek bedroeg 76 procent voor vrouwen van 50-69 jaar. De op-
komst was veel lager bij vrouwen geboren in niet-westerse landen (Suriname 59%, 
Turkije 44%, Marokko 37%). Ook in Amsterdam was de opkomst relatief laag (68 pro-
cent voor alle geboortelanden samen). Het verwijscijfer, het detectiecijfer en het inter-
valcarcinoomcijfer voor vrouwen geboren in niet-westerse landen was respectievelijk 
5,1, 2,2 en 1,2 per 1000 gescreende vrouwen, tegen 8,8, 4,0 en 2,2 voor in Nederland 
geboren vrouwen (p<0,05). De positief voorspellende waarde was 45 procent voor 
vrouwen geboren in Nederland en westerse landen, tegen 43 procent voor vrouwen 
geboren in niet-westerse landen. Hoewel vrouwen geboren in niet-westerse landen 
minder deelnemen aan het bevolkingsonderzoek op borstkanker dan vrouwen die in 
Nederland zijn geboren, is ook het detectiecijfer en het intervalcarcinoomcijfer laag. 
Deze laatste bevinding rechtvaardigt een passieve houding ten opzichte van de lage 
opkomst.  
De eerste studie in hoofdstuk 3 is een voorbeeld van een ecologische (correlatie-) stu-
die (hoofdstuk 3.1). Schiphol is al lange tijd een bron van klachten over geluidsover-
last, veiligheidsrisico’s en aan geluidsoverlast en luchtvervuiling gerelateerde gezond-
heidschade, waaronder kanker. Deze klachten waren de aanleiding om te onderzoeken 
hoeveel kanker zich in de periode 1988-2003 voordeed bij inwoners van de regio rond 
Schiphol. Omdat op basis van de beschikbare meetgegevens over de luchtvervuiling in 
de regio geen studiegebied kon worden gedefinieerd, hebben we een gebiedsindeling 
gemaakt op basis van geluidscontouren van vliegtuiglawaai en 4-cijferige postcodege-
bieden. Bij inwoners van het studiegebied werden in totaal 13 207 gevallen van kanker 
vastgesteld, hetgeen vrijwel gelijk was aan het aantal dat kon worden verwacht op 
basis van landelijke cijfers (SIR 1,02). Bij nadere beschouwing van de verschillende 
vormen van kanker werd voor de meeste kankersoorten geen verhoogd of verlaagd 
risico waargenomen. Kanker van de luchtwegen kwam statistisch significant minder 
voor dan verwacht (SIR 0,94, BI 0,90-0,99) doordat het vooral bij mannen minder 
vaak voorkwam (SIR 0,89). Kanker van bloedvormend en lymfatisch weefsel kwam 
juist vaker voor dan verwacht (SIR 1,12, BI 1,05-1,19), vooral doordat non-
hodgkinlymfoom (SIR 1,22, BI 1,12-1,33) en acute lymfoblastenleukemie (SIR 1,34, BI 
0,95-1,83) relatief veel voorkwamen. In de kernzone van het studiegebied - het gebied 
met de hoogste geluidbelasting – was de incidentie van kanker iets hoger dan in het 
omringende gebied (verhouding tussen kernzone en omringende gebied: 1,05, BI 
1,01-1,10). Dit werd veroorzaakt doordat in de kernzone kanker van de luchtwegen, 
van de prostaat en van de vrouwelijke geslachtsorganen in verhouding meer voor-
kwamen dan in het omringende gebied. 
In deze studie waren geen gegevens beschikbaar met betrekking tot de individuele 
blootstelling aan luchtvaart-gerelateerde luchtvervuiling. Ook ontbrak informatie over 
migratie van en naar het onderzoeksgebied of over andere factoren die de resultaten 
kunnen beïnvloeden, zoals rookgewoonten, beroep, sociaal-economische status, alco-
holgebruik, voeding, seksueel gedrag, enz. Hierdoor is de interpretatie van de resulta-
ten van deze ecologische studie moeilijk. Daarom is verder onderzoek nodig om de 
oorzaak van de relatief hoge incidentie van kanker van de bloedvormende en lymfati-
sche weefsels te achterhalen, hoewel de totale kankerincidentie niet verhoogd was. 
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Het tweede onderzoek naar de invloed van het milieu op het voorkomen van kanker 
(hoofdstuk 3.2) verschilt van de het eerste onderzoek, omdat in de tweede studie ge-
gevens met betrekking tot de individuele blootstelling beschikbaar waren. In deze stu-
die hebben we de relatie onderzocht tussen de verkeersintensiteit en het voorkomen 
van kanker in de periode 1989-1997 in Amsterdam. Gegevens over de verkeersintensi-
teit van individuele adressen langs het hoofdverkeersnet zijn gekoppeld aan de regio-
nale kankerregistratie. Gegevens over rookgewoonten zijn verkregen uit een enquête. 
In de periode 1989-1997 werden in totaal 27 157 gevallen van kanker vastgesteld bij 
inwoners van Amsterdam. Gebruikmakend van de leeftijdsgroep- en geslachtspecifieke 
kankerincidentie bij de bevolking die niet langs het hoofdverkeersnet woonde als refe-
rentie, was de SIR van de bevolking die wel langs het hoofdverkeersnet woonde 1,03 
(3 384 gevallen van kanker), waarbij het 95% betrouwbaarheidsinterval liep tot 1 
(1,00-1,07). Voor de meeste vormen van kanker was de SIR dicht bij 1, behalve voor 
kanker van de spijsverteringsorganen in mannen (SIR 1,16, BI 1,04-1,28), kanker van 
de luchtwegen in vrouwen (SIR 1,13, BI 0,97-1,31) en kanker van bloedvormend en 
lymfatisch weefsel in volwassen vrouwen  (SIR 1,23, BI 1,04-1,44). Er werden vijf 
gevallen van acute lymfoblastenleukemie vastgesteld bij kinderen die woonden langs 
het hoofdverkeersnet (SIR 2,5, BI 0,8-5,9). De rookgewoonten verschilden niet tussen 
de bevolking die langs het hoofdverkeersnet woonde en de bevolking die in andere 
straten woonde. Hoewel we geen duidelijk bewijs hebben gevonden voor een relatie 
tussen wonen langs het hoofdverkeersnet en het voorkomen van kanker bij volwasse-
nen, kunnen we niet uitsluiten dat er een relatie bestaat met kanker van bloedvor-
mend en lymfatisch weefsel bij vrouwen en kinderen. 
Hoofdstuk 4 bevat een aantal studies over de prognose van kankerpatiënten, waarvoor 
gebruik gemaakt is van vervolggegevens van de kankerregistratie. 
Hoewel het stadium van de ziekte de belangrijkste factor is die de overleving bepaalt 
van kankerpatiënten, worden overlevingscijfers naar stadium zelden gepubliceerd. In 
hoofdstuk 4.1 worden deze gegevens gepresenteerd voor een grote groep kankerpati-
enten woonachtig in de regio van de IKA-kankerregistratie bij wie in de periode 1989-
2001 kanker is vastgesteld (n=108 251). Alle gevallen werden gerubriceerd naar soort 
kanker en het stadium op basis van de TNM-classificatie. Voor alle soorten kanker 
werd een sterke invloed van het stadium op de overleving waargenomen. Het stadium-
specifieke 5-jaarsoverlevingscijfer varieerde van vrijwel 100% voor stadium I (het gun-
stigste stadium) carcinoom van de speekselklieren, schildklier, darm, huid, borst, 
vrouwelijke geslachtsorganen en urinebuis tot 1% of minder voor stadium IV (het on-
gunstigste stadium) carcinoom van de slokdarm, maag, lever, galblaas, alvleesklier en 
long. Tussen 1989-1991 en 1999-2001 werd een stijging van het stadium-specifieke 5-
jaarsoverlevingscijfer waargenomen bij carcinoom van de darm (stadium II-IV), long 
(stadium I-II), borst (stadium I-III) en prostaat (stadium II-IV). Nadere beschouwing 
van de trends in stadiumverdeling en behandeling van kankerpatiënten ondersteunt de 
veronderstelling dat veranderingen in diagnostiek (borst, prostaat), stadiëringsonder-
zoek (long), nieuwe/verbeterde chirurgische technieken (endeldarm, prostaat) en aan-
vullende behandelingen (borst, dikke darm) hebben bijgedragen aan de waargenomen 
verbetering van de stadium-specifieke overlevingscijfers. 
In de volgende studie hebben we het voorkomen en de overleving van carcinoïden 





tumoren, die hormonen kunnen produceren en daarmee het carcinoïd-syndroom ver-
oorzaken. In 1992 werd octreotide in Nederland geïntroduceerd als een palliatieve 
behandeling voor patiënten met een carcinoïd-syndroom ten gevolge van een uitge-
zaaid carcinoïd. Het doel van de studie was het beschrijven van de beschikbare epide-
miologische gegevens (naar leeftijd, geslacht, lokalisatie en stadium) van carcinoïden 
in Nederland (op basis van gegevens van de Nederlandse Kankerregistratie) en het 
onderzoeken van de invloed van octreotide op de overleving (op basis van de IKA- en 
IKZ-kankerregistraties). In de periode 1989-1996 werd in totaal bij 2391 personen in 
Nederland een carcinoïd vastgesteld (1,95 geval per 100000 inwoners). Onder de 50 
jaar werd bij vrouwen vaker een carcinoïd gevonden dan bij mannen. De appendix was 
de meest voorkomende lokalisatie van een carcinoïd bij personen jonger dan 35 jaar. 
Uitzaaiingen op afstand kwamen weinig voor bij carcinoïden in de appendix (1,6%) en 
de long (5,5%), maar in 40% van de gevallen bij carcinoïden in andere organen. De 
relatieve 5-jaarsoverleving bedroeg 72% voor alle carcinoïden samen en varieerde van 
93% voor gelokaliseerde ziekte, 74% voor carcinoïden met regionale uitbreiding en 
19% in het geval van uitzaaiingen op afstand. In een multivariate analyse bleken ho-
gere leeftijd en hoger stadium onafhankelijke factoren die een slechtere overleving 
veroorzaken; carcinoïden gelokaliseerd in de appendix veroorzaken juiste een gunsti-
ger overleving. In een analyse met alleen uitgezaaide ziekte bleek dat carcinoïden die 
na 1992 werden gediagnosticeerd een gunstiger overleving hadden (p=0,012). Het feit 
dat vrouwen onder 50 jaar vaker carcinoïden hebben dan mannen suggereert dat 
hormonen invloed hebben op het ontstaan van carcinoïden. De verbeterde overleving 
na 1992 zou veroorzaakt kunnen zijn door de toepassing van octreotide na 1992. 
In 1995 is het bevolkingsonderzoek op baarmoederhalskanker gereorganiseerd. In 
hoofdstuk 4.3 is, ter evaluatie van het bevolkingsonderzoek, onderzocht hoe de inci-
dentie en overleving van baarmoederhalskanker zich hebben ontwikkeld in de regio 
van de IKA-kankerregistratie. Er werd een significante daling waargenomen van het 
naar leeftijd gestandaardiseerde incidentiecijfer van plaveiselcelcarcinoom, de meest 
voorkomende variant van baarmoederhalskanker (van 9,2 gevallen per 100000 vrou-
wen in 1988 naar 5,9 in 2000). Het incidentiecijfer van adenocarcinoom van de baar-
moederhals veranderde niet (1,6 gevallen per 100000 vrouwen). Na correctie voor 
leeftijd, stadium en betrokkenheid van lymfklieren in het ziekteproces, bleek dat vrou-
wen met een adenocarcinoom een hogere sterftekans (relatief risico op sterfte 1,6, BI 
1,3-2,1) hebben dan vrouwen met een plaveiselcelcarcinoom van de baarmoederhals. 
Gedurende de onderzoeksperiode is de prognose van vrouwen met plaveiselcelcarci-
noom significant verbeterd, maar een significante verbetering deed zich niet voor bij 
vrouwen met adenocarcinoom. Deze resultaten suggereren dat het bevolkingsonder-
zoek op baarmoederhalskanker in Nederland is geassocieerd met een daling van de 
incidentie en een stijging van de overleving van plaveiselcelcarcinoom, maar dat (voor-
stadia van) adenocarcinoom onvoldoende wordt opgespoord. Omdat meer dan 92% 
van de (voorstadia van) adenocarcinomen humaan papillomavirus bevatten, zou het 
toevoegen van een test op humaan papillomavirus aan de huidige cytologische scree-
ning het aantal opgespoorde (voorstadia van) adenocarcinomen kunnen verhogen. 
In de vierde studie van hoofdstuk vier (hoofdstuk 4.4) is de overleving van patiënten 
met blaaskanker onderzocht, alsmede de kans op het terugkomen van de kanker (‘lo-
kaal recidief’) na operatieve verwijdering van de blaas (‘cystectomie’). Alle gevallen 
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van blaaskanker die vastgesteld werden in de periode 1988-2001 werden geselecteerd 
uit de IKA-kankerregistratie. Van alle patiënten bij wie de blaas operatief werd verwij-
derd in de periode 1988-1997, werden aanvullende gegevens (lokaal recidief en even-
tuele overlijdensdatum) verzameld in 18 deelnemende ziekenhuizen. De relatieve 5-
jaarsoverleving bedroeg 75% voor alle gevallen van blaaskanker samen (n=8321). 
Voor klinisch stadium 0-a bedroeg de overleving 99%, dalend naar 85% voor stadium 
0-is en 82% voor stadium I, en tot 44%, 28% en 9% voor respectievelijk stadium II, 
III en IV. De relatieve 5-jaarsoverleving na cystectomie was 81%, 44% en 23% voor 
respectievelijk stadium II, III en IV. Na cystectomie (n=566) kwam de blaaskanker 
terug in 19% van alle gevallen. De blaaskanker kwam vaker terug bij hogere stadia en 
bereikte waarden van 11%, 23% en 31% voor respectievelijk stadium II, III en IV. 
Het percentage was iets lager in oncologische centra (18%) dan in algemene zieken-
huizen (20%) (niet significant). De overleving was hoger dan het Europese gemiddel-
de, maar lager dan in de Verenigde Staten. Slechts een op de drie patiënten met sta-
dium II-III onderging een cystectomie. Na cystectomie werd een relatief hoge stadi-
um-specifieke overleving waargenomen, ondanks het feit dat bij een op de vijf patiën-
ten de ziekte terugkwam.  
In hoofdstuk 5 (de discussie) worden de resultaten van de verschillende studies be-
sproken. Ook komen mogelijkheden voor toekomstig onderzoek aan de orde. Behalve 
studies waarvan in dit proefschrift al voorbeelden zijn opgenomen, zijn er mogelijkhe-
den om de kankerregistratie te gebruiken als instrument om de kwaliteit te meten van 
de oncologische zorg, bijvoorbeeld met betrekking tot het volgen van richtlijnen, het 
percentage patiënten waarbij de ziekte terugkomt na een behandeling, ziekte-
specifieke overleving (voor de gehele regio of per ziekenhuis) of andere indicatoren 
(bijv. wachtlijsten, bijwerkingen van de behandeling, bijkomende ziekten, enz.). Als 
voor het beantwoorden van een vraagstelling aanvullende gegevens moeten worden 
verzameld, moet dit bij voorkeur gebeuren voor een beperkt aantal gevallen van kan-
ker gedurende een beperkte periode in een zogeheten documentatieproject. Tenslotte 
is een ‘population-based’ kankerregistratie een ideaal instrument voor onderzoek naar 
het optreden van tweede tumoren na een eerdere vorm van kanker. In de toekomst 
kan de kankerregistratie een belangrijke bijdrage leveren aan de opheldering van 
thans onbekende associaties tussen verschillende vormen van kanker of de invloed van 
de behandeling. Omdat met het verstrijken der jaren het aantal geregistreerde patiën-
ten met een lange overlevingsduur blijft toenemen, nemen ook de mogelijkheden om 
met de kankerregistratie dergelijke associaties waar te nemen toe. 
Met de invoering van het burgerservicenummer in het publieke domein, waaronder de 
gezondheidszorg, zal het vervolgen van patiënten in de toekomst veel gemakkelijker 
worden, indien het gebruik van dit nummer ook aan de kankerregistratie zal worden 
toegestaan. Omdat het burgerservicenummer anonieme koppelingen (bij voorkeur via 
een derde partij om de privacy van de geregistreerden te beschermen) mogelijk maakt 
met andere registraties, opent dit nieuwe perspectieven voor studies met de kankerre-







Aan de basis van dit proefschrift ligt het werk van vele mensen ten grondslag, met 
name de registratiemedewerkers van het IKA. Aan hen en aan Tinie Benraadt, die een 
uitstekende registratie heeft opgezet en jarenlang nieuwe registratiemedewerkers 
heeft opgeleid en bijgestaan, ben ik bijzondere dank verschuldigd. Met z’n allen heb-
ben zij gezorgd voor meer dan 200 000 registraties van kankerpatiënten, op basis 
waarvan ik bijna alle onderzoeken in dit proefschrift heb kunnen uitvoeren. 
De onderzoeken over allochtonen waren waarschijnlijk niet tot stand gekomen als ik 
het aanstekelijke enthousiasme van Ferko Öry had moeten missen. Esther Busquet 
heeft met name voor het onderzoek over baarmoederhalskanker bij allochtonen veel 
werk verzet  waarop ik kon voortborduren. André van Peppen wil ik bedanken voor het 
ter beschikking stellen van gegevens over de opkomst bij de borstkankerscreening, 
Karin van der Kooy voor het ter beschikking stellen van IKW-gegevens over het voor-
komen van borstkanker in Den Haag. 
Joop van Wijnen is de initiator geweest van de onderzoeken over milieu en kanker. 
Zonder zijn kennis en ideeën op dit gebied, alsmede de bestanden die ik door zijn be-
middeling heb verkregen van de gemeente Amsterdam, had ik deze onderzoeken nooit 
kunnen realiseren. 
Voor de studies in hoofdstuk 4 waren de gegevens die de gemeenten in de provincies 
Noord-Holland en Flevoland, alsmede het Centraal Bureau voor de Genealogie, hebben 
verstrekt over overleden personen onontbeerlijk. Jakko Nieuwenhuijzen, Simon Horen-
blas, Saskia Bulk, Pascal Quaedvlieg, met jullie heb ik een artikel mogen schrijven 
waarbij gebruik werd gemaakt van follow-up gegevens. Dank voor de prettige samen-
werking! Maryska Janssen-Heijnen wil ik danken voor de IKZ-overlevingscijfers die ik 
heb mogen gebruiken in het onderzoek over carcinoïden. 
Willeke Heijbroek-de Clercq wil ik bedanken voor haar vermogen mij – natuurlijk bin-
nen de kaders van het IKA-beleid – toch voor een groot deel mijn eigen gang te laten 
gaan.  
Tenslotte wil ik vanzelfsprekend Floor van Leeuwen bedanken voor haar inbreng in 
bijna alle onderzoeken in dit proefschrift. Haar altijd opbouwende en grondige kritieken 
op mijn stukken heeft er uiteindelijk voor gezorgd dat een en ander heeft kunnen re-
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